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aging in C.elegans. It has since become clear that the ability of this pathway to modify aging is phylogenetically
conserved. Aging is a major risk factor for a variety of neurodegenerative diseases including the motor neuron
disease, Amyotrophic Lateral Sclerosis (ALS). This raises the possibility that the IIS pathway might have
therapeutic potential to modify the disease progression of ALS. In a C. elegans model of ALS we found that
decreased IIS had a beneficial effect on ALS pathology in this model. This beneficial effect was dependent on
activation of the transcription factor daf-16. To further validate IIS as a potential therapeutic target for
treatment of ALS, manipulations of IIS in mammalian cells were investigated for neuroprotective activity.
Genetic manipulations that increase the activity of the mammalian ortholog of daf-16, FOXO3, were found to
be neuroprotective in a series of in vitro models of ALS toxicity.
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also found to be protective in mammalian in vitro models of ALS toxicity as well as a fly and worm model of
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viable drugs have certain physico-chemical properties that fall within a well-defined set of values, which
unfortunately PA does not share. Due to its poor "drug-likness", an investigation into the mechanism of action
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This investigation revealed the heterogeneous nuclear ribonucleoprotein K (HNRNPK) is a direct physical
target of PA. PA modifies the ability of HNRNPK to stabilize rRNA but does not affect many of HNRNPK's
other functions. How changes in rRNA stability modify IIS or whether these changes definitively underlie
PA's neuroprotective mechanism remains to be determined.
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ABSTRACT: 
GENETIC AND PHARMACOLOGICAL APPROACHES TO PREVENTING 
NEURODEGENERATION 
Marco Boccitto 
Robert G. Kalb 
 
The Insulin/Insulin-like Growth Factor 1 Signaling (IIS) pathway was first identified as a 
major modifier of aging in C.elegans.  It has since become clear that the ability of this pathway to 
modify aging is phylogenetically conserved.  Aging is a major risk factor for a variety of 
neurodegenerative diseases including the motor neuron disease, Amyotrophic Lateral Sclerosis 
(ALS).  This raises the possibility that the IIS pathway might have therapeutic potential to modify 
the disease progression of ALS.  In a C. elegans model of ALS we found that decreased IIS had 
a beneficial effect on ALS pathology in this model.  This beneficial effect was dependent on 
activation of the transcription factor daf-16.  To further validate IIS as a potential therapeutic 
target for treatment of ALS, manipulations of IIS in mammalian cells were investigated for 
neuroprotective activity.  Genetic manipulations that increase the activity of the mammalian 
ortholog of daf-16, FOXO3, were found to be neuroprotective in a series of in vitro models of ALS 
toxicity.   
The small molecule Psammaplysene A (PA) is known to increase the nuclear abundance 
of FOXO3.  PA was also found to be protective in mammalian in vitro models of ALS toxicity as 
well as a fly and worm model of neurodegeneration.  Due to the wide variety of 
neurodegenerative diseases that share aging as a risk factor, a small molecule modifier of 
FOXO/daf-16 such as PA could hold great therapeutic potential.  Most clinically viable drugs have 
certain physico-chemical properties that fall within a well-defined set of values, which 
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unfortunately PA does not share.  Due to its poor “drug-likness”, an investigation into the 
mechanism of action of PA was undertaken in order to potentially identify more “drug-like” 
compounds with similar activities. 
This investigation revealed the heterogeneous nuclear ribonucleoprotein K (HNRNPK) is 
a direct physical target of PA.  PA modifies the ability of HNRNPK to stabilize rRNA but does not 
affect many of HNRNPK’s other functions.  How changes in rRNA stability modify IIS or whether 
these changes definitively underlie PA’s neuroprotective mechanism remains to be determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
TABLE OF CONTENTS 
 
ABSTRACT:................................................................................................................................. IV 
LIST OF TABLES .................................................................................................................... IX 
LIST OF FIGURES ................................................................................................................... X 
CHAPTER 1 ................................................................................................................................ 1 
BACKGROUND......................................................................................................................... 1 
Introduction........................................................................................................................................... 1 
Insulin Signaling Pathways: ...................................................................................................................... 1 
Amyotrophic Lateral Sclerosis .................................................................................................................. 6 
Heterogeneous Nuclear Ribonucleoprotein K ........................................................................................ 11 
CHAPTER 2 ................................................................................................................................ 15 
DAF-2 SIGNALING MODIFIES MUTANT SOD1 TOXICITY IN C. ELEGANS ............... 15 
Abstract: ................................................................................................................................................ 15 
Introduction: .......................................................................................................................................... 16 
Results: .................................................................................................................................................. 17 
Discussion: ............................................................................................................................................. 28 
Materials and Methods: ......................................................................................................................... 32 
Acknowledgments: ................................................................................................................................ 34 
Author Contributions: ............................................................................................................................ 34 
CHAPTER 3 ................................................................................................................................ 35 
vii 
 
THE SMALL MOLECULE PSAMMAPLYSENE A IS NEUROPROTECTIVE IN 
MULTIPLE MODELS OF MOTOR NEURON DISEASE ..................................................... 35 
Abstract: ................................................................................................................................................ 35 
Introduction: .......................................................................................................................................... 35 
Results: .................................................................................................................................................. 37 
Discussion: ............................................................................................................................................. 45 
Materials and Methods: ......................................................................................................................... 46 
Acknowledgments: ................................................................................................................................ 52 
Author Contributions: ............................................................................................................................ 53 
CHAPTER 4 ................................................................................................................................ 53 
THE NEUROPROTECTIVE DRUG PSAMMAPLYSENE A BINDS THE RNA BINDING 
PROTEIN HNRNPK .................................................................................................................. 53 
Abstract: ................................................................................................................................................ 53 
Introduction: .......................................................................................................................................... 54 
Results: .................................................................................................................................................. 56 
Discussion: ............................................................................................................................................. 75 
Methods: ............................................................................................................................................... 79 
Acknowledgments: ................................................................................................................................ 85 
Author Contributions: .......................................................................................................................... 100 
CHAPTER 5 ............................................................................................................................. 100 
FUTURE DIRECTIONS: ........................................................................................................ 100 
APPENDIX .............................................................................................................................. 109 
APPENDIX 1 ........................................................................................................................... 109 
REGULATION OF FOXO-DEPENDENT TRANSCRIPTION BY POST-
TRANSLATIONAL MODIFICATIONS ............................................................................... 109 
viii 
 
Abstract ............................................................................................................................................... 109 
Introduction ......................................................................................................................................... 109 
Foxo Inhibitory Kinases ........................................................................................................................ 111 
Foxo Activating Kinases ........................................................................................................................ 116 
Kinases That Dictate a Transcriptional Profile ...................................................................................... 118 
Acetylation of Foxo .............................................................................................................................. 120 
Ubiquitination of Foxo ......................................................................................................................... 123 
Foxo Cofactors and Foxo as a Cofactor ................................................................................................. 127 
Foxo Signaling as a Potential Therapeutic Target for Disease ............................................................... 129 
APPENDIX 2 ........................................................................................................................... 130 
FOXO3A IS BROADLY NEUROPROTECTIVE IN VITRO AND IN VIVO AGAINST 
INSULTS IMPLICATED IN MOTOR NEURON DISEASES. ........................................... 130 
Abstract: .............................................................................................................................................. 131 
Introduction: ........................................................................................................................................ 131 
Methods: ............................................................................................................................................. 133 
Results: ................................................................................................................................................ 140 
Discussion: ........................................................................................................................................... 160 
Acknowledgements: ............................................................................................................................. 163 
Author Contributions: .......................................................................................................................... 164 
BIBLIOGRAPHY .................................................................................................................. 165 
 
 
 
 
 
 
ix 
 
List of Tables 
Chapter 4 Table 1   pages 61-62 
Chapter 4 Supplemental Table 1  pages 88-99 
Chapter 4 Supplemental Table 2  page 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
List of Figures 
Chapter 1 Figure 1   page 5 
Chapter 1 Figure 2   page 11 
Chapter 2 Figure 1   page 20 
Chapter 2 Figure 2   page 23 
Chapter 2 Figure 3   page 26 
Chapter 2 Figure 4   page 27 
Chapter 3 Figure 1   page 39 
Chapter 3 Figure 2   page 41 
Chapter 3 Figure 3   page 43 
Chapter 3 Figure 4   page 44 
Chapter 4 Figure 1   page 60 
Chapter 4 Figure 2   page 66 
Chapter 4 Figure 3   page 68 
Chapter 4 Figure 4   page 71 
Chapter 4 Figure 5   page 75 
Chapter 4 Supplemental Figure 1 page 88 
Chapter 4 Supplemental Figure 2 pages 100-101 
 
 
 
 
 
 
1 
 
 
 
CHAPTER 1 
Background 
Introduction 
 Aging is the greatest risk factor for the development of a variety of neurodegenerative 
diseases including Amyotrophic Lateral Sclerosis (ALS).  Although numerous mutations have 
been identified which invariably lead to neurodegenerative disease, the onset of disease 
pathology typically does not occur until mid to late life.  This suggests that there is an innate 
capacity for cells/organisms to cope with the stresses of mutant proteins associated with 
disease, but that these systems lose their ability to cope with toxic proteins as they age.  
Therefore, manipulations that prevent the changes associated with cellular/organismal aging 
represent potential therapeutic interventions for neurodegenerative diseases.   
Insulin Signaling Pathways: 
 
One of the most well characterized modifiers of longevity and aging is the 
Insulin/Insulin-like Growth Factor Signaling (IIS) pathway.  IIS was first implicated as a modifier 
of longevity when it was found that C. elegans with a hypomorphic allele of the insulin receptor, 
daf-2, had increased activation of the downstream transcription factor, daf-16, and lived roughly 
twice as long as wild type worms1.  Since this original characterization, a more complete 
understanding of the role of the IIS pathway in aging has emerged.  Upon ligand binding, a series 
of downstream phosphorylation events occur which conclude in phosphorylation of daf-16.  
Phosphorylated daf-16 is retained in the cytoplasm and is unable to execute its pro-survival 
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transcriptional output.  The downstream kinase age-1, which is activated by daf-2, acts to 
promote phosphorylation of daf-16 and exclude it from the nucleus.  Mutants which are null for 
age-1 are extremely long lived and have a lifespan approximately ten times greater than wild 
type worms2.  Nuclear localization of daf-16, although necessary, is not sufficient to promote 
longevity3, suggesting that other signaling events need to be integrated in order for daf-16 to 
execute its beneficial transcriptional profile.  The transcription factor hsf-1 is thought to be an 
important cofactor for expression of a subset of daf-16 longevity promoting genes, with 
overexpression of hsf-1 leading to a daf-16 dependent increase in longevity4.  There is also a 
level of cross talk between stress induced signaling pathways and IIS.  The c-Jun N-terminal 
Kinase (JNK) which is a stress responsive kinase, directly interacts with daf-16 and leads to its 
nuclear accumulation5.  TGFβ signaling is also known to influence IIS and modify longevity in 
adult worms.  There are two canonical TGFβ signaling pathways in the worm.  One functions to 
regulate reproductive lifespan independently of longevity while the other functions in a daf-16 
dependent fashion to significantly enhance longevity6,7.  The family of Forkhead box O (FOXO) 
transcription factors represent the mammalian orthologs of daf-16.  The FOXO family regulates 
cellular processes including metabolism, stress response, DNA damage repair and cell death and 
has also been implicated in lifespan extension in mammals.  Many of the post-translational 
modifications that modify the function of daf-16 have also been found to regulate the function 
of the FOXO transcription factors.  For a complete discussion of post-translational modifications 
that regulate FOXO function, see appendix 1. 
Interestingly, mutations resulting in increased longevity in C. elegans often increase 
stress resistance as well.  For example, alterations in the IIS pathway that lead to increased 
lifespan, such as mutations in daf-2 or age-1, also increase organismal resistance to a wide 
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variety of stresses such as heat shock, oxidative stress, heavy metal stress, UV damage and 
infection8-11.  Changes in IIS have also been found to increase resistance to proteotoxic insults 
such as expression of: polyglutamine expanded proteins, and mutant TDP-434,12-14.  Decreased 
IIS signaling has also been shown to be protective against amyloid beta toxicity.  A cooperative 
effect between daf-16 and hsf-1 has been described for protection against amyloid beta toxicity, 
with both playing a role in reducing amyloid beta toxicity in a model of Alzheimer ’s disease 
when IIS is reduced15.  The transcriptional profile of daf-16 and hsf-1 helps to explain the robust 
increase in stress resistance that accompanies their activation when IIS is decreased.  They 
initiate transcription of a number of chaperones, including members of the small heat shock 
protein family, reactive oxygen scavenging enzymes, and anti-microbial genes16.  A role for 
reduced IIS in protecting against mutant SOD1 toxicity in the worm had not previously been 
described, so we investigated the potential for mutations in daf-2 that promote daf-16 nuclear 
localization to protect against SOD1 toxicity13.  The ability of reduced IIS to broadly increase 
stress resistance and protect against such varied insults makes this pathway of particularly 
broad therapeutic interest.  Our work, along with other findings in the worm, suggests that 
genetic or pharmacological manipulations that enhance the transcriptional activity of daf-
16/FOXO could beneficially modify disease progression in numerous neurodegenerative 
diseases.   
Lifespan extending alterations in IIS signaling are mediated cell nonautonomously. 
Mosaic analysis of worms with a hypomorphic allele of daf-2 revealed that reductions in IIS are 
not required throughout the whole organism to promote longevity17.  Rather, reduced IIS in 
specific cells leads to a signaling cascade which coordinates aging throughout the worm.  A 
specific subset of neurons, as well as the intestine, were strongly longevity promoting when IIS 
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was reduced in these cells.  Drosophila FOXO has also been shown to regulate the expression of 
insulin responsive genes in a non-cellautonomous fashion18,19.  While descriptions of cell 
nonautonomous effects of reduced IIS on longevity exist, similar studies have not been 
undertaken to describe cell autonomous/nonautonomous changes in stress resistance under 
conditions of reduced IIS.  In order to explore whether reduced IIS signaling functions in a cell 
autonomous or cell nonautonomous fashion, we employed a worms strain with a genetic 
background that increases the effectiveness of feeding RNAi in the nervous system.  Our work 
suggested that reduced IIS in the periphery had little or no effect on SOD1 toxicity the nervous 
system.  A thorough description of cell autonomous/nonautonomous changes in stress 
resistance after reduced IIS may be of clinical importance.  When designing therapeutics based 
on decreased IIS activity it will be important to know which cell types should be targeted in 
order to elicit the maximal increase in stress resistance. 
Although the worm has become a favorite tool for the study of longevity and aging, due 
to its relatively short lifespan and ease of genetic manipulation, the IIS pathway is an 
evolutionarily conserved regulator of longevity.  As in C. elegans, mutations which lead to 
decreased IIS signaling, either through reduced activity of the drosophila insulin-like receptor 
InR or reduction of its ligand chico, result in lifespan extension20.  dFOXO, the drosophila 
ortholog of daf-16 has also been shown to extend lifespan when over expressed in the adult 
pericerebral fat body19.    
Regulation of longevity by the IIS pathway is conserved in mammals as well.  A number 
of transgenic mice have been generated that have reduced IIS, including: fat specific insulin 
receptor knockout, insulin receptor substrate -/-, IGF-1R +/- and klotho over expression (klotho 
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is a circulating factor which represses signaling from insulin and IGF receptors), all of these mice 
have been found to have increased lifespan21-24.  Another interesting line of support for IIS 
regulating aging in mice comes from four different naturally occurring long-lived mouse strains. 
The Ames dwarf, Snell dwarf, Laron dwarf and Little dwarf mice all have significantly increased 
lifespans and all have very low levels of circulating IGF-125.  Correlations between reduced IIS 
and longevity have even been observed in human cohorts.  An association between longevity 
and decreased IGF-1R activity was reported in a cohort of Ashkenazi Jewish centenarians26.  
Similarly, mutations in the FOXO1 and FOXO3 transcription factors have been reported to 
correlate with longevity in other long lived human cohorts27-30.  Taken together these data 
suggest that the IIS pathway is an evolutionarily conserved regulator of longevity and aging.  The 
conserved nature of the IIS pathway suggests that findings from C. elegans regarding effects of 
IIS on SOD1 toxicity may be of therapeutic interest in humans as well. 
Figure 1. 
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Figure 1.  The DAF-16/FOXO transcription factors act as an integrator of signals mediated by IIS, 
stress responsive pathways, germline signaling and changes in metabolism in order to 
coordinate control of longevity and aging. 
 
Amyotrophic Lateral Sclerosis 
 
 Amyotrophic Lateral Sclerosis (ALS) is a progressive degenerative disorder of upper and 
lower motor neurons that results in progressive paralysis and finally death from respiratory 
failure.  The incidence of ALS is approximately 2 per 100,000 individuals with more men affected 
than women.  Average age of onset is between 55-60 years and after the onset of symptoms 
average survival is only 3 years.  While the earliest and most overt symptoms of ALS affect 
motor neurons, it is becoming apparent that ALS is not a pure motor neuron disease.  Recent 
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findings have demonstrated involvement of sensory neurons as well as spino-cerebellar 
pathways in ALS pathology, particularly in certain subsets of patients with frontotemporal 
dementia31,32.  Approximately 10% of ALS cases are familial (fALS) and mutations in 15 genes, as 
well as a hexa-nucleotide repeat expansion of an intron in C9orf72, have been associated with 
fALS33.  Despite the identification of numerous fALS associated genes, no clear pathogenic 
mechanism has yet been identified. 
Potential Mechanisms of Toxicity in ALS 
Damage from Reactive Oxygen Species 
 One potential cause of toxicity in ALS is ROS.  ROS became a prime candidate for toxicity 
in ALS when the first genetic linkages to fALS were identified as mutations in SOD1, a Cu/ZN 
superoxide dismutase34.  SOD1 acts to convert harmful ROS into H2O2, thus protecting the cell 
against ROS damage.  Elevated levels of oxidative damage to lipids, proteins, DNA and RNA have 
all been reported either in post mortem tissue from ALS patients or in mouse models of ALS.  
Although ALS associated mutations in SOD1 have been found in all five SOD1 exons35 these 
mutations do not seem to cause toxicity through a loss of function mechanism.  In mutant SOD1 
mouse models of ALS, an fALS associated SOD1 mini-gene is inserted into the mouse genome.  
This results in mutant human SOD1 being expressed under the control of its endogenous 
promoter.  These mice develop a sporadic, fatal, motor neuropathy despite having fully 
functional mouse SOD135.  This argues strongly for a gain of function toxicity of mutant SOD1.  
Mice null for SOD1 develop normally and show no sporadic motor abnormalities, again arguing 
against a loss of function model.  ROS scavenging enzymes are known targets of daf-16/FOXO, 
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and reduced ROS damage may represent one way that genetic and pharmacological 
manipulations which increase daf-16/FOXO activity protects against mutant SOD1 toxicity. 
Proteotoxic Aggregates  
 Like all other neurodegenerative diseases, insoluble protein aggregation is a hallmark of 
ALS.  In a study of 102 autopsies of sporadic ALS cases with various ages of onset and clinical 
presentation between 1962 and 2000, all 102 cases presented with ubiquitin positive skein-like 
and/or spherical inclusions36.  TDP-43, SOD1 and FUS have all been identified as prominent 
protein constituent of inclusions in sporadic and familial ALS37-39.  Two genes linked to fALS, 
Ubiquilin2 and valosin containing protein, are involved in facilitating the degradation of 
improperly folded proteins, further supporting a link between protein aggregation and toxicity 
in ALS.   The exact mechanism of protein aggregate toxicity remains a mystery.  Much debate 
exists about the exact nature of the toxic species in ALS and other neurodegenerative diseases.  
While protein aggregates are a hallmark of neurodegenerative disease, their abundance often 
doesn’t correlate well with toxicity.  This has led to the suggestion that large aggregated 
inclusions may not be the toxic species.  When disease associated proteins adopt non-native 
conformations, they can form aggregates ranging in size from soluble oligomers all the way up 
to macro-aggregates, which can be viewed by optical microscopy.  It has been suggested that 
the large protein aggregates, which are easily observable in many neurodegenerative diseases, 
may represent a protective mechanism (i.e. sequestration), where smaller toxic oligomers are 
sequestered into large aggregates by the cell in order to diminish their toxicity.  The mechanism 
of toxicity of aggregated proteins and the exact nature of the toxic species continues to be a 
contentious topic in the field of neurodegenerative disease40.  We explored the capacity of 
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reduced IIS to modulate SOD1 toxicity and found that decreased IIS leads to an increase in the 
ratio of soluble to insoluble SOD1.  We also found that total SOD1 burden was not correlated 
with impaired movement but rather that the soluble to insoluble ratio of SOD1 was a better 
predictor of changes in motor function.  Reduced IIS elicits a significant increase in protein 
solubility at the whole proteome level41.  This fact coupled with the ubiquity of protein 
aggregates in neurodegenerative disease suggests that activation of daf-16/FOXO may be 
broadly therapeutic against many proteotxic insults associated with neurodegeneration. 
Abnormal RNA Processing 
 A number of genes associated with fALS are known to play a role in RNA processing.  
These include TDP-43, FUS and Senataxin42.  TDP-43 is an RNA binding protein involved in 
translational control, RNA splicing and miRNA processing.  TDP-43 is a prominent component of 
ALS inclusions37.  While TDP-43 is usually present in both the cytoplasm and nucleus, once TDP-
43 inclusions appear in the cytoplasm there appears to be a loss of nuclear TDP-43 with TDP-43 
becoming predominantly cytoplasmic and entering stress granules43.  This potentially represents 
a scenario where the aggregation of mutant TDP-43 results in a loss of function of wild type 
TDP-43 through nuclear exclusion.  TDP-43 has been found to interact with roughly 30% of the 
mouse transcriptome.  Immunoprecipitation of TDP-43 followed by deep sequencing of 
associated RNAs has revealed that TDP-43 preferentially binds GU rich sequences44.  This binding 
can occur in exons, introns and 3’UTRs but a strong bias exists for binding to introns.  More 
specifically, intronic bindings sites that are relatively far (>500bp) from the nearest exon-intron 
boundary make up 82% of TDP-43 binding sites identified in adult mouse brain.  After TDP-43 
knockdown, mRNAs with the greatest reduction in abundance have a mean intron size 6x 
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greater than unaffected messages.  This has led to the hypothesis that TDP-43 acts to stabilize 
messages with exceptionally long introns45.  Interestingly this class of messages is particularly 
abundant in the brain and could potentially explain the susceptibility of neurons to mutations in 
a ubiquitously expressed gene such as TDP-43.  Loss of TDP-43 also significantly effects 
alternative splicing, with knockdown resulting in changes in 203 alternative splicing events in the 
mouse brain45.  While TDP-43 toxicity may be entirely dependent on changes in its own activity, 
TDP-43 is also known to regulate the stability and splicing of other genes associated with ALS 
and neurodegeneration including FUS, SMN2, progranulin, parkin and huntingtin45,46. 
 Fused in Sarcoma (FUS), another fALS associated gene involved in RNA processing, 
regulates mRNA transport, translation, and miRNA processing.  Similarly to TDP-43, ALS 
associated mutations in FUS result in cytoplasmic localization of FUS in stress granules and the 
formation of FUS containing aggregates.  This seems to be a result of a defect in nuclear 
transport caused by mutations in the C-terminal region47,48.   
Hexanucleotide expansions of the first intron of C9orf72 were recently discovered to 
represent the most common genetic cause of ALS49.  Patients with this expansion present with 
ubiquitin and p62 positive inclusions that are TDP-43 negative.  One possibility is that like 
mutations of TDP-43 and FUS C9orf72 expansion causes foci of aggregated RNA binding proteins 
resulting in disrupted RNA processing50. 
The potential involvement of abnormal RNA processing in ALS made the identification of 
HNRNPK as the target of Psammaplysene A (PA) all the more interesting.  While our original 
interest in PA stemmed from the fact that it was able to activate FOXO transcription, we do not 
know definitively that this is its therapeutic mechanism.  The fact that PA binds HNRNPK 
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suggested the possibility that PA is acting to correct toxicity associated with abnormal RNA 
processing in neurons.  Alternatively it presented the possibility that there is a signaling pathway 
that links RNA processing with FOXO activity.  Both are novel concepts that we wish to explore. 
Heterogeneous Nuclear Ribonucleoprotein K 
  
 In our work identifying the target of PA we identify the Heterogeneous Nuclear 
Ribonucleoprotein K (HNRNPK) as a PA target.  HNRNPK is a member of the family of 
heterogeneous nuclear ribonucleoproteins (hnRNP), historically characterized for their ability to 
bind and form a complex with heterogeneous RNA polymerase II transcripts in the nucleus.  
Further studies have revealed that HNRNPK is not only present in the nucleus but also functions 
in the cytoplasm and mitochondria.  HNRNPK has a modular structure with three K homology 
(KH) RNA/DNA binding domains, a classical nuclear localization sequence (NLS), a K nuclear 
shuttling (KNS) domain which facilitates bi-directional shuttling across the nuclear membrane, 
and a highly unstructured protein-protein interaction domain (KI) (figure 2).  It is believed that 
the highly unstructured nature of the KI domain allows this domain to take on various structures 
based on protein-protein interactions and accounts for the fact that HNRNPK has over 100 
binding partners51.  HNRNPK is phosphorylated at numerous sites by a variety of kinases and has 
two distinct isoforms.  HNRNPK binds tenaciously to poly-C stretches and has been shown to 
interact with both coding and non-coding RNAs.  The ability of HNRNPK to interact with such a 
wide variety of proteins as well as RNA and DNA make it an excellent protein for integrating 
cellular signals and facilitating cross talk between environmental signals and RNA 
processing/transcription.  HNRNPK’s role as an integrator of signaling pathways, including stress 
responses, made it an intriguing target of PA.  Unfortunately, the broad range of HNRNPK 
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activities made identification of a specific PA dependent change in HNRNPK function quite 
challenging.   
Figure 2. 
 
 
Activities of HNRNPK: 
 
Transcriptional Control:  HNRNPK is capable of binding DNA as well as RNA and acts as a 
transcriptional regulator of various genes52.  While HNRNPK is thought to constitutively 
associate with a number of promoters, including c-myc, its recruitment to many sites is thought 
to be dependent on extracellular stimuli.  For example serum shock selectively recruits HNRNPK 
to the immediate early genes egr-1 and c-myc53.  HNRNPK plays a crucial role in execution of the 
p53 transcriptional profile after cellular stress.  HNRNPK has been found to act as a 
transcriptional co-activator of p53 target genes.  HNRNPK and p53 are both recruited to p53 
target gene promoters in a p53 dependent manner and loss of HNRNPK is found to inhibit p53 
target transcription54.  Interestingly, a number of genes are known to be downregulated upon 
cellular stress and induction of p53, but the mechanism by which p53 inhibited these genes was 
largely unknown.  Recent findings indicate that p53 regulates the expression of a number of long 
intergenic non-coding RNAs (linc).  Linc-p21 acts as a transcriptional repressor of genes which 
had previously been identified as being downregulated upon activation of p53.  Interestingly, 
this transcriptional repression by linc-p21 is dependent upon linc-p21 interaction with 
HNRNPK55.  HNRNPK acts as a regulator of transcription and is involved in transcriptional 
responses to a variety of external stimuli. 
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RNA Shuttling:  HNRNPK is an unusual member of the hnRNP family because unlike many other 
hnRNPs it is capable of shuttling in and out of the nucleus.  Evidence suggests that an important 
function of this shuttling ability is to move mRNAs out of the nucleus and load them onto 
polysomes.  Knockdown of HNRNPK in Xenopus embryos leads to terminally differentiated 
neurons with a severely disorganized axonal cytoskeleton.  Immunoprecipitation of HNRNPK 
followed by microarray analysis of its associated mRNAs revealed that messages encoding many 
of the dysregulated cytoskeletal components are associated with HNRNPK.  Analysis of nuclear 
versus cytoplasmic abundance of mRNAs revealed a specific reduction in export and polysome 
loading of some HNRNPK target mRNAs, suggesting a role of HNRNPK in mRNA nuclear export56.  
Translational Repression:  One of the best characterized examples of HNRNPK translational 
control occurs in developing erythrocytes.  These cells undergo a complex maturation that 
involves loss of both the nucleus and mitochondria.  This requires them to synthesize all of the 
necessary mRNAs needed for their development before loss of nuclear structure.  These 
messages then need to be controlled at the level of translational activation for the remainder of 
the developmental process.  Loss of mitochondria is one of the last steps in erythrocyte 
development and occurs immediately before these cells take on a purely oxygen carrying 
function.   15-lipoxygenase (LOX) plays a key role in the maturational degradation of 
mitochondria57.  Temporal control of LOX translation is achieved through binding of HNRNPK to 
LOX mRNA.  HNRNPK binds to the differentiation control element (DICE) sequence in the 3’ UTR 
of LOX mRNA and prevents assembly of the 80s ribosome by inhibiting joining of the 60s subunit 
to the 40s subunit.  In a developmentally regulated fashion, phosphorylation of HNRNPK by c-src 
inhibits its binding to DICE and allows for translation of LOX58. 
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RNA Stability:  HNRNPK has recently been demonstrated to regulate the stability of rRNAs.  
Homeostasis of translational machinery is crucial for normal cellular function.  Regulation of 
rRNA abundance is one mechanism by which cells are able to alter translational capacity.  
Degradation of rRNAs is an important cellular response to stress and dysregulation of rRNA 
degradation has been implicated in certain types of cancer59.  Under conditions of cellular stress 
the eukaryotic initiation factor 3 subunit f (eIF3f) interacts with HNRNPK causing HNRNPK to 
dissociate from rRNAs and allowing for their degradation.  Loss of eIF3f or overexpression of 
HNRNPK leads to abnormal stabilization of rRNAs and may contribute to malignant 
transformation60.  In addition to non-coding rRNAs HNRNPK has also been found to bind and 
stabilize mRNAs such as collagen 1A1, 1A2 and 3A161. 
Alternative Splicing:  Many of the hnRNPs, including HNRNPK, have been found to influence 
alternative splicing.  Analysis of the effects of 14 different hnRNPs on 56 alternative splicing 
events in genes associated with apoptosis identified HNRNPK and HNRNPC as having the 
broadest effects62.  Further investigation of the effects of HNRNPK on alternative splicing of 
apoptotic genes revealed that HNRNPK promotes the generation of the anti-apoptotic Bcl-x(L) 
isoform over the pro-apoptotic Bcl-x(S) isoform63. 
Summary:  HNRNPK is a DNA/RNA binding protein that is capable of integrating cellular signals, 
particularly those involved in stress response, and effecting downstream nucleic acid based 
processes.  Our identification of HNRNPK as the target of PA is particularly interesting because 
of the important role HNRNPK plays in response to stress stimuli.  We monitored many of the 
above functions for changes after PA treatment in order identify which aspects of HNRNPK 
biology were being affected by PA.  No previous link between HNRNPK function and FOXO 
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activity has been described.  Previous work in the worm has shown that knockdown of 
ribosomal proteins can be lifespan extending in a daf-16 dependent manner.  although the 
ability of HNRNPK to modulate translation initiation through regulation of rRNA stability 
suggests a potential link to aging and FOXO.  No small molecules have previously been described 
to interact with HNRNPK. 
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Abstract:  The DAF-2 Insulin/IGF-1 signaling (IIS) pathway is a strong modifier of 
Caenorhabditis elegans longevity and healthspan.  As aging is the greatest risk factor for 
developing neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), we were 
interested in determining if DAF-2 signaling modifies disease pathology in mutant superoxide 
dismutase 1 (SOD1) expressing C. elegans.  Worms with pan-neuronal G85R SOD1 expression 
demonstrate significantly impaired locomotion as compared to WT SOD1 expressing controls 
and they develop insoluble SOD1 aggregates.  Reductions in DAF-2 signaling, either through a 
hypomorphic allele or neuronally targeted RNAi, decreases the abundance of aggregated SOD1 
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and results in improved locomotion in a DAF-16 dependant manner.  These results suggest that 
manipulation of the DAF-2 Insulin/IGF-1 signaling pathway may have therapeutic potential for 
the treatment of ALS.  
Introduction:  ALS is an adult onset neurodegenerative disease characterized by progressive 
weakness, due to dysfunction and eventual death of motor neurons.  The majority of cases of 
ALS are sporadic but single gene mutations have been described that lead to inherited versions 
of the disease.  These genes include SOD1, TAR DNA binding protein (TDP43), fused in sarcoma, 
progranulin, ubiquilin 2 and a hexanucleotide repeat expansion of a noncoding region in 
C9ORF7234,64-69.  Expression of some of these mutant proteins in model organisms has been used 
to successfully model ALS pathology.  
Point mutations in SOD1 (e.g., G85R) are an example of a genetic cause of familial ALS 
that has been successfully modeled in transgenic mice and nematodes70.  The G85R point 
mutation causes a toxic gain-of-function, which in mice leads to ubiquitinated SOD1 aggregates 
and motor neuron death 71.  C. elegans expressing human G85R SOD1 in the nervous system 
accumulate SOD1 aggregates and demonstrate reduced mobility compared to WT SOD1 
expressing worms 72.  The availability of numerous loss-of-function mutants affecting highly 
conserved signaling pathways make C. elegans an ideal system in which to explore the 
relationship between such pathways and SOD1 aggregation and toxicity in an in vivo setting. 
Aging is the greatest risk factor for the development of ALS.  The Insulin/IGF-1 signaling 
(IIS) pathway is a robust modifier of longevity and aging in C. elegans1.  Loss of function of the 
Insulin/Insulin-like growth factor receptor, DAF-2, promotes longevity via signaling cascades 
mediated by inhibition of the phosphoinositide 3-kinase (age-1) and activation of the forkhead 
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transcription factor DAF-16 via its nuclear localization 4.  While nuclear localization of DAF-16 is 
required for it to execute its transcriptional activities, it is not sufficient to enhance longevity 
and stress resistance 3.  Other pathways are known to interact with the IIS pathway and 
modulate stress resistance and/or aging by regulating  transcriptional activity of DAF-16, 
without modifying its nuclear abundance 73,74.  In addition to promoting longevity, loss of 
function alleles of daf-2 or age-1 protects the worm against exogenous stressors including heat 
shock, oxidative stress, heavy metal stress, UV damage and infection 8-11.  The beneficial effects 
of reduced IIS rely, in part, on the ability of decreased IIS to activate the transcription factor 
DAF-16, leading to increased expression of numerous stress resistance genes, such as small heat 
shock proteins and reactive oxygen species scavenging enzymes 11,16.  Additionally, reduced IIS 
also results in changes in protein glycosylation, metabolism, mitochondrial abundance and lipid 
biosynthesis, all of which are thought to contribute to the stress resistant phenotype of reduced 
IIS75-78 .  Reduced DAF-2 signaling has been shown to have beneficial effects on other age related 
neurodegenerative diseases such as polyglutamine expansion proteinopathy and Alzheimer’s 
disease4,15. The ability to easily control the IIS pathway both genetically and via RNA interference 
(RNAi) makes the worm an excellent system for studying the interactions between aging and the 
toxicity of mutant SOD1.  In the present study we asked if manipulation of IIS pathway can 
improve the reduced mobility and insoluble protein aggregation seen in G85R SOD1 expressing 
worms. 
Results:   
Decreased crawling speed of G85R worms is ameliorated by decreased IIS signaling 
 We began by monitoring the average crawling speed of G85R, G85R;daf-2(e1370), 
G85R;daf-16(mgDf50), daf-2(e1370) and daf-16(mgDf50) worms on a bacterial lawn (OP50) at 
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96, 120, 144 and 168 hours after depositing eggs onto plates with bacteria (figure 1 A).  Group 
differences were observed at 96, 120 and 144hrs post egg drop (96, 120 and 144hrs: 
F(4,25)=22.96, F(4,25)=11.08, F(4,28)=12.57 respectively by single factor ANOVA p<0.01 at all 
timepoints).  At 96, 120 and 144hrs after growth initiation, the G85R;daf-2(e1370) worms 
crawled approximately twice as fast as G85R worms (p<0.05 at 96, 120 and 144 hrs by Tukey’s 
post-hoc) while at the 168hr time point no significant difference was observed.  Although not 
statistically significant, G85R;daf-16(mgDf50) worms tended to perform worse than G85R 
worms at all time points.  These results suggest that reduced IIS ameliorates the toxic effects of 
mutant SOD1, and while this benefit is maintained for 144hrs of life, it can not be sustained 
after this point.  The fact that G85R worms that are also null for DAF-16 tend to perform worse 
than G85R worms suggests that part of the worm’s endogenous response to proteotoxic insults, 
such as mutant SOD1, may include activation of DAF-16.   
In order to control for any potential variation in locomotion and/or behavioral 
differences in worms with the daf-2(e1370) or daf-16(mgDf50) mutations, we examined the 
average crawling speed of worms carrying these mutations on a non-SOD1 background.  There 
were no statistically significant differences between these two groups in locomotory activity at 
any time point observed (by Tukey’s post-hoc), suggesting that these mutations are modulating 
the toxicity of G85R as opposed to altering other aspects of behavior or locomotion in general. 
Decreased swim speed of G85R worms is ameliorated by decreased IIS signaling 
While the crawling assay allowed us to identify an improvement in the locomotory 
activity of G85R worms when they were on the daf-2(e1370) background, the inability to control 
for behavior during a given observation window made speed measurements variable.  In order 
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to reduce variability we examined swimming worms, a context which elicits continual 
movement.   
We compared the following worm strains in the swimming assay: WT SOD1, G85R, 
G85R;daf-2(e1370), G85R;daf-16(mgDf50), and G85R;daf-2(e1370);daf-16(mgDf50) (figure 1 B).  
Between group differences were detected at all timepoints by single factor ANOVA (72, 96, 120, 
144, and 168hrs: F(4,25)=15.53, F(4,26)=14.22, F(4,25)=8.67, F(4,25)=10.82, F(4,25)=9.56 p<0.01 at all 
timepoints).  WT SOD1 worms were significantly faster than G85R worms at all timepoints 
(p<0.01 by Tukey’s post-hoc).  G85R;daf-2(e1370) worms were also significantly faster than 
G85R worms at all timepoints (p<0.05 by Tukey’s post-hoc) and had mobility equivalent to WT 
SOD1 worms at all time points (no significant difference by Tukey’s post-hoc).  Ablation of daf-16 
in the G85R;daf-2(e1370) worms eliminated the observed rescue effect of daf-2(e1370) as no 
statistically significant difference was observed between G85R and G85R;daf-2(e1370);daf-
16(mgDf50) worms (by Tukey’s post-hoc).  These observations provide further data in support of 
the hypothesis that the daf-2(e1370) background is strongly protective against the toxicity of 
G85R SOD1 as assessed by locomotory function and that this protection is daf-16 dependent.   
There was a trend for G85R;daf-16(mgDf50) worms to perform worse than either G85R 
or (G85R;daf-2(e1370);daf-16(mgDf50) worms although it was only significant at 96hrs (p<0.05 
by Tukey’s post-hoc). The observation that G85R;daf-16(mgDf50) worms tended to perform 
worse than G85R;daf-2(e1370);daf-16(mgDf50) worms suggests that part of the beneficial effect 
of daf-2(e1370) may be daf-16 independent.  As in the crawling assay, the fact that G85R;daf-
16(mgDf50) worms tended to perform worse than G85R worms also suggests a potential role of 
daf-16 in the worm’s endogenous response to proteotoxic insults.  Like the crawling assay, the 
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swimming assay further supports the hypothesis that reduced IIS activity reduces G85R SOD 
toxicity. 
In order to determine the specificity of daf-2(e1370) on SOD1 toxicity we tested the 
effects of daf-2(e1370) on worms expressing TDP-43 in the nervous system (Psnb-1::hTDP-43) 
(Figure 1 C).  Like the mutant SOD1 expressing worms, transgenic expression of TDP-43 in the C. 
elegans nervous system causes locomotory defects and protein aggregation14.   In a comparison 
of swim speed of TDP-43 worms versus TDP-43;daf-2(e1370) worms, we found daf-2(e1370) 
improved TDP-43 induced swimming deficit (p<0.01 by t-test) . 
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Improvement of the G85R phenotype is dependent on decreased IIS in the nervous system. 
Figure 1. 
A) Videos of worms crawling on OP50 at the indicated 
times were taken and used to calculate worm speed 
using the parallel worm tracker software.  B) Average 
swim speed normalized to size was calculated at the 
indicated times using the parallel worm tracker. C) Swim 
speed normalized to size was calculated for TDP43 and 
TDP43;daf-2(e1370) worms 72hrs post egg drop. 
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daf-2(RNAi) has previously been described to mimic the longevity/healthspan promoting 
effects of the daf-2(e1370) hypomorphic allele and RNAi to daf-16 has been shown to abrogate 
the benefits of loss of function of daf-2 79.  We next compared locomotion of G85R worms fed 
daf-2, daf-16 or empty vector (EV) RNAi.  Unexpectedly, feeding neither daf-2 nor daf-16 RNAi 
to G85R worms had a significant effect on locomotion (Figure 2 D,E).  One possible explanation 
for these differences is the variable effectiveness of RNAi in the worm nervous system. 
The resistance of worm neurons to RNAi can be mitigated by transgenic over expression 
of SID-1 in the nervous system80.  SID-1 allows for passive cellular uptake of double stranded 
RNA, therefore increasing a cells response to RNAi.  SID-1 is not normally expressed in neurons, 
therefore one way to selectively increase the nervous systems response to RNAi is through 
transgenic expression of SID-1 in the nervous system of worms that are null for sid-1 in 
peripheral tissues.  In order to maximize the efficacy of RNAi in the nervous system of G85R 
worms we generated Psnb-1::G85R::YFP; sid-1(pk3321)[Punc119::sid-1];Pmyo-6::mcherry 
worms, hereafter referred to as G85R;sid-1.  G85R and G85R;sid-1 worms were fed G85R-YFP or 
empty vectro (EV) RNAi.  G85R;sid-1 worms fed G85R-YFP RNAi showed decrease YFP intensity 
in the nervous system and a significant (p<0.05 by t-test) increase in locomotory activity 
compared to G85R;sid-1 worms fed EV RNAi (Figure 2 A-B).  Feeding G85R worms G85R-YFP 
RNAi had no effect on fluorescence intensity or locomotory activity (Figure 2 A and data not 
shown).  These observations lead to two important conclusions 1) they confirm the increased 
efficacy of neuronal RNAi in the sid-1 nervous system expressing sid-1(pk3321)[Punc119::sid-
1];Pmyo-6::mcherry background and 2) demonstrate that the locomotory phenotype in these 
worms is likely to be due to mutant G85R SOD1 expression and not integration of the transgene 
into a critical locus.  
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To better understand the role of IIS in the nervous system on G85R toxicity we 
compared the following groups: RNAi to daf-2, daf-16 and EV fed to G85R and G85R;sid-1 
worms.  While G85R worms fed daf-2 RNAi showed no significant improvement in mobility 
compared to G85R worms fed EV, G85R;sid-1 worms fed daf-2 RNAi had significantly improved 
mobility compared to all other groups (ANOVA F(3,16)=13.66 p<0.01 and p<0.01 by Tukey’s post-
hoc) (Figure 2 E).  This disparity between the effects on G85R versus G85R;sid1 worms suggests 
the need for decreased IIS activity in the nervous system in this model to rescue locomotory 
activity.   
We also compared locomotion of G85R;daf-2(e1370) worms fed daf-16 RNAi or EV.  
Feeding G85R;daf-2(e1370) worms daf-16 RNAi abrogated a significant (p<.05 by t-test) amount 
of the daf-2(e1370) induced rescue of locomotory function as compared to feeding EV RNAi 
(figure 2 C).  It is interesting that the daf-16 (RNAi) appears to diminish daf-2(e1370) rescue on a 
non- Punc119::sid1;sid1(pk3321) background suggesting it is working outside of the nervous 
system.  This raises the possibility that although reduced IIS is required in the nervous system to 
rescue locomotory activity in this model, there are daf-16 dependent effects in non-nervous 
system tissues. 
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Figure 2. 
A) YFP signal was imaged in G85R or G85R;unc119p::sid1;sid1(pk3321) worms fed empty vector 
(EV) or G85R:YFP RNAi in order to demonstrate the efficacy of RNAi in neurons on the 
unc119p::sid1;sid1(pk3321) background B-E) Average speed normalized to size of swimming 
worms fed bacteria expressing the indicated RNAi  
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IIS activity modulates the solubility of SOD1 
 Aging in the worm is known to be a major modifier of generalized protein solubility and 
aggregation, and decreased daf-2 signaling has been found to decrease the amount of 
aggregation that occurs41.  Since aggregated SOD1 generally correlates with toxicity in ALS we 
wanted to determine if the daf-2(e1370) background was decreasing aggregation in  G85R 
worms.  Zhang et. al. demonstrated that the daf-2(e1370) background significantly reduces the 
steady state abundance of insoluble TDP-43 in the worms we assessed in our swimming assay 14.  
To determine if IIS was modifying the solubility of SOD1 in this model, soluble versus insoluble 
fractions were prepared from G85R, G85R;daf-2(e1370) and G85R;daf-2(e1370);daf-16(mgDf50) 
and immunoblotted for SOD1 and actin (figure 3A).  We found a significant amount of insoluble 
SOD1 in the G85R worms which was greatly diminished in the daf-2(e1370) background.  
Deletion of daf16 in the G85R;daf-2(e1370);daf-16(mgDf50) worms suppressed this effect.  
While the absolute values of soluble SOD1 were not constant between the three groups the 
ratio of insoluble to soluble SOD1 was significantly greater in the G85R;daf-2(e1370);daf-
16(mgDf50) and G85R worms as compared to G85R;daf-2(e1370) (figure 3B) (p<.05 by single 
factor ANOVA, F(2,6)=7.719 and p<0.05 for both comparisons by Tukey’s post-hoc).  This 
suggested that daf-2(e1370) improves the solubility of SOD1, leading to an increased steady-
state abundance of the soluble species.  These data were collected from a mixed population of 
animals so we were interested in further characterizing SOD1 abundance at various ages. 
Total SOD1 burden does not correlate with locomotor activity 
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While no differences in YFP intensity were evident by eye when observing the different 
worm strains, we wished to explore the total burden of SOD1 at various times more closely.  In 
order to do this we used the COPAS worm sorter to measure YFP intensity and time-of-flight 
(TOF, i.e., length)  in individual animals from a mixed population of approximately ten thousand 
worms from the following groups: G85R, G85R;daf-2(e1370) and G85R;daf-2(e1370);daf-
16(mgDf50) (figure 3C).  Using TOF as a proxy for age, we were unable to identify a direct 
correlation between total SOD1 burden and locomotory activity.  The data were binned into TOF 
measurements of 100 units and significant differences between groups were observed in all bins 
by ANOVA (0-100 TOF F(2,11369)=881.69, 101-200 TOF F(2,7209)=250.90, 201-300 TOF F(2,4880)=48.1, 
301-400 TOF F(2,3075)=243.23, 401-500 TOF F(2,1435)=411.05, 501-600 TOF F(2,708)=277.65).  In young 
worms( 0-200 TOF) SOD1 intensity was equivalent between G85R and G85R;daf-2(e1370) worms 
(no significant differences between groups by Scheffe’s post-hoc), yet significant locomotory 
differences were observed between these groups at all ages assessed using the swimming assay.  
Conversely, young G85R;daf-2(e1370);daf-16(mgDf50) worms have significantly less YFP 
intensity than G85R and G85R;daf-2(e1370) worms (p<0.05 by Scheffe’s post-hoc), yet they 
perform worse than G85R;daf-2(e1370) worms and equivalent to G85R worms in our 
locomotory assays.  Looking at older worms (300-600 TOF), G85R worms have a total SOD1 
burden that significantly exceeds that of G85R;daf-2(e1370);daf-16(mgDf50) worms (p<0.05 by 
Scheffe’s post-hoc in 301-400, 401-500 and 501-600 bins) yet they show similar locomotory 
activity in the swim test.  This is unlikely to simply be a floor-type effect as G85R;daf-16(mgDf50)  
worms perform worse in the swimming assay than both G85R and G85R;daf-2(e1370);daf-
16(mgDf50) worms, suggesting that there is room for decline in the locomotory phenotype.  
Taken together these results suggest that overall SOD1 burden is not responsible for the 
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locomotory differences observed between these groups, but rather suggest that the locomotory 
differences result from changes in how SOD1 toxicity is handled in these various backgrounds. 
 
Figure 3. 
A) Representative western blot from three experiments looking at soluble vs insoluble SOD1 B) 
Quantification of SOD1 insoluble : soluble ratio C) COPAS data showing average YFP intensity for 
bins of various worm TOF 
 
IIS effects on longevity in the SOD1 background 
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 The toxicity of mutant SOD1 expression in the C. elegans nervous system was previously 
reported to have a negative effect on lifespan72.  In order to determine whether decreased daf-2 
signaling in this background has a beneficial effect on lifespan, similar to its effect on 
locomotion,  longevity was monitored in WT SOD1, G85R;daf-2(e1370) and G85R;daf-
2(e1370);daf-16(mgDf50) worms (figure 4).  WT SOD1 and G85R;daf-2(e1370);daf-16(mgDf50) 
worms had similar lifespans, while the G85R;daf-2(e1370) worms had a modest but statistically 
significant increase in lifespan (p<0.05 by Mann-Whitney analysis).  Interestingly, there is no 
correlation between health and lifespan as assayed by locomotory activity. 
 
Figure 4. 
Longevity analysis, percent alive per day 
 
Discussion: 
 Aging is a common risk factor for many neurodegenerative diseases81.  The IIS pathway 
is a well characterized genetic modifier of aging in C. elegans 1 and we demonstrate here that 
alterations in this pathway can robustly modify the toxicity of mutant SOD1 as assessed by 
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mobility, protein aggregation and longevity.  We find that reduced daf-2 activity has a beneficial 
effect on the toxicity of G85R SOD1 and that this beneficial effect is daf-16 dependent.  While 
aging in the worm has previously been shown to be coordinated at the organismal level, we 
found a requirement for IIS to be reduced in the nervous system in order to modify SOD1 
toxicity.  Although the genetic modifiers of aging are less well characterized in humans, these 
data suggest that IIS and pathways which beneficially modify lifespan/healthspan in humans 
may be potential targets for therapeutic intervention in ALS. 
 Although their exact role in disease pathology is not entirely understood, aggregated 
proteins are associated with numerous neurodegenerative diseases, including ALS82,83.  As aging 
occurs, the total burden of aggregated proteins increases, suggesting a diminished capacity for 
proper folding and/or degradation of aggregation prone proteins with age 84.  In this study we 
demonstrate that a LOF mutation of daf-2 diminishes the amount of insoluble SOD1; an effect 
that might be due to an increased capacity for clearance/folding in these worms.  Similar 
observations have been made regarding the ability of modifications of IIS to modulate the 
solubility and toxicity of other disease related proteins 4,12,14.  This is likely due to the ability of 
decreased IIS to induce expression of chaperones such as the HSP family of proteins 16.  An RNAi 
screen performed on these worms identified chaperones as the most highly represented 
functional class of proteins found to negatively modify SOD1 aggregation in this model 72.  
Increased capacity for folding/clearance in worms with reduced IIS is likely to contribute to 
decreasing the toxcicity of mutant SOD1 in this model.  We can not rule out the contribution of 
other changes in metabolism, lipid biogenesis, and free radical scavenger expression which have 
also been linked to increased lifespan and stress resistance due to decreased IIS 11,77,78. 
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 Our data from the COPAS support both the concept that: 1) the daf-2(e1370) 
background can help reduce buildup of insoluble protein and 2) the ratio of soluble to insoluble 
G85R SOD1, rather than its total abundance, is associated with toxicity in this model.  Using TOF 
as an approximation for age, it appears that G85R worms accumulate less G85R SOD1 on the 
daf-2(e1370) as opposed to wild type background over time.  This suggests an increased 
capacity for clearance of SOD1 over time in the daf-2(e1370) background.  The abundance of 
SOD1 in G85R;daf-2(e1370);daf-16(mgDf50) worms is less than both G85R and G85R;daf-
2(e1370) in young animals yet their mobility is reduced compared to G85R;daf-2(e1370) and 
equivalent to G85R at all time points assessed.  Although the relative abundance of SOD1 varies 
between these strains over time, their relative locomotory activity remains constant, suggesting 
that it is not total SOD1 abundance that dictates toxicity. 
Previous work with a worm model of Aβ toxicity has demonstrated that the daf-
2(e1370) allele is protective against Aβ1-42 aggregates in two distinct ways.  First daf-2(e1370) led 
to activation of hsf-1 which resulted in breakdown of Aβ1-42 fibrils.  Second daf-2(e1370) led to 
activation of daf-16 which increased the abundance of Aβ1-42 in high molecular weight 
aggregates.   It is possible that both activities  diminish Aβ1-42 toxicity by removing Aβ1-42from the 
putatively toxic fibril pool15.  If these observations can be generalized, they could account for the 
lack of correlation between total SOD1 abundance and locomotory deficits in these worms.   
G85R;daf-2(e1370);daf-16(mgDf50) worms may not show the robust increase in SOD1 over time 
seen in the G85R worms because they are not accumulating the large aggregates of protein.  
These worms still suffer from SOD1 toxicity due to high levels of insoluble SOD1, but may never 
reach the same YFP intensity as G85R worms due to a lack of high molecular weight aggregation 
facilitated by daf-16.  Activation of hsf-1 in the G85R;daf-2(e1370);daf-16(mgDf50) worms may 
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also explain their increased mobility compared to G85R;daf-16(mgDf50) worms in the motility 
assay. 
Using worms with neuronal expression of SID1, we demonstrate that the beneficial 
effect of reduced daf-2 is likely to be mediated by decreased IIS signaling in the nervous system.  
This contrasts with its effects on longevity, where daf-2 RNAi (on a background lacking pk3321 
to enhance neuronal RNAi) mimics the lifespan extending effects of the daf-2(e1370) allele.  In 
this setting, daf-2 RNAi does not influence gene expression in the nervous system 17.  G85R;daf-
2(e1370) worms fed daf-16 RNAi should have normal levels of DAF-16 in their nervous system 
and it would be activated due to the daf-2(e1370) background.  If the beneficial effect of 
decreased daf-2 activity was completely mediated by the nervous system, then these worms 
should have comparable locomotory function to G85R;daf-2(e1370) worms fed empty vector.  
We find these worms to have an intermediate phenotype with a significant reduction in 
locomotory activity as compared to worms on empty vector RNAi plates.  This suggests that part 
of the beneficial effect of daf-2(e1370) might be mediated through non-neuronal tissue(s).  
Alternatively, daf-16(RNAi) may partially, although not completely, reduce daf-16 expression in 
both neuronal and non-neuronal cells.  Taken together, these findings suggest that although 
decreased IIS is required in the in the nervous system in order to have a beneficial effect on 
SOD1 toxicity, some of the downstream actions of reduced neuronal IIS may be functioning in 
the periphery. 
Our results demonstrate the strong capacity of the IIS pathway to modulate G85R 
proteotoxicity.  One possible mechanism of action for this beneficial effect is through the ability 
of this pathway to increase the cellular capacity to prevent toxic insoluble protein accumulation.  
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Interestingly this beneficial activity of IIS may not be completely cell autonomous but may be in 
part a manifestation of alterations in cellular aging coordinated at the organismal level.  This 
pathway may represent a possible therapeutic target for proteotoxic diseases cause by insoluble 
proteins. 
Materials and Methods: 
 Worm Strains and Handling:  C. elegans were cultured under standard conditions at 
20⁰C and fed the E. coli strain OP5085.  The following worm strains were used: daf-16(mgDf50) 
and daf-2(e1370) were obtained from the CGC.  Psnb-1::hTDP-43;Pmtl-2::GFP and daf-2(e1370); 
Psnb-1::hTDP-43;Pmtl-2::GFP  were a generous gift of Chris Link.  Psnb-1::G85R SOD1::YFP and 
Psnb-1::WT SOD1::YFP were a generous gift from Arthur Horwich and Jiou Wang.  
Punc119::sid1;sid1(pk3321) was a generous gift from Martin Chalfie.  Double and triple worms 
were generated by standard genetic crosses and verified by PCR or fluorescence expression.     
Locomotory Assay:  Video recordings of worms were made using the image acquisition 
tool in Matlab 2009b.  These videos were then analyzed using the parallel worm tracker 
software (downloaded from the Goodman lab http://wormsense.stanford.edu/tracker/).  For 
monitoring locomotion on OP50 a 1 minute video was recorded from each plate at the center of 
the lawn of OP50.  At 50 worms were analyzed for each genotype at each timepoint.  The 
number of worms was greater than 30 for each genotype at each timepoint.  For the swimming 
assay worms were suspended in a pool of M9 and their swimming was recorded for 30 seconds.  
At least 30 worms were analyzed per group per timepoint.  Statistics were performed using the 
average of each video as an n of 1 for speed or size/speed. 
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 Feeding RNAi:  HT115 bacteria containing the indicated genes in the L4440 vector were 
grown overnight at 37⁰C in 50ug/ml ampicillin.  They were then seeded on to NGM plates 
supplemented with 12.5ug/ml tetracycline and 4mM IPTG and allowed to grow overnight at 
room temperature.  Gravid adults were allowed to drop eggs on the RNAi plates for 2 hrs and 
were then removed.   Plates were then kept at 20⁰C until they were assayed.  
 Imaging:  Worms were immobilized in 25mM levamisole on agar pad slides and then 
coverslipped.  Images were acquired at a constant intensity on a confocal microscope using a 
40uM Zstack.  
 Soluble vs Insoluble Protein Assay:  Approximately 100ul of packed worms were lysed 
via sonication in 300ul RIPA buffer (150mM NaCl, 50mM Tris pH 8.0, 1mM EGTA, 5mM EDTA, 1% 
NP40, 0.5% Sodium Deoxycholate, 0.1% SDS) with complete protease inhibitor cocktail.  A soft 
spin of 800g for 5 min was performed to remove unlysed worms and large debris from the 
lysate.  The supernatant was then spun at 99,000 x g for 30min @ 4⁰C.  The supernatant was 
kept as the soluble fraction.  The pellet was sonicated again in RIPA as a wash step to ensure 
removal of all soluble protein.  It was centrifuged again at 99,000 x g for 30min @ 4⁰C.  The 
pellet was then solublized in 50ul urea buffer (40mM Tris, 7M urea, 2M thiourea, 1% CHAPS).  
Equal volumes of sample were run on SDS-page gels under reducing conditions and probed with 
anti SOD1 antibody (Cell Signaling #2770) and anti actin (Sigma).  Westerns were visualized using 
the Odyssey system and quantified using ImageJ. 
 COPAS:  COPAS was used to sort and collect fluorescence intensity from 10,000 worms 
from each group as described in 86. 
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 Longevity Assay:  An egg drop was performed on NGM plates with OP50.  The lifespan 
assay was carried out at 20⁰C and worms were transferred to fresh NGM OP50 plates as 
necessary in order to avoid starving the animals.  Each day worms were counted.  FUDR  was not 
included in this assay so during the active reproductive period of the worms they were 
transferred to a new plate each day. 
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Chapter 3 
The Small Molecule Psammaplysene A is Neuroprotective in 
Multiple Models of Motor Neuron Disease 
 
Adapted from:  
FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor 
neuron diseases. J Neurosci. 2009 Jun 24;29(25):8236-47.  For complete article see Appendix 2 
 
Abstract: 
 
Aging is a risk factor for the development of adult-onset neuro-degenerative diseases.  While 
some of the molecular pathways regulating longevity and stress resistance in lower organisms 
are defined (i.e., those activating the transcriptional regulators DAF-16 and HSF-1 in C. elegans), 
their relevance to mammals and disease susceptibility are unknown.  Although the mammalian 
ortholog of daf-16 has been implicated in regulating longevity in mammals varying effects have 
been reported regarding its ability to increase stress resistance and cell survival.  Using a 
compound (Psammaplysene A, PA) that increases nuclear localization of FOXO3 we demonstrate 
that PA protects against insults associated with motor neuron disease. 
Introduction: 
 
Although motor neuron diseases due to single gene mutations are unusual (~10% of 
cases), the affected genes have been successfully used to model these diseases in experimental 
systems 87.  Rare, genetic forms of motor neuron disease that arise from mutations in 
superoxide dismutase (SOD) or p150glued  have a disease phenotype that strongly resembles 
sporadic ALS with lower motor neuron predominance 88.  Another predominantly lower motor 
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neuron disease, called spinobulbar muscular atrophy (SBMA or Kennedy’s Disease) is due to a 
polyglutamine expansion in the androgen receptor 89.  Despite identification of the “disease 
protein”, the underlying pathogenic mechanism(s) remain incompletely understood. 
In most cases of sporadic ALS, motor neuron death is triggered by the interaction of a 
genetic pre-disposition and environmental factors 90.  Genome-wide association studies have 
failed to reveal consistent susceptibility loci 91,92.  Correlative evidence suggests that aging is a 
risk factor for the development of ALS as well as other adult-onset neurodegenerative disorders 
93.  Studies from a variety of experimental systems have provided insight into the genetic factors 
controlling aging, in particular, the insulin/insulin-like growth factor signaling pathway 94,95.  In 
Caenorhabditis elegans, hypomorphic alleles of the daf-2 gene (mammalian homolog, 
insulin/insulin-like growth factor receptor) and the downstream signaling molecule age-1 
(mammalian homolog, phosphotidylinositol-3’-kinase, PI3’K) promote longevity and lifespan 
extension.  These effects require the activity of the DAF-16 transcription factor (mammalian 
homolog, FOXO3a)96.   
 DAF-16/FOXO3a shuttles between the cytoplasm (where it is inactive) and the nucleus 
in a process that is controlled by its phosphorylation state 97.  Phosphorylation of DAF-
16/FOXO3a by the PI3’K substrate kinases Akt and SGK 98 leads to the 14-3-3 protein-dependent 
export of nuclear DAF-16/FOXO3a and re-entry into the nucleus requires dephosphorylation and 
release of 14-3-3 98,99.  Within the nucleus, DAF-16/FOXO3a leads to the expression of a number 
of genes that have context-dependent effects on cellular physiology.  Expression of a 
constitutively nuclear FOXO3a can promote the death of purified motor neurons and cerebellar 
granule cells and this has been linked to the expression of FasL 97,100.  In contrast, active FOXO3a 
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protects a variety of quiescent cells against death evoked by oxidative stress or glucose 
deprivation and this has been linked to the expression of manganese superoxide dismutase 
(MnSOD) and catalase 101,102.  Thymocyte survival and differentiation is FOXO3a-dependent 103.  
Differences in beneficial versus harmful effects of FOXO3a probably relate to cell-circumstance-
specific level of activation and post-translational modifications 104. (For a review of post-
translational modifications effecting the activity of FOXO transcription factors see Appendix 1) 
 Some of the stresses that contribute to motor neuron death in ALS include 
excitotoxicity, reactive oxygen species, accumulation of insoluble aggregates of neurofilaments, 
and defects in axonal transport 87,105-107. Since DAF-16/FOXO3a-dependent gene transcription, in 
some contexts, combats cellular stresses, we inquired whether manipulating FOXO3a nuclear 
abundance using the small molecule PA protected neurons from insults relevant to motor 
neuron diseases.  We show that PA is neuroprotective across phyla and that its neuroprotective 
qualities are likely due to enhancement of DAF-16/FOXO3a activity.  
 
Results: 
 
A chemical-genetic screen reported the identification of a series of compounds that can 
inhibit FOXO1a nuclear export.  Compounds fell into two classes: 1) inhibitors of general nuclear 
export machinery and 2) inhibitors specific to the FOXO1a pathway 108.  We inquired whether 
compounds in the second class would also block the nuclear export of FOXO3a since they would 
be predicted (based on the results above) to display neuro-protective activity.  We focused on 
Psammaplysene A (PA), which was isolated from a marine sponge, because it was the most 
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potent of the class 2 inhibitors (Figure 1A) 109.  In addition PA was reported to have no effect on 
AKT phosphorylation suggesting it acted either downstream of AKT or in a synergistic pathway. 
We began by looking at the effect of a synthetic sample of PA (for synthesis see 110) on 
the distribution of FOXO3a endogenously expressed by neurons.  We biochemically isolated 
nuclei from spinal cord cultures treated with PA or vehicle (Figure 1B).  Based on the distribution 
of the nuclear envelope protein lamin, it is clear that our subcellular fractionation procedure 
greatly enriched nuclei.  There was an ~ 2.5 fold increase in the nuclear FOXO3a/nuclear lamin 
ratio in the PA treated cultures in comparison to vehicle-treated cultures.  Total FOXO3a and 
lamin levels were unaffected by drug treatment.  These observations indicate that PA promotes 
the sequestration of FOXO3a into nuclei.   
We next tested the ability of PA to promote FOXO-dependent transcription.  HEK 293 
cells were transfected with a plasmid containing a minimal promoter containing 3x Fork Head 
Response Elements (3x FHRE) driving luciferase expression and then treated with various 
concentrations of PA or vehicle for 72 hours.  As a control for a non-specific action of PA on 
transcription, a parallel set of cells were transfected with the parent plasmid (pGL3) that lacked 
the 3x FHRE.  In all experiments, an internal control plasmid expressing Renilla luciferase was 
cotransfected and all results are expressed as the ratio Luciferase/Renilla fluorescence.  PA 
treatment led to a dose-dependent increase in luciferase signal in 3x FHRE, but not pGL3, -
expressing cells (Figure 1C).  As an added control for specificity we looked at the ability of PA to 
enhance transcription from a 3x retinoic acid response element (RARE) luciferase construct and 
found that PA had no effect on this promoter.  These results indicate that PA can promote FOXO 
transcriptional activity.   
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To determine if PA had neuroprotective activity, spinal cord cultures were treated with 
the drug (10 nM) for two days and then subjected to an excitotoxic challenge (Figure 1D).  The 
percent of KA-induced cell death was ~50 % in vehicle-treated cultures (65 ± 2 versus 35 ± 3 
vehicle versus KA, p < 0.01, Student’s t-test) and ~3 % in PA treated cultures (67 ± 3 versus 65 ± 2 
vehicle versus KA,  p < 0.6, Student’s t-test) indicating that PA protected motor neurons from 
excitotoxic challenge.  Next we looked at mutant AR proteotoxicity (Figure 1D). Significant 
differences between groups (F(2,6) = 18.84, by ANOVA)  were found in the three-way comparison 
of 1) No DHT, 2) DHT + vehicle, and 3) DHT + PA).  The post hoc analysis demonstrated a DHT-
dependent ~25 % loss of motor neurons in vehicle-treated cultures (p < 0.01) and 
neuroprotection in the PA treated cultures (P > 0.05 in the comparison of no DHT versus DHT + 
PA).  
 We followed up these observations by asking if PA blocked the proteotoxicity of SOD or 
p150glued.  Spinal cord cultures were infected with HSV engineered to express the WT or mutant 
forms of SOD or the WT or mutant forms of p150glued and received PA (or vehicle) every other 
day for 4 days.  The drug treatment had no effect on transgene expression (not shown).  After 4 
days, the cultures were fixed and motor neuron number was determined.  ANOVA revealed 
statistically significant differences between groups in LacZ versus WT SOD versus mutant SOD (± 
PA) comparisons (F(5,12) = 18.41, p < 0.001) as well as LacZ versus WT p150
glued versus mutant 
150glued (± PA)  comparisons (F(5,12) = 19.26, p < 0.001) (Figure 1E).  The post hoc analysis revealed 
that statistically significant protection against the toxicity of mutant SOD or p150glued was 
conferred by PA treatment on motor neuron survival.  PA had no adverse effect on survival of 
motor neurons expressing LacZ or wild type versions of SOD or p150glued.  Thus PA is non-toxic 
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on its own, but can protect against four different insults in vitro that are directly relevant to 
motor neuron diseases. 
 
In light of the neuroprotective effect of PA in vitro, we examined the effects of the drug 
in two in vivo model systems of neuronal degeneration. Expression of polyglutamine-expanded 
AR in the Drosophila eye leads to DHT-dependent degeneration 111,112.  We found that flies 
reared on food supplemented with 0.5 mM PA had a reduced degenerative phenotype when 
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compared with vehicle treated flies (Figure 2a, b). These in vivo results complement the 
observations made in spinal cord cultures from mice expressing polyglutamine-expanded AR 
wherein we found treatment with PA blunts DHT-dependent mutant AR toxicity. 
We next asked if the neuroprotective action of PA depended on FOXO.  To this end, we 
examined the efficacy of PA in flies that both expressed the polyglutamine expanded AR and 
were haploinsufficient for Drosophila Foxo (dFOXO) (Figure 2c, d).  In a dFOXO-deficient 
background (foxoBG01018 allele)113, PA lost its ability to protect against DHT-dependent 
degeneration.  To corroborate these observations, we studied two additional dFOXO loss-of-
function alleles (foxo21 and foxo25) and one predicted loss-of function allele (foxoC01841) 114,115.  As 
above, on all of these dFOXO-deficient backgrounds, PA lost its ability to protect against DHT-
dependent degeneration.  Using a quantitative rating score, we found that PA led to a 
statistically significant mitigation of polyglutamine-expanded AR degeneration but this was lost 
in the dFOXO haploinsufficient flies (Figure 2 bar graph).  Variation in the baseline (no PA 
provided) level of neurodegeneration phenotype among the studied fly lines is likely due to 
differences in the background genotype.  These observations indicate that PA confers protection 
against mutant AR proteotoxicity in a FOXO-dependent manner. 
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We developed a C. elegans model system of neurodegeneration by combining a null 
mutation in the glutamate transporter GLT-3 (∆glt-3) with a transgenic strain (nuIs5 - 116) in 
which the glr-1 promoter drives expression of an activated form of Gs (abbreviated Gs*) and 
GFP in glutamatergic neurons 117.  The ∆glt-3; nuIs5 double mutants exhibit necrotic neuron 
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death at all stages of postembryonic development, with the strongest effect seen in 
developmental stage L3.  PA had a dose-dependent neuroprotective effect at the L3 stage, with 
complete rescue from death using 10 nM PA (Figure 3A).  This concentration of PA had no 
adverse effect on WT nematodes. We asked if the effect of PA is mediated by changing the 
timing of neurodegeneration or by reducing it throughout development (Figure 3B).  To examine 
this, we studied the effect of PA on the ∆glt-3; nuIs5 double mutants as a function of larval stage 
and we found neuronal death was reduced in all developmental stages, with the strongest effect 
observed in the developmental stages most prone to excitotoxicity.  Neuron death was reduced 
in a statistically significant manner in larval stages L2 (3.4 ± 0.2 versus 2.5 ± 0.2 dying 
neurons/animals, n = 44 versus n = 49, vehicle versus PA, p = 0.006) and L3 (4.2 ± 0.2 versus 2.2 
± 0.1 dying neurons/animals, n = 63 versus n = 65, vehicle versus PA, p < 0.001) (Figure 3B).   
Finally, while we showed that PA leads to accumulation of FOXO3a in mammalian 
neuronal nuclei, we wished to determine if the same was true in C. elegans.  To this end, we 
studied nematodes in which a DAF-16::GFP fusion protein was expressed in body wall muscles.  
Addition of PA, but not vehicle, to the growth substrate led to nuclear localization of the fusion 
protein and quantification of the nucleus/cytoplasm ratio of DAF-16::GFP revealed a statistically 
significant effect of PA (1.46 ± 0.05 versus 3.44 ± 0.55, n = 36 versus n=27, vehicle versus PA, p < 
0.0001) (Figure 3C).  This result indicates that PA has an evolutionarily conserved capacity to 
promote nuclear localization of the DAF16/FOXO3a transcription factor and this is associated 
with resistance to necrotic neuron death.   
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 Many post-translational modifications of FOXO3 have previously been described that 
modify FOXO3’s activity and subcellular localization (see appendix 1).  In order to better 
understand how PA was influencing FOXO3 localization, we explored whether treatment with PA 
led to any significant changes in the activity level of some of the kinases known to phosphorylate 
FOXO3.  In addition we monitored the abundance of 14-3-3, the protein responsible to shuttling 
FOXO3 into the nucleus.  As seen in figure 4, no changes in phosphorylation of FOXO3 at Thr32 
or Ser253 were identified.  These residues play a key role in regulating FOXO3’s nuclear 
localization.  Similarly no changes were seen in AKT or MAPK activity.  Also no change in the 
abundance of 14-3-3 was observed.  These finding suggest that PA is acting in a previously 
undefined manner to regulate the nuclear localization of FOXO3a. 
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Figure 4. 
 
 
Discussion: 
 
 Biochemical pathways that regulate longevity in yeast, C. elegans, Drosophila 
melanogaster and mice also play a fundamental role in resistance to stresses such as UV 
radiation, oxidative conditions, heat shock and misfolded and aggregation-prone proteins 118.  
Two transcription factors, Heat-shock factor 1 and DAF-16/FOXO3a, are essential mediators of 
this longevity/stress resistance program in nematodes 4,119.  Here we show that treatment with 
PA enhances nuclear localization of FOXO3 and protects mammalian motor neurons in vitro 
from insults directly relevant to motor neuron diseases as well as abrogating neurodegeneration 
in two in vivo invertebrate model systems.  The broad neuroprotective action of PA suggests it 
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acts on a phylogenetically conserved, core stress resistance pathway, most likely the daf-
16/FOXO transcriptional pathway. 
Our results suggest that the neuroprotective actions of PA are mediated, at least in part, 
by FOXO3a/daf-16.  First, in both rat neuron cultures and C. elegans, application of PA promotes 
nuclear accumulation of FOXO3a or DAF-16.  Second, PA evokes a dose-dependent increase in 
FOXO-dependent transcription.  Third, PA-mediated protection against mutant AR-evoked 
degeneration is dFOXO-dependent.  Even without knowledge of the direct molecular target of 
PA, this evidence favors the view that PA acts, at least in part, in a FOXO3a transcription-
dependent manner.  
The onset of many neurodegenerative diseases in adulthood raises the possibility that 
the causes of aging are specific contributors to disease pathogenesis.  To the extent that this is 
true, applying our understanding of the molecular biology of longevity may lead to new types of 
therapy for neurodegenerative diseases.  The present work on FOXO3a is an example of how 
manipulation of a phylogenetically conserved, longevity-promoting signaling pathway can 
effectively block neurodegeneration.  This is particularly interesting in light of a recent 
population-based study of human longevity showing a strong association of FOXO3a and healthy 
aging 27.  Agents such as PA which enhance the activity of daf-16/FOXO transcription factors may 
therefore act to repress disease progression in a wide variety of neurodegenerative diseases.   
Materials and Methods: 
 
  Tissue Culture: Embryonic Sprague-dawley rat spinal cord neurons were grown on confluent 
monolayers of cortical astrocytes, as previously described 120.  The substratum was acid washed 
glass coverslips when imaging was performed and Primaria tissue culture plasticware (Falcon, 
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Becton-Dickinson) when biochemistry was performed.   Culture media consisted of astrocyte-
conditioned media supplemented with 10 ng/ml CNTF, BDNF, NT 4, CT 1 and GDNF and 50% of 
media was replaced with fresh media every 3 days. 
 Male SBMA mice transgenic for the prion protein promoter-driven androgen receptor 
cDNA containing an expanded (112) CAG repeat tract were mated with non-transgenic C57Bl/6 
female mice 121.  Dissociated, mixed spinal cord cultures obtained from 13.5-day embryos were 
grown for 3 weeks in conditioned medium (conditioned on normal mouse astrocytes) containing 
charcoal-stripped serum to remove hormones. At 3 weeks, motor neurons were well 
differentiated and distinguishable from other neurons, including sensory neurons, by size and 
morphology.  At this time, cultures were treated with indicated conditions for 7 days; cells were 
then fixed with 4% paraformaldehyde and immunostained using antibodies to neurofilament 
heavy chain (NF-H) (SMI32; Sternberger Monoclonal Inc.). Motor neurons were visualized using 
a Leica DMR fluorescence microscope, photographed, and analyzed using IP Labs software.  
Statistical analyses of results were carried out using Student's t-test (viral infections) or ANOVA 
(compound treatments; SigmaStat).  
Recombinant HSV: cDNAs were cloned into the PrpUC amplicon plasmid to generate 
recombinant HSV as previously described 122.  The titer of virus used in these studies was 
routinely 3-5 x 107 plaque-forming units/ml.  The sources of constructs were: Michael 
Greenberg, Harvard University (HA-tagged wild type and triple mutant human FOXO3a), David 
Borchelt, University of Florida (WT and G85R mutant SOD), Erika Holzbaur, University of 
Pennsylvania (WT and mutant p150glued) and Anne Brunet (3xFHRE-luciferase). 
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Excitotoxicity Assay:  After 14 days in vitro (DIV), culture media was removed (and saved) and 
cells were exposed to 100 µM kainic acid (KA) for 1 hour.  Subsequently they were washed three 
times in Locke’s buffer not containing KA, the original media was replaced and incubated for 
another 24 hours at 37 oC. in 5% CO2 before fixation in 4% paraformaldehyde.  Motor neurons 
were identified in mixed culture by immunostaining for nonphosphorylated neurofilaments and 
counting only labeled cells with cell body diameter of 25 µm or greater.  We have previously 
validated this method as a means of specifically recognizing motor neurons (Figure 1 in 123).  In 
experiments involving recombinant HSV, 1 µL of viral stock was added to 1mL of culture media 
24 hours or more prior to the next manipulation.  Tubes containing viruses were color coded so 
that the operator was blinded to the specific virus used. 
 
Quantification of motor neurons:  The # of immunostained cells were counted in 3 randomly 
selected fields/coverslip and the mean value obtained.  In each experiment 3+ independent 
coverslips were used per condition and the results presented were obtained for 4+ independent 
cultures and experiments. 
 
Immunocytochemistry:  Tissue culture cells were fixed in freshly prepared 4% paraformaldehyde 
in 0.1 M pH 7.4 phosphate buffer for 30 minutes prior to extensive washing in phosphate 
buffered saline.  Overnight incubation with primary antibody was performed at room 
temperature and after washing, coverslips were incubated with Alexafluor conjugated 
secondary antibody (2 – 4 hrs.).  When double labeling experiments were performed, species-
specific secondary antibodies with distinct emission spectra were employed.  Coverslips were 
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washed prior to mounting in PermaFluor (Thermo Electron Corporation) and viewing on an 
Olympus FV300 Fluoview laser confocal microscope.   
 
Western Blots and quantification:  Cultures were lysed in NP-40 lysis buffer (1% NP-40, 40 mM 
Tris pH = 7.4, 0.15 M NaCl, 10% glycerol, 0,1% SDS, 0.1% deoxycholate + protease inhibitors and 
phosphatase inhibitors), sonicated, particulate matter removed by centrifugation and subjected 
to PAGE-SDS prior to transfer to nitrocellose.  Equal amounts of protein (determined using BCA 
reagents from Pierce) were loaded in each lane.  After blocking in 5% milk in phosphate buffer 
saline, membranes were incubated in primary antibody overnight, washed, incubated with 
secondary antibody, washed and visualized to GE Healthcare (Buckinghamshire, U.K.) 
chemiluminescent substrate according to the manufacturers directions.  Densitometric analysis 
of films was obtained using TINA (Isotopenmegeräte, GmbH) from 4+ independent 
experiments, the results averaged and mean values ± S.E. formed the basis of the statistical 
comparisons.  Quantitative data on band intensity was expressed as the fold change in 
comparison with values of HSV-LacZ infected cultures.  The displayed western blot data are 
representative of the results obtained from at least 4 independent cultures.  In some 
experiments the LI-COR Odysseus system was used for visualizing and quantifying western blot 
bands.  Secondary antibodies were from LI-COR Biosciences (IR 800 or 680 goat anti-mouse IgG 
or anti-rabbit IgG).The source of primary antibodies was: (Calbiochem, Oncogene Research 
Products, rabbit anti- MnSOD (Stressgen Bioreagents, Victoria, British Columbia, Canada), rabbit 
anti- FKHRL1/FOXO3a and anti-phospho FKHRL1/FOXO3a (T32) (Upstate, Lake Placid, NY), anti-
phosphoFOXO3a (S253) (Abcam) and rabbit anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA).   
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Species-specific HRP-conjugated secondary antibodies were from Amersham  (GE Healthcare, 
Buckinghamshire, U.K.) and Alexa 488-conjugated anti rabbit secondary antibody from 
Molecular Probes, Invitrogen (Eugene, OR). 
 
Subcellular fractionation 
Nuclear protein lysate was prepared using Sigma N-Xtract Tm kit. Briefly, cells collected from 
one 60 mm dish were suspended in 150 ul hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM 
MgCl2, and 10 mM KCl). After incubating on ice for 10 minutes, 10% IGEPA CA-630 was added to 
final concentration of 0.6%. Vortexed vigorously for 10 seconds and centrifuged immediately at 
10,000-11,000g for 30 seconds. The supernatant is cyoplasmic fraction and the pellet is nuclear 
fraction. 
 
Luciferase reporter assay 
Human embryonic kidney 293 cells were grown to approximately 80% confluence and then 
transfected either 3x Fork Head Response Element Luciferase (FHRE), the parent vector lacking 
the FHREs (pGL3), or pGL3 vector containing 3x Retinoic Acid Response Element (RARE-
luciferase from Addgene).  In all cases, the Renilla luciferase reporter construct, driven by the 
thymidine kinase promoter (pRL-TK), was co-transfected as an internal control for transfection 
efficiency and cell death.  After 24 hrs the cells were trypsinized and replated into media 
containing the appropriate concentration of PA or vehicle.  After 48 hrs the cells were 
trypsinized again and replated into a 96 well plate in fresh media containing PA or vehicle (12 
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replicates per condition).  Twenty four hours later the plates were analyzed using the Dual-Glo 
Luciferase Assay System (Promega) on the Xenogen In Vitro Imaging System.  The ratio of 
Luciferase signal to Renilla signal for each well was calculated and the various treatment groups 
were compared to vehicle. 
Study of Drosophila 
Drosophila stocks were crossed on standard cornmeal agar media at 29°C. Food was 
supplemented with DHT (Steraloids) and Psammaplysene A once it had cooled to <50 °C, to final 
concentrations of 1 mM and 0.5 mM, respectively. Eye phenotypes of female flies of each 
condition were examined and blindly scored according to the criteria described with one scoring 
modification to increase sensitivity to differences in affected eye areas 111.   
Flies haploinsufficient for dFOXO were generated by mating GMR-GAL4, AR52Q flies to 
the following fly stock lines: foxoBG01018 (Bloomington stock 12530); foxo21, foxo25 114 and 
foxoc01841 (Exelixis, Harvard). 
 
Study of C. elegans 
The following C. elegans strains were obtained from the C. elegans Genetic Center 
(biosci.umn.edu/CGC) or constructed by us: ∆glt-3: ZB1096 glt-3(bz34) IV; nuIs5: KP742[glr-
1::gfp; glr-1::Gs(Q227L) V; lin-15(+)]; ∆glt-3; nuIs5: ZB1102 glt-3(bz34) IV; nuIs5 V. Pmyo-3:daf-
16::gfp Strain ZB2283 was produced by Jian Xue and Carolina Ibanez-Ventoso by making 
transgenic animals carrying an extra-chromosomal array containing Pmyo-3:daf-16:gfp. 
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For PA treatment, we soaked the diluted drug into standard NGM culture plates. We 
transferred freshly growing nematode cultures to these plates and allowed them to grow for 2 
days before assessing the effect.  To determine the ratio of nuclear vs. cytoplasmic DAF-16 levels 
we used a strain transgenic for Pmyo-3:daf-16::gfp, where the DAF-16::GFP reporter is expressed 
in body wall muscle cells. We compared the intensity of GFP labeling in the nucleus and adjacent 
cytoplasm using NIH-Image. We monitored the effect of PA or age-1 on nematode excitotoxicity 
by measuring the extent of neurodegeneration in ∆glt-3; nuIs5 animals ± PA or ± age-1 
mutation. We observed free-moving animals with an inverted scope under Nomarski DIC optics 
with no anesthetics. Swollen cells in the nerve-ring region were counted as head necrotic figures 
indicative of neurodegeneration. 
 
Statistics.  Pairwise comparisons employed two-tailed Students’s t-test and when three or more 
groups were compared we used Analysis of Variance (ANOVA) and post hoc analysis with 
significance set at p< 0.05. 
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The Neuroprotective Drug Psammaplysene A Binds the RNA 
Binding Protein HNRNPK 
Marco Boccitto, Nayoung Lee, Satoshi Sakamoto, Hiroshi Handa, John Clardy, Benoit Chabot,  
Steve Seeholzer, Robert Kalb 
Abstract:  We previously characterized the compound Psammaplysene A as having strong 
neuroprotective properties in a number of in vitro and in vivo models of neurodegeneration.  
Based on the physico-chemical properties of Psammaplysene A it is not considered to be drug-
like.  Therefore we attempted to identify the target of Psammaplysene A in order to determine 
its mechanism of action.  Two separate methods were used in parallel to purify the protein 
target of Psammaplysene A from cell lysates.  Mass spectrometry was employed to identify the 
Psammaplysene A target as the RNA binding protein HNRNPK.  We investigated the effects of 
Psammaplysene A on a number of HNRNPK regulated processes.  The most consistent 
observation is that treatment of cells with Psammaplysene A results in decreased abundance of 
rRNAs.  Coupled with prior work indicating HNRNPK can stabilize rRNAs, we suggest that the 
ability of Psammaplysene A to decrease rRNA abundance may represent its mechanism of 
neuroprotection. 
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Introduction: 
 
 Psammaplysene A (PA) is a marine sponge derivative which was originally described in a 
chemical screen to identify agents that promote FOXO1 nuclear localization in PTEN deficient 
cancer cells109,110.  We became interested in the potential neuroprotective qualities of PA based 
on the role of the FOXO transcription factors as phylogenetically conserved regulators of 
longevity81.  Increased activity of the C. elegans ortholog of FOXO, daf-16, is associated with 
lifespan extension ranging from 2-10 fold in worms, and polymorphisms in FOXO1 and FOXO3 
have been linked to longevity in human cohorts1,2,27,30.  Many long lived C. elegans mutants also 
exhibit increased stress resistance, including protection against reactive oxygen species, heat 
stress, and proteotoxicity11,13,14.  Age is also a major risk factor for numerous neurodegenerative 
diseases.  Based on these observations we investigated the potential of PA to act as a 
neuroprotective agent via activation of FOXO3.   Indeed, we found that PA protects against 
neuronal death in numerous in vitro and in vivo models of neurodegeneration124. 
 Unfortunately the physico-chemical properties of PA make it an unlikely candidate for 
further development as a therapeutic.  Testing in vitro and in small model organisms such as the 
worm and fly allows for the use of DMSO for drug solubalization and delivery.  This allows for 
the characterization of compounds which would otherwise be inactive if delivered orally.  Chris 
Lipnski and colleagues defined a set of four characteristics that suggest whether a molecule is 
“drug-like” based on its molecular weight (max 500 Da) , Log P (max 5), number of hydrogen 
bond donors (max 5) and number of hydrogen bond acceptors (max 10)125.  Each time a 
compound violates one of these criteria it is given a flag and the total number of flags are tallied 
giving a compound a score between 0 and 4.  Compounds with a score greater than 1 are 
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considered to be of marginal value for further development126.   PA receives a score of 2 for 
having a molecular weight of 769 Da and a Log P value of 6.57 suggesting it would be or 
marginal clinical relevance.  Owing to PA’s powerful neuroprotective qualities that we wanted to 
characterize its mechanism of action, with the hope that more drug-like compounds could be 
found that share the same activity as PA. 
 Using two parallel purification methods, we generated a list of PA target candidates that 
consisted almost exclusively of RNA binding proteins.  From this list we identified the target of 
PA as heterogeneous nuclear ribonucleoprotein K (HNRNPK) and confirmed saturable binding 
using surface plasmon resonance.  HNRNPK is a member of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family.  This family of proteins was historically identified for its ability 
to bind heterogeneous nuclear RNA produced by RNA polymerase II as part of the hnRNP 
complex127.  Although originally described as part of the hnRNP complex, it is now appreciated 
that HNRNPK is present in the cytoplasm and mitochondria, as well as the nucleus.  HNRNPK 
participates in a wide variety of cellular functions including transcriptional control, translational 
control, RNA transport, splicing, chromatin remodeling and RNA stability128.  HNRNPK contains 
three RNA binding motifs and exhibits robust binding to poly-C regions129.  In addition to its 
ability to interact with RNA, HNRNPK interacts with a very large number of proteins and can 
receive numerous posttranslational modifications.  More than 100 HNRNPK binding partners 
have been characterized residing in the cytoplasm, nucleus and mitochondria51.  Many of these 
interactions are thought to be mediated through the K protein interactive (KI) domain, which is 
a highly unstructured region within the protein thought to allow for a great diversity of binding 
partners.  HNRNPK is also the target of numerous posttranslational modifications including 
phosphorylation and methylation which act to integrate numerous signaling pathways130-132.  
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Taken together these characteristics make HNRNPK an excellent platform for integrating protein 
based signaling cascades with the regulation of DNA/RNA based processes, making it an 
intriguing target for a neuroprotective compound. 
Results:   
 
HNRNPK is a target of Psammaplysene A based on two parallel target purification strategies: 
 In order to characterize the mechanism of action of PA, we attempted to purify its 
target from cell lysates.  Two separate but complementary approaches were used to purify the 
target of PA.  The first approach involved a modified version of PA that allowed tagging with a 
biotin moiety or fluorescent probe. The second approach involved covalently linking PA to 
magnetic nanobeads using a flexible linker sequence. 
 Four different PA derivatives were generated (supplemental figure 1).  We wanted to 
verify that the modifications made to PA did not alter its activity so we compared the activity of 
the four PA derivatives to PA in a forkhead response element (FHRE) luciferase assay(figure 1 A).  
We had previously characterized PA as significantly increasing FHRE luciferase activity with a 
72hr treatment124.  We found that PA as well as all four PA derivatives elicited an increase in 
FHRE activity upon 72hr treatment compared to vehicle.   Single factor ANOVA showed a 
significant effect of treatment on FHRE luciferase activity.  Post hoc analysis showed vehicle 
treated cells to have significantly less FHRE activity compared to all other groups (Vehcile vs : 
PA, 1A, 1B, 2A, 2B F(5,22)=2.76, F(5,22)=5.8, F(5,22)=3.81, F(5,22)=2.64, F(5,22)=3.17 respectively.  p<0.05 
when comparing vehicle versus all drug treated groups by Sheffe’s post hoc).  Our original 
characterization of PA suggested that its neuroprotective properties were tied to its ability to 
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influence FOXO activity.  Since the derivative compounds retained the ability to alter FOXO 
activity we presumed that they were still capable of binding the target of PA.  The 
photoactivatable crosslinker and azide groups on compound 2B provided a versatile platform to 
work with therefore we conducted all derivative based purification assays with compound 2B. 
 We determined that 2B was binding to a discrete target and that it could be displaced 
from that target using an excess of PA.  We incubated HEK293 cell lysate and C. elegans lysate 
with 2B, 2B + 100x PA, or no drug.  After a one hour incubation we UV illuminated the lysates to 
crosslink 2B to its target and then used click chemistry to label 2B containing complexes with 
carboxytetramethylrhodamine (TAMRA).  After labeling the proteins were dissolved in loading 
buffer and resolved by SDS-PAGE .  TAMRA labeled proteins were then visualized using in gel 
fluorescence scanning (figure 1 B).  Three specific bands were identified in HEK293 lysates and 
two specific bands were identified in C. elegans lysates.  Next, in order to identify the proteins in 
the HEK293 lysate, we incubated 2B with lysate, UV crosslinked and then used click chemistry to 
attach a biotin to crosslinked target-2B complexes.  We then purified target-2B-biotin complexes 
using magnetic avidin beads.  The purified proteins were digested off of the avidin beads and 
analyzed by LC MS/MS.  We identified 37 candidate targets via this approach (figure 1 D and 
supplemental table 1). 
 As a second parallel approach we covalently coupled a PA derivative to feriteglycidyl 
methacrylate (FG) nano-beads.  These beads are particularly well suited for this type of analysis 
because their small size and uniform structure creates a large surface area for small molecule 
presentation while minimizing non-specific interactions133.  FG beads were coupled to PA at two 
different concentrations of PA, 1X and 5X.  We incubated HEK293 lysates with uncoupled FG 
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beads, 1X PA coupled FG beads and 5X PA coupled FG beads.  Beads were washed, and then 
boiled in loading buffer to elute the associated proteins.  Eluted proteins were run on a SDS-
PAGE gel and visualized via coomassie brilliant blue staining (figure 1 C).  We attempted to 
identify bona fide PA interacting proteins by looking for bands whose abundance increased in a 
dose-dependent manner.  We were able to clearly identify two bands whose intensity was 
strongly dose dependent (black *’s figure 1 C).  These bands were also of roughly equivalent 
molecular weight to two of the bands identified by the 2B approach.  These bands were excised 
and submitted to LC MS/MS.  One additional band was excised (red * figure 1 C) based on its 
molecular weight, as it roughly matched the molecular weight of the largest binding partner 
identified by the 2B approach.  Since the PA-FG beads were not covalently linked to their target 
in this approach we were unable to wash as stringently as in the 2B approach.  Subsequently we 
identified 175 proteins in the three bands that were excised (figure 1 D and supplemental table 
1). 
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Figure 1. 
 
Figure 1. A) Normalized luciferase signal from Forkhead Response Element (FHRE) Luciferase after treatment with PA or PA 
derivative compounds.  All PA derivatives retain the ability to induce FHRE activity. B) Identification of discrete protein targets of PA 
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by 2B labeling (HEK lysates and C. elegans lysates) and C) pull down with PA-FG beads (HEK lysates).  D) Representation of PA 
candidate list identified by two parallel approaches. 
 Based on our two parallel approaches we generated a list of 207 candidate targets of 
PA, with five proteins identified by both approaches.  Although an overlap of five proteins was 
significantly less than we had expected, there were functional similarities in the proteins 
purified by the two approaches.  A bioinformatics analysis of the purified proteins indicated that 
both approaches identified proteins which were highly enriched for RNA processing (i.e. 
stability, splicing, metabolism, posttranscriptional gene expression) (Table 1).  This also 
potentially helped explain the large number of proteins that we purified.  While the FG beads 
are designed to have very few non-specific interactions, if the target of PA is a member of a 
large ribonucleo protein (RNP) complex we may have pulled down a macromolecular complex of 
proteins interacting with the specific target of PA. 
Table 1. 
Gene Ontology for 2B Purified 
Proteins 
    
Gene Ontology Term Count % PValue 
Fold 
Enrichment FDR 
GO:0008380~RNA splicing 14 13.9 
1.73E-
12 15.51 
2.34E-
09 
GO:0016071~mRNA metabolic process 15 14.9 
2.71E-
12 12.75 
3.66E-
09 
GO:0006397~mRNA processing 13 12.9 
1.52E-
10 12.74 
2.05E-
07 
GO:0006396~RNA processing 15 14.9 
4.92E-
10 8.63 
6.65E-
07 
GO:0000375~RNA splicing, via 
transesterification reactions 10 9.9 
7.75E-
10 20.56 
1.05E-
06 
GO:0000398~nuclear mRNA splicing, via 
spliceosome 10 9.9 
7.75E-
10 20.56 
1.05E-
06 
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GO:0000377~RNA splicing, via 
transesterification reactions with bulged 
adenosine as nucleophile 10 9.9 
7.75E-
10 20.56 
1.05E-
06 
      Gene Ontology for PA-FG Purified 
Proteins 
   
Gene Ontology Term Count % PValue Fold Enrichment FDR 
GO:0006396~RNA processing 44 23.7 1.26E-25 7.35 
1.99E-
22 
GO:0016071~mRNA metabolic 
process 37 19.9 1.56E-24 9.14 
2.47E-
21 
GO:0006397~mRNA 
processing 34 18.3 3.03E-23 9.68 
4.79E-
20 
GO:0008380~RNA splicing 32 17.2 1.25E-22 10.30 
1.97E-
19 
GO:0000375~RNA splicing, via 
transesterification reactions 22 11.8 1.31E-17 13.14 
2.08E-
14 
GO:0000377~RNA splicing, via 
transesterification reactions 
with bulged adenosine as 
nucleophile 22 11.8 1.31E-17 13.14 
2.08E-
14 
GO:0000398~nuclear mRNA 
splicing, via spliceosome 22 11.8 1.31E-17 13.14 
2.08E-
14 
GO:0043489~RNA stabilization 6 3.2 3.89E-07 36.56 
6.16E-
04 
GO:0048255~mRNA 
stabilization 6 3.2 3.89E-07 36.56 
6.16E-
04 
GO:0010608~posttranscriptio
nal regulation of gene 
expression 14 7.5 4.96E-07 6.06 
7.84E-
04 
GO:0043488~regulation of 
mRNA stability 6 3.2 3.21E-06 24.93 
5.08E-
03 
GO:0043487~regulation of 
RNA stability 6 3.2 5.09E-06 22.85 
8.05E-
03 
   
We began screening candidates from our list with a specific focus on the overlapping 
proteins.  Due to the large number of candidates, we adopted a multi-pronged approach to 
identifying the PA target.  To screen candidates we obtained plasmids for recombinant 
expression, over expression or knockdown of candidate proteins and then screened lysates 
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using the 2B TAMRA coupling assay.  We screened 14 targets by this method (supplemental 
table 2) before identifying a positive hit.  In a bacterial expression system, induction of HNRNPK 
expression with Isopropyl β-D-1 thiogalactopyranoside (IPTG) yielded a strong band which is not 
present in un-induced lysates (figure 2 A).  This band has approximately the same molecular 
weight as the smallest band identified in HEK293 lysates.   
The target purification with 2B and PA-FG beads had suggested some other 
characteristics of the target of PA which HNRNPK fit.  HNRNPK is an RNA binding protein known 
to be involved in numerous aspects of RNA processing, including translation, mRNA stability, and 
splicing.  This makes HNRNPK a good fit for the types of processes that we suspect PA is involved 
in based on our bioinformatics analysis of candidate proteins.  Secondly HNRNPK is thought to 
be a “hub” protein, interacting with numerous protein partners and acting to integrate various 
signaling cascades.  HNRNPK is known to have over 100 interacting proteins51.  This is thought to 
be facilitated by its highly unstructured KI domain.  This breadth of protein-protein interactions 
might help explain the high number of candidates identified by our purification methods.  An 
analysis of the literature suggested that of the 37 proteins identified by 2B purification followed 
by on bead digest 12 were previously described as HNRNPK binding partners. 
Characterization of the PA interaction with HNRNPK by Surface Plasmon Resonance 
 In order to better characterize the interaction between PA and HNRNPK we attempted 
to demonstrate specificity and characterize the Kd of PA binding to HNRNPK by surface plasmon 
resonance.  We began by comparing PA binding to GST-HNRNPK versus GST.  We were unable to 
identify saturable binding in this paradigm (figure 2 B), indicative of a non-specific interaction.  
We speculated that because HNRNPK participates in such a wide variety of protein, RNA and 
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DNA binding events, many aspects of its native structure may not be recapitulated during 
recombinant expression and purification.  This may be particularly true of domains like KI which 
are thought to derive their 3D structure from partner binding51.  Without these secondary 
structural features, a non-specific interaction may be occurring between PA and HNRNPK.  
Although it would be impractical to try and introduce all of the potential HNRNPK interacting 
proteins into the system to see if they allowed for specific PA binding to HNRNPK, it was feasible 
to introduce RNA.   
We began by observing whether RNA could be stably bound to HNRNPK.  We applied 
whole cell RNA extracts over the GST-HNRNPK and GST surfaces and found a saturable and 
stable binding of RNA to GST-HNRNPK but not GST alone (data not shown).  We then repeated 
the PA binding experiment and were now able to generate a saturable binding curve (figure 2 C).  
In addition to the interaction now being saturable, concentrations of 50, 100 and 150uM PA 
elicited a significantly higher response when HNRNPK was pre-bound with RNA.  This suggested 
that the structure of HNRNPK was modified by RNA binding in such a way that its affinity for PA 
was increased.   
In order to control for the possibility that PA was interacting with RNA rather than RNA 
bound HNRNPK, and to further demonstrate specificity of PA for HNRNPK, we used a second 
RNA binding protein as a control.  We compared PA binding to GST-HNRNPK versus GST-HNRNPI 
(PTBP1).  We considered HNRNPI to be a good control based on the fact that it binds pyrimidine 
rich tracts.  HNRNPK binds cytosine rich domains so there is potentially some overlap in the 
RNAs that the two proteins will bind.  In this paradigm we were again able to show specific, 
saturable binding of PA to HNRNPK after saturating both proteins with RNA (figure 2 D).  From 
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these measurements we were able to generate a binding curve and estimate the Kd of PA for 
HNRNPK at 166 uM.  Based on our work with 2B, we suspect that this Kd is not truly indicative of 
PA binding to HNRNPK in vivo.  We are able to visualize PA interactions with HNRNPK in bacterial 
lysates with concentrations as low as 100 nM and PA binding appears saturated at 5 uM in 
HEK293 lysates (data not shown).  This discrepancy may be due to the absence of HNRNPK 
binding partners or lack of post-translational modifications to the GST-HNRNPK used in the 
surface plasmon resonance system.  Never the less these data support a specific interaction of 
PA with HNRNPK. 
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Figure 2. 
 
Figure 2.  A) 2B binding and TAMRA visualization of PA binding to HNRNPK in induced and un-induced bacteria expressing an IPTG 
inducible HNRNPK construct.  B) Surface plasmon resonance analysis of PA binding to HNRNPK. 
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PA Increases the Abundance of a Disulfide Linked HNRNPK Complex 
 As a first step in characterizing the mechanism of action of PA we began by monitoring 
any changes in HNRNPK abundance after PA treatment.  We were unable to identify any 
changes in the total abundance of HNRNPK or its nuclear versus cytoplasmic localization after 
PA treatment (figure 3 C).  Interestingly, on non-reducing western blots, we found a high 
molecular weight species using anti-HNRNPK antibodies which was lost under reducing 
conditions (figure 3 A).  The abundance of this complex did appear to be PA responsive (figure 3 
B).  In order to better characterize the composition of this putative HNRNPK containing complex 
we immunoprecipitated HNRNPK, then resolved it by SDS PAGE and stained with coomassie 
brilliant blue under reducing and non-reducing conditions.  Using this approach, we were able to 
visualize the high molecular weight complex under non-reducing conditions and excise the 
complex as well as the corresponding area in the reduced lane and analyze them by LC MS/MS.  
Based on semi-quantitative analysis, the complex appeared to be made up of HNRNPK, DDX17, 
and Lamin B1 (supplemental table 2).  The combined molecular weight of these three proteins is 
consistent with the molecular weight of the non-reduced HNRNPK complex.  
Immunoprecipitation of HNRNPK from HEK293 lysates confirmed a strong interaction between 
HNRNPK and DDX17 as well as Lamin B1 (figure 3 D).  While PA appears to increase the 
abundance of this high molecular weight HNRNPK containing complex, it is unclear what role 
this complex plays in normal cellular function or what the functional consequences of increasing 
the abundance of this complex are. 
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Figure 3. 
 
Figure 3. A) Detection of a high molecular weight HNRNPK containing complex in non-reducing cell lysates B) PA treatment increases 
the abundance of this high molecular weight HNRNPK containing complex in a dose-dependent manner. C)  PA treatment does not 
alter total abundance or subcellular distribution of HNRNPK. D)  HNRNPK co-immunoprecipitates with DDX17 and Lamin B1 
PA Has No Effect on Numerous Functions of HNRNPK Biology 
 HNRNPK plays a role in a multitude of biological processes.  We attempted to focus our 
investigation on PA induced changes in HNRNPK biology based on the knowledge that PA is 
neuroprotective, and the observation that PA seems to increase the abundance of an HNRNPK-
DDX17-LaminB1 disulfide linked complex.   
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HNRNPK is known to act on κB enhancer elements and affect their transcriptional 
activities134.  Abnormalities in NF-κB signaling have recently been implicated in forms of 
inherited ALS135,136 so we wanted to determine whether PA might be modifying NF-κB signaling.  
We used two separate NF-κB luciferase constructs to monitor possible interactions between PA 
treatment and NF-κB signaling.  We monitored normalized luciferase activity in PA and vehicle 
treated cells in an IL-1 stimulated and un-stimulated state (figure 4 A).  PA did not have a 
significant effect on either basal or stimulated NF-κB activity. 
HNRNPK is known to play an important role in p53 induced apoptosis54.  Under 
conditions of p53 activation there is an increase in the abundance of the long intergenic non-
coding (LINC) p21.  LINCp21 then interacts with HNRNPK and facilitates the repression of 
numerous pro-survival genes, thus facilitating cell death55.  We hypothesized that PA could 
disrupt this interaction and thereby increase cell survival.  To test this, we generated 
biotinylated LINCp21 in vitro.  Cells were treated with various doses of PA, lysed and then 
incubated with biotinylated LINCp21.  Biotinylated LINCp21 was purified with avidin beads and 
then boiled in loading buffer to release associated proteins.  We were able to clearly identify 
HNRNPK by western blot.  All three HNRNPK bands were observed under non-reducing 
conditions, but there abundance was not influenced by PA treatment (figure 4 B). 
DDX17 is part of the DROSHA microprocessor complex137.  Based on our observation 
that PA appears to increase the interaction between HNRNPK and DDX17, we wanted to know 
whether PA was modifying miRNA biogenesis.  Interestingly other components of the 
microprocessor were identified in our PA target purification including: DROSHA, DDX1, DDX3X, 
DDX5, DHX15, HNRNPH1, HNRNU-like1 and FUS.  The DROSHA microprocessor complex cleaves 
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pri-miRNAs into pre-miRNAs which are then exported into the cytoplasm and undergo a final 
cleavage step to become mature miRNAS138.  As important regulators of gene expression, any 
changes in miRNA abundance due to association/dissociation of HNRNPK with DDX17 as part of 
the microprocessor complex could be an important function of PA.  In order to explore this 
possibility, cells were transfected with flag-DROSHA and treated with PA or vehicle.  Cells were 
then lysed and immunoprecipitated for flag tag to assess the abundance of HNRNPK and DDX17 
associated with the microprocessor complex.  No changes in the abundance of co-precipitated 
HNRNPK or DDX17 with DROSHA were detected after treatment with PA (figure 4 C). 
Both HNRNPK and DDX17 are known to be involved in alternative splicing.  Venables et. 
al. previously described an assay for monitoring multiple alternative splicing events of genes 
involved in apoptosis and found a broad effect of HNRNPK knockdown which they were able to 
replicate in multiple cell lines62.  We used this assay to monitor alternative splicing events under 
6 conditions: 1) mock transfected with HNRNPK, 2) over expressing HNRNPK, 3) treated with PA, 
4) treated with vehicle, 5) HNRNPK knockdown, or 6) HNRNPK knockdown with PA trearment.  
While we identified splicing events which were influenced by HNRNPK knock down or 
overexpression, PA treatment did not result in significant changes in any alternative splicing 
events (figure 4 D for representative examples, see supplemental figure 2 for heatmap of entire 
dataset).  This suggested that PA  was not acting to modulate alternative splicing. 
While none of these assays is a definitive proof that the neuroprotective activity of PA is 
not mediated by one of these processes, we found the lack of a robust effect in any of these 
assays sufficiently compelling to suggest that the neuroprotective properties of PA are operating 
through a different mechanism. 
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Figure 4. 
 
Figure 4. A) PA does not alter NFκB signaling. B) PA does not alter the association between HNRNPK and Linc p21. C) PA treatment 
does not alter the abundance of DDX17 or HNRNPK associated with DROSHA.  D)  PA treatment does not alter alternative splicing. 
PA treatment decreases rRNA Abundance 
 A recent study in Xenopus laevis by Liu et. al. used a RIP-Chip approach to characterize 
RNA targets of HNRNPK in the developing Xenopus brain56.  They identified numerous neuron 
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specific cytoskeletal components important for axonogenesis that interact with HNRNPK.  In 
order to analyze whether PA was changing the abundance or distribution of any of these 
transcripts we treated cortical cultures with PA and then performed qPCR to monitor message 
abundance.  We analyzed our data using the ∆∆CT method for relative quantitation and found 
that when normalizing to 5.8s rRNA all other messages appeared to increase, while when 
normalizing to beta actin or GAPDH we found no change.  This led us to suspect that there may 
be alterations in the abundance of rRNAs upon treatment with PA.   
HNRNPK was recently described as playing an important role in stabilizing rRNAs against 
stress dependent degradation60.   Another potential link between PA and rRNA abundance lies in 
the fact that the DEAD box RNA helicases are the largest family of rRNA processing proteins and 
DDX17 has been characterized as playing a role in rRNA biogenesis.  We investigated this further 
by analyzing the abundance of 28s, 18s, 5.8s and 5s rRNAs in both cortical cultures and HEK293 
cells after PA treatment (figure 5A).  Interestingly we found a statistically significant interaction 
between message and PA treatment by two way ANOVA in both groups (p<0.01 in both groups), 
with a specific reduction in the 5.8s and 5s rRNAs in both cortical neurons and HEK293 cells after 
PA treatment (F(5,6)=7.93 and F(5,6)=11.08 in HEK cells and F(7,6)=7.02 and F(7,6)=6.15 in CT neurons 
respectively by Tukey’s post hoc).  We did not detect a significant difference in RNA levels of 
HNRNPK targets identified by Liu et. al. in cortical neurons, or in beta or gamma actin in HEK293 
cells.  Wen et al specifically describe a role for HNRNPK in protection of rRNAs after stress.  In 
order to determine if HNRNPK has an effect on rRNA levels in unstressed cells we transfected 
HEK cells with GFP or GFP tagged HNRNPK and assessed rRNA levels 48 hours post transfection 
(figure 5B).  We found that overexpression of HNRNPK significantly increased the abundance of 
the 5.8s and 5s rRNAs, the same rRNAs which were negatively regulated by PA in both HEK cells 
72 
 
and cortical neurons (Two way ANOVA shows significant interaction of HNRNPK overexpression 
on rRNA abundance, p<0.01 and F(3,4)=10.57 and F(3,4)=4.06 respectively by Tukey’s post hoc).  
This leads to the hypothesis that PA acts to inhibit HNRNPK dependent promotion of rRNA 
stability. 
 
PA Treatment does not Alter Global Levels of Translation 
Reductions in translation through knockdown of ribosomal proteins, rRNA processing 
proteins or changes in the abundance of ribosomal subunits have all been linked to lifespan 
extension in worms, and yeast139-141.  This suggested that the neuroprotective properties of PA 
could potentially be mediated through its capacity to decrease rRNA abundance by inhibiting 
HNRNPK dependent stabilization of rRNA, potentially leading to decreased translation. We 
wanted to determine if changes in rRNA abundance that occur after PA treatment were 
affecting the abundance of ribosomes and/or levels of global translation.  First we generated 
polysome profiles from cells treated with PA or vehicle (figure 5 D).  An overlay of representative 
polysome profiles from PA and vehicle treated cells is shown as well as the quantification of six 
PA treated and six vehicle treated profiles.  No significant changes were observed in the 
polysome profiles after treatment with PA.  Overall abundance of monomeric 40s and 60s 
ribosomal subunits was unchanged, as was the abundance of the 80s dimer.  No change in the 
abundance of polysomes was observed.   
To confirm whether our polysome observations were of functional significance, we 
monitored global protein translation after PA treatment using [35S]-methionine with 
cyclohexamide treated cells as a positive control.  No changes in global protein synthesis were 
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observed after PA treatment (Figure 5 C).  It is possible that modulation of rRNA abundance by 
PA results in changes that are subtle and below the sensitivity of this assay.   
 
Figure 5. 
 
Figure 5. A) PA treatment reduces 5s and 5.8s rRNA abundance in HEK293 cells as well as cortical neurons. B) Overexpression of 
HNRNPK increases 5s and 5.8s rRNA abundance in HEK293 cells.  C) PA treatment does not decrease rate of total translation.  D) PA 
treatment does not alter the cellular polysome profile. 
PA Increases 5.8s rRNA Abundance in Stressed Cells 
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 While the majority of our screening for an effect of PA on HNRNPK activity was 
undertaken in HEK293 cells, our previous characterization of PA’s neuroprotective action was 
characterized in mixed spinal cord cultures under conditions of stress associated with motor 
neuron disease.  Now that we had characterized an alteration in rRNA abundance in HEK293 
cells we wanted to explore PA’s activities on rRNA abundance in mixed spinal cord cultures 
under conditions of stress.  To do this we infected cultures overnight with HSV- LacZ, WT SOD1, 
and MutSOD1.  The next day cultures were treated with 250nM PA for 24 hours and then total 
rRNA was collected and analyzed by qPCR for the abundance of 5.8s rRNA.  We found that when 
culutures expressed an innocuous gene such as LacZ, PA had no effect on rRNA abundance after 
24 hours, similar to what we had previously seen at 24 hours in HEK293 cells (Figure 6A and data 
not shown).  Interestingly, expression of wild type SOD1, which is mildly stressful to motor 
neurons, elicited a significant increase in the abundance of 5.8s rRNA; treatment with PA 
significantly further increased the abundance of 5.8s rRNA (figure 6A).  Expression of mutant 
SOD1, a very stressful insult, led to even greater 5.8s rRNA expression which was again 
significantly enhanced by PA (figure 6A).  This effect appears to be specific to rRNA and most 
robust in the 5.8s rRNA (figure 6B). 
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Discussion: 
 
 Using two parallel purification methods to identify candidate targets of PA followed by a 
secondary screen for direct interaction, we identified HNRNPK as a likely direct physical target of 
the neuroprotective compound PA.  Follow up analysis of this interaction by surface plasmon 
resonance confirmed saturable binding of PA to HNRNPK and suggested that the interaction is 
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likely to be dependent on HNRNPK binding to RNA.  Our original characterization of PA as being 
neuroprotective focused heavily on models of motor neuron disease, including ALS.  The 
identification of FUS, TDP-43, and a hexa-nucleotide repeat expansion in the first intron of 
C9orf72 as causative gene mutations in ALS has put a recent focus on potential dysregulation of 
RNA processing as a mechanism of toxicity37,39,49.  For this reason, we were particularly intrigued 
by the fact that HNRPK is an RNA binding protein involved in many aspects of RNA metabolism.   
 Interestingly, we find that treatment of cells with PA leaves many HNRNPK dependent 
processes unaffected, suggesting a high level of specificity in PA’s activity.  We do find a 
significant effect of PA on the ability of HNRNPK to influence the abundance of specific rRNAs.  
Although our analysis of total translation and polysome profiles did not show any significant 
differences in PA treated cells; it is possible that while no overt changes in translation are 
detectable, the cell is able to sense reduced rRNA levels and initiates a prosurvival response 
accordingly.  Work by Li and Gu suggests that this could be the case.  They find that RNAi 
knockdown of 5s rRNA in U2OS cells has no overt effect on translation or the generation of the 
large ribosomal subunit.  They do observe a decrease in 5s rRNA associated with Mdmx and a 
subsequent decrease in Mdmx abundance.  Mdmx is a negative regulator of p53 transcriptional 
activity and they find that knockdown of 5s rRNA leads to increased expression of p53 targets 
such as p21142.  These observations as well as previous studies showing that 5.8s rRNA is 
covalently linked to p53 suggest that the rRNAs form non-ribosomal complexes that are 
potentially involved in stress signaling outside of translation143.  While we find a reduction in 
rRNA after PA treatment in unstressed cells, possibly the more biologically relevant observation 
is the fact that stressed spinal cord cultures treated with PA show increased rRNA abundance.   
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Another possibility is that a subtle reduction in translation exists upon treatment with 
PA that our methods are simply not sensitive enough to detect.  Knockdown of numerous 
ribosomal proteins (rps-3,6,8,10,11,15,22,26 and rpl-4,6,9,19,30) and translation initiation 
factors (ifg-1, iftb-1, eif-3.B, inf-1, eif-3.F, egl-45) in the worm lead to enhanced lifespan and 
resistance to stress139,141.  The lifespan and stress resistance phenotype of many of these 
knockdowns is dependent on the worm ortholog of FOXO, daf-16.  PA may be initiating a similar 
cellular response through reduction in rRNA abundance and this may explain our previous 
observation that PA’s neuroprotective activities were FOXO dependent in a Drosophila model of 
SBMA124. 
Translation inhibition is a common response to a variety of cellular stresses.  One way 
the cell inhibits translation is through rRNA degradation.  rRNA degradation and subsequent 
translation inhibition could have prosuvival effects by allowing the cell to save energy under 
adverse conditions.  Another potential mechanism of protection relies on the fact that certain 
apoptotic pathways require de novo protein synthesis, inhibition of protein synthesis slows 
translation of apoptosis inducing proteins and therefore allows time for the cell to cope with 
stressful stimuli.  It is possible that PA’s neuroprotective properties stem from the ability to 
disrupt HNRNPK stabilization of rRNAs, thus allowing the cell to inhibit translation upon stress 
more quickly, and or efficiently. 
Conversely, apoptotic stimuli have been shown to induce extensive degradation of 5.8s 
rRNA in yeast144.  Reductions in rRNA are thought to potentially represent a turning point where 
cells commit to apoptosis as opposed to cellular repair.  In neurons degradation of rRNA may act 
as a signal to activate p53145.  Our data from stressed neurons demonstrates that under 
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conditions of neuronal stress PA acts to enhance rRNA abundance, this may in turn act to 
prevent apoptosis.  It is interesting to note that neurons seem to increase their abundance of 
5.8s rRNA when stressed with wild type or mutant SOD1 suggesting that increases in 5.8s rRNA 
may represent an endogenous pro-survival response to stress.  Assuming increased 5.8s rRNA is 
a consequence of stress, the fact that PA does not change 5.8s rRNA abundance in LacZ infected 
cells suggests that PA is specifically modifying a stress signal, likely associated with HNRNPK, and 
not simply stressing neurons. 
 Unfortunately, due to the plethora of functions of HNRNPK it was difficult for us to 
perform a complete analysis of every HNRNPK activity for PA dependent changes.  Therefore it 
remains possible that PA impacts some of the HNRNPK functions that we considered to be 
unchanged.  Based on our observation that PA alters rRNA abundance differently under 
conditions of stress, it is also possible that PA specifically alters a stress induced change in one of 
the HNRNPK activities that we considered to be unchanged.  For example PA might alter the 
interaction between HNRNPK and other target RNAs such as those described by Liu et al under 
conditions of stress.  Although we did not detect any changes in the abundance of these mRNAs 
after PA treatment, they may simply not be targeted for degradation under basal conditions.   
Many of these analyses lent themselves to being done in HEK293 cells as opposed to 
neurons.  We can not rule out the possibility that cell type specific HNRNPK activities, or 
complexes, exist in neurons and that we are unable to recapitulate some PA activities in HEK293 
cells. 
 In our current analysis we identify a novel function of the small molecule PA as a 
modifier of rRNA abundance.  Based on the role of HNRNPK in rRNA stability, we favor the view 
79 
 
that PA alters rRNA abundance through its interaction with HNRNPK.  The extent to which this 
action of PA accounts for its neuroprotective activity is not entirely clear at this time. 
Methods: 
 
Luciferase Assays:  HEK293 cells were transfected with pGL3-FHRE and pRL-TK plasmids for 
monitoring FOXO activity or pBIIx-firefly luciferase and pRL-TK for monitoring NFκB activity.  
24hrs after transfection cells were trypsinized and replated into a 96-well plate in drug or 
vehicle treated media, cells were re-dosed at 48 hours.  72 hours after drug treatment, the ratio 
of firefly to renilla luciferase was determined using a Veritas Microplate Luminometer 
(Promega) in conjunction with the Dual-Luciferase Reporter Assay Kit (Promega). 
Psammaplysene A and Derivatives:  For synthesis of PA see: Georgiades, S. N. & Clardy, J. Total 
synthesis of psammaplysenes A and B, naturally occurring inhibitors of FOXO1a nuclear export. 
Organic letters 7, 4091-4094, doi:10.1021/ol0513286 (2005).  PA derivatives used for covalent 
crosslinking and purification were generated from reaction intermediaries.  For schematic of 
synthesis of the PA derivative used for FG bead coupling see supplemental figure 3. 
Preparation of psammaplysene A-immobilized polymer-coated affinity magnetic beads (FG 
beads): Polymer-coated affinity magnetic beads with amine groups (FG beads: Nishio, K. et al, 
2008; Sakamoto, et al, 2009; TAS8848 N1130 (Tamagawa Seiki Co. Ltd., Iida, Japan)), stocked in 
pure water, were suspended in ethanol. Prior to immobilization step, ethanol was removed by 
centrifugation (15000 rpm, room temperature) of the beads. Then, ethanol, N-
methylmorpholine in ethanol, PA derivative solution in ethanol, EDC•HCl (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride) solution in ethanol, and 1-
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hydroxybenztriazole in DMF (N,N-dimethyformamide) were added to centrifuged beads. After 
the beads were dispersed well into the medium, the suspension was incubated for 1 day at 
room temperature. This immobilization step gave psammaplysene A-immobilized FG beads with 
unreacted amine groups. Then, the beads were washed with ethanol once and suspended in 
DMF. Masking of unreacted amine groups on the beads was performed by incubation with 1% 
acetic anhydride in DMF for 3 hours at room temperature. DMF was removed and the PA-FG 
beads were resuspended in distilled water. Finally, suspension of PA-FG beads in pure water was 
kept at 4°C. 
PA Target Identification with 2B:  Cell lysates were prepared from HEK293 cells or C. elegans in 
Triton-X 100 buffer (50mM Tris pH 7.8, 150mM NaCl, 1% Triton-X 100, complete protease 
inhibitor cocktail).  Lysates were incubated with 250nM of the PA derivative 2B for 1hr at 4⁰ C 
with rotation.  The lysate was then UV illuminated to activate the photo-affinity tag.  
Crosslinking was performed with 365nm UV illumination using a Spectroline 6 watt UV lamp on 
ice.  Crosslinked lysates were then processed using the Click-iT protein reaction buffer kit 
(Molecular Probes) to attach either TAMRA-azide or biotin-azide (Molecular Probes) to the 
alkyene group on 2B.  TAMRA tagged lysates were run on a 4-15% gradient gel and then 
visualized by in gel laser scanning with the Typhoon 9400 imaging system (GE life sciences).  
Biotin tagged lysates were incubated with hydrophilic streptavidin magnetic beads (New 
England Biolabs) at 4⁰ C for 1 hr with rotation.  Beads were washed three times with high 
stringency wash buffer (PBS with 1 M KCl and 500mM Urea) to decrease pulldown of indirect 
binding partners.  Beads were submitted for mass spec analysis to identify binding partners. 
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Purification of PA Targets with PA-FG Beads:  HEK293 lysates were incubated with 0x, 1x, and 
5x PA-FG beads for 1 hr at 4⁰ C.  Beads were then washed 3x in PBS, moved to a new tube and 
washed 2 additional times in PBS.  The beads were then resuspended in 1x SDS-PAGE loading 
buffer and boiled for 5 min.  These samples were then run on a 4-15% gradient gel and 
visualized with coomassie stain.  The bands indicated in figure 1 were excised and submitted for 
mass spec. 
Surface Plasmon Resonance:  PA binding to GST-HNRNPK was analyzed using a CM5 sensor chip 
on a BIACORE 3000.  Anti GST antibody was immobilized on the sensor chip using the GST 
Capture Kit (GE).  A capture/crosslink strategy was used to prevent dissociation of GST and GST 
fusions from the GST antibody over time.  The anti GST antibody was saturated with GST or GST 
fusion protein and then briefly pulsed (60 sec) with NHS/EDC followed by a brief pulse (60 sec) 
of ethanolamine.  The buffer used for dissolving PA and washing the surface was composed of 
5% DMSO and 0.05% Tween-20 in PBS.  PA was injected at a flow rate of 30uL per minute for 60 
seconds followed by a 120 second wash before administration of the next drug concentration. 
In Vitro Transcription and Purification of Biotinylated Transcripts:  Plasmid DNA containing the 
non-coding RNA of interest downstream from a T7 promoter element was linearized by 
overnight restriction enzyme digest.  Linearized plasmid was recovered by gel purification using 
the QIAquick Gel Extraction kit (Qiagen).  Biotinylated transcripts were then generated using the 
Ampliscribe T7-Flash Biotin-RNA Transcription Kit (Epicentre) with linearized plasmid as the 
template.  Biotinylated RNA was purified by ammonium acetate precipitation and resuspended 
in rnase free water.  Biotinylated RNAs were incubated with cell lysates for 1 hour and then 
pulled down with hydrophilic streptavidin magnetic beads (New England Biolabs).  Beads were 
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washed 3x in TBS-T and then boiled in 1x SDS-PAGE loading buffer.  Samples were run on an 
SDPS-PAGE gel and western blots were performed to identify associated proteins. 
Alternative Splicing Event Assay:  Total RNA was isolated from HEK293 cells using the RNeasy 
Plus Mini Kit (Qiagen).  RNA was then analyzed for changes in alternative splicing events as 
described in: Venables, J. P. et al. Multiple and specific mRNA processing targets for the major 
human hnRNP proteins. Molecular and cellular biology 28, 6033-6043, doi:10.1128/MCB.00726-
08 (2008). 
qPCR:  Total RNA was isolated from HEK293 cells using the RNeasy Plus Mini Kit (Qiagen).  RNA 
yield was quantified by A260 and 1ug of total RNA was used as template for reverse trascription 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  RNA abundance 
was then quantified by qPCR using Power SYBR Green Master Mix (Applied Biosystems) on a 
Step One Plus Real Time PCR System (Applied Biosystems).  All quantification was done using the 
∆∆CT method to determine realtive fold changes compared to GAPDH.  Primers used were as 
follows:   
5s rRNA forward 5’ GTC TAC GGC CAT ACC ACC 3’, reverse  5’ AAG CCT ACA GCA CCC G 3’ 
5.8s rRNA forward 5’ GGT GGA TCA CTC GGC TCG T 3’, reverse 5’ GCA AGT GCG TTC GAA GTG TC 
3’ 
18s rRNA forward 5’ GAT ATG CTC ATG TGG TGT TG 3’, reverse 5’ AAT CTT CTT CAG TCG CTC CA 
3’ 
28s rRNA forward 5’ TTG AAA ATC CGG GGG AGA G 3’, reverse 5’ ACA TTG TTC CAA CAT GCC AG 
3’ 
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GAPDH forward 5’ AAT GAA GGG GTC ATT GAT GG 3’, reverse 5’ AAG GTG AAG GTC GGA GTC AA 
3’ 
Beta actin forward 5’ ATA GCA CAG CCT GGA TAG CAA CGT AC 3’, reverse CAC CTT CTA CAA TGA 
GCT GCG TGT G 3’ 
Gamma actin forward 5’ GCA AAA CCA GCT TTG CAC AT 3’, reverse CTC GCA CTC TGT TCT TCC G 
3’ 
NCOR1 forward 5’ TTG TGA CGA GCA GTG AGA CAC G 3’, reverse 5’ TCA GCT TTG GTT TGC ACA 
CTC CTG 3’ 
RAB5A forward 5’ GGC TGC CTT TCT AAC CCA AAC TG 3’, reverse 5’ TAC ACA ACT ATG GCGGCT 
TGT G 3’ 
APP forward 5’ AAC CAG CAT TGC CAC CAC TAC C 3’, reverse 5’ AGC TTG TTC AGA GCA CAC CTC 
TC 3’ 
NF-M forward 5’CAG TCC TCT TCG CTG CTT AAC G 3’, reverse 5’CTG CAG CTG CTC TTT CTC GTT 
TG 3’ 
 
Immunoprecipitation:  Cells were lysed in Triton-X 100 buffer (50mM Tris pH 7.8, 150mM NaCl, 
1% Triton-X 100, complete protease inhibitor cocktail) and sonicated at 20% amplitude for 5 
seconds with a Branson sonicator.  Lysates were cleared of insoluble material by centrifugation 
at max speed ~13,000 g for 10 min at 4⁰ C.  Antibodies were prebound to Dynobead protein G 
(Invitrogen) and then incubated with cell lysates for 1hr at room temperature.  Beads were 
washed 3x in PBS, transferred to a new tube and washed 2x in PBS.  Beads were then 
resuspended in 1x SDS-PAGE buffer and boiled for 5 minutes.  Samples were resolved on an SDS-
PAGE gel and western blotted for the protein of interest. 
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Polysome Profiling:  Two 100mm dishes of HEK cells were used for each sample.  Cells were 
treated for 72 hours with PA or vehicle prior to polysome profiling.  Cells were treated for 15 
minutes with 100 µg/ml cyclohexamide.  Cells were then washed twice with PBS + 100 µg/ml 
cyclohexamide and then scraped from the plate in this same solution.  Cells were spun for 2 
minutes at 1,000 x g to pellet cells.  Supernatant was aspirated and cells were lysed in 20 mM 
Hepes pH 7.4, 100 mM KCl, 15 mM MGCl2, 0.5% NP-40, 2 mM DTT, 100 µg/ml cyclohexamide, 
100 U/ml RNasin plus (Promega) and 1x complete protease inhibitor cocktail by passage through 
a 26 gauge needle.  Lysates were layered onto 15-45% continuous sucrose gradients containing 
100 µg/ml cyclohexamide, 100 U/ml RNasin plus (Promega) prepared with DEPC treated water.  
Samples were spun in a SW-41 Ti rotor (Beckman) for 2.5 hours at 38,000 rpm with no brake.  A 
peristaltic pump was used to through a UV monitor at 800 µl/min and A260 was plotted using 
Labview Signal Express. 
Incorporation of [35S]-methionine:  Cells were treated for 72 hours with PA prior to translation 
assay.  Cells were washed two times in DMEM before replacing the media with cysteine and 
methionine free media for 1 hour with PA or vehicle.  After 20 minutes, [35S]-methionine was 
added to the media at a concentration of 100 µCi/ml and translation was allowed to occur for 
1hr.  After labeling, media was removed and cells were washed once with PBS.  Cells were lysed 
in TNNB (50mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5% NP-40, 0.5 mM PMSF, 0.1% BSA) with 
100mM iodoacetamide at a final volume of 1 ml.  3 µl of each lysate was spotted onto filter 
paper and dried.  Filters were incubated in 10% TCA at 4⁰ C overnight.  Incorporation of [35S]-
methionine was quantified on a Wallac 1409 DSA liquid scintillation counter (Perkin Elmer). 
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Figure S1. PA derivative compounds 
Suplemental Table 1 
Protein names Gene names 
2B Pulldown 
 Actin, beta (Actin, beta, cytoplasmic) Actb mCG_23209 
cDNA FLJ37875 fis, clone BRSSN2018771, highly similar to 
Poly(A)-binding protein 1   
cDNA FLJ39996 fis, clone STOMA2002166, highly similar to 
Splicing factor 3B subunit 4   
cDNA FLJ52880, highly similar to Malate dehydrogenase, 
mitochondrial (EC 1.1.1.37)   
cDNA FLJ75163, highly similar to Homo sapiens heterogeneous 
nuclear ribonucleoprotein U-like 1 (HNRPUL1), transcript 
variant 4, mRNA   
cDNA FLJ75556, highly similar to Homo sapiens ribosomal 
protein L14, mRNA   
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cDNA, FLJ92798, highly similar to Homo sapiens annexin A7 
(ANXA7), transcript variant 2, mRNA   
cDNA, FLJ93744, highly similar to Homo sapiens keratin 6E 
(KRT6E), mRNA   
D-3-phosphoglycerate dehydrogenase (3-PGDH) (EC 1.1.1.95) PHGDH PGDH3 
DNA-directed RNA polymerase II subunit RPB1 (RNA 
polymerase II subunit B1) (EC 2.7.7.6) (DNA-directed RNA 
polymerase II subunit A) (DNA-directed RNA polymerase III 
largest subunit) (RNA-directed RNA polymerase II subunit RPB1) 
(EC 2.7.7.48) POLR2A POLR2 
EIF4G1 protein EIF4G1 
Elongation factor 1-alpha   
Elongation factor 2 (EF-2) EEF2 EF2 
Ewing sarcoma breakpoint region 1 (Uncharacterized protein) EWSR1 AC002059.7-007 
Fused in sarcoma FUS 
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) 
(Helix-destabilizing protein) (Single-strand RNA-binding protein) 
(hnRNP core protein A1) HNRNPA1 HNRPA1 
Heterogeneous nuclear ribonucleoprotein H3 (hnRNP H3) 
(Heterogeneous nuclear ribonucleoprotein 2H9) (hnRNP 2H9) HNRNPH3 HNRPH3 
Heterogeneous nuclear ribonucleoprotein K Hnrnpk Hnrpk 
Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP 
A2/B1) Hnrnpa2b1 Hnrpa2b1 
Inducible heat shock protein 70 Hspa1a 
Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-
10) (K10) KRT10 KPP 
Keratin, type I cytoskeletal 14 (Cytokeratin-14) (CK-14) (Keratin-
14) (K14) KRT14 
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) 
(K9) KRT9 
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-
1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin 
Kb1) KRT1 KRTA 
Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK-
2e) (Epithelial keratin-2e) (Keratin-2 epidermis) (Keratin-2e) 
(K2e) (Type-II keratin Kb2) KRT2 KRT2A KRT2E 
MCG9909 (Small nuclear ribonucleoprotein B) 
Snrpb mCG_9909 RP23-
20A6.3-001 
Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) PPIA 
Phosphoglycerate kinase (EC 2.7.2.3) PGK1 hCG_20034 
Profilin-1 (Profilin I) PFN1 
Putative MAPK activating protein   
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Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Cytosolic 
thyroid hormone-binding protein) (CTHBP) (Opa-interacting 
protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle 
isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor 
M2-PK) (p58) PKM2 OIP3 PK2 PK3 PKM 
RNA-binding motif protein, X chromosome (Glycoprotein p43) 
(Heterogeneous nuclear ribonucleoprotein G) (hnRNP G) 
[Cleaved into: RNA-binding motif protein, X chromosome, N-
terminally processed] RBMX HNRPG RBMXP1 
RNA-binding protein 14 (Paraspeckle protein 2) (PSP2) (RNA-
binding motif protein 14) (RRM-containing coactivator 
activator/modulator) (Synaptotagmin-interacting protein) (SYT-
interacting protein) RBM14 SIP 
Splicing factor, proline- and glutamine-rich (DNA-binding 
p52/p100 complex, 100 kDa subunit) (Polypyrimidine tract-
binding protein-associated-splicing factor) (PSF) (PTB-
associated-splicing factor) Sfpq 
Tubulin alpha-1A chain (Alpha-tubulin 3) (Tubulin B-alpha-1) 
(Tubulin alpha-3 chain) TUBA1A TUBA3 
Uncharacterized protein (cDNA FLJ77026, highly similar to 
Homo sapiens ataxin 2-like (ATXN2L), transcript variant E, 
mRNA) ATXN2L 
Zinc finger protein 207 ZNF207 
  PA Nanobead Pulldown 
 60S ribosomal protein L6   
78 kDa glucose-regulated protein (GRP-78) (Endoplasmic 
reticulum lumenal Ca(2+)-binding protein grp78) (Heat shock 70 
kDa protein 5) (Immunoglobulin heavy chain-binding protein) 
(BiP) HSPA5 GRP78 
A-kinase anchor protein 8 (AKAP-8) (A-kinase anchor protein 95 
kDa) (AKAP 95) AKAP8 AKAP95 
Amyloid beta A4 protein-binding family B member 1 transcript 
variant 3 (cDNA FLJ53829, highly similar to Amyloid beta A4 
protein-bindingfamily B member 1) (cDNA FLJ61679, highly 
similar to Amyloid beta A4 protein-binding family B member 1) APBB1 
AP-3 complex subunit delta-1 (AP-3 complex subunit delta) 
(Adapter-related protein complex 3 subunit delta-1) (Delta-
adaptin) AP3D1 PRO0039 
Apoptosis-inducing factor 1, mitochondrial (EC 1.-.-.-) 
(Programmed cell death protein 8) AIFM1 AIF PDCD8 
ATPase family AAA domain-containing protein 3A ATAD3A 
ATPase family AAA domain-containing protein 3B ATAD3B KIAA1273 
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ATP-binding cassette, sub-family F (GCN20), member 2 (ATP-
binding cassette, sub-family F (GCN20), member 2, isoform 
CRA_b) (Putative uncharacterized protein ABCF2) ABCF2 hCG_1643314 
ATP-dependent RNA helicase A (RHA) (EC 3.6.4.13) (DEAH box 
protein 9) (Leukophysin) (LKP) (Nuclear DNA helicase II) (NDH II) DHX9 DDX9 LKP NDH2 
ATP-dependent RNA helicase DDX1 (DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 1, isoform CRA_d) (DEAD box polypeptide 1) 
(cDNA, FLJ94573, Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 1 (DDX1), mRNA) DDX1 hCG_15914 
ATP-dependent RNA helicase DDX3X (EC 3.6.4.13) (DEAD box 
protein 3, X-chromosomal) (DEAD box, X isoform) (Helicase-like 
protein 2) (HLP2) DDX3X DBX DDX3 
ATP-dependent RNA helicase DHX29 (EC 3.6.4.13) (DEAH box 
protein 29) (Nucleic acid helicase DDXx) DHX29 DDX29 
Bcl-2-associated transcription factor 1 (Btf) BCLAF1 BTF KIAA0164 
BMP-2-inducible protein kinase (BIKe) (EC 2.7.11.1) BMP2K BIKE HRIHFB2017 
CD55 molecule, decay accelerating factor for complement 
(Cromer blood group) CD55 RP11-357P18.1-003 
cDNA FLJ10686 fis, clone NT2RP3000252, highly similar to 
Nucleolar GTP-binding protein 1   
cDNA FLJ10711 fis, clone NT2RP3000917, highly similar to 5'-3' 
exoribonuclease 2 (EC 3.1.11.-)   
cDNA FLJ16043 fis, clone BRCAN2028355, highly similar to 
Calcium/calmodulin-dependent protein kinasetype II gamma 
chain (EC 2.7.11.17)   
cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to 
Tubulin alpha-ubiquitous chain   
cDNA FLJ36409 fis, clone THYMU2010448, highly similar to 
Regulator of nonsense transcripts 3B   
cDNA FLJ46863 fis, clone UTERU3011558   
cDNA FLJ50778, highly similar to Protein flightless-1 homolog   
cDNA FLJ53353, highly similar to ATP-binding cassette sub-
family D member 3   
cDNA FLJ54081, highly similar to Keratin, type II cytoskeletal 5   
cDNA FLJ54345, highly similar to Homo sapiens neuropathy 
target esterase (NTE), mRNA   
cDNA FLJ54552, highly similar to Heterogeneous nuclear 
ribonucleoprotein K   
cDNA FLJ55635, highly similar to pre-mRNA-splicing factorATP-
dependent RNA helicase DHX15 (EC 3.6.1.-)   
cDNA FLJ55671, highly similar to Ubiquitin-associated protein 2-
like   
cDNA FLJ56474, highly similar to Histone deacetylase 6   
cDNA FLJ58171, moderately similar to Melanoma-associated   
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antigen D2 
cDNA FLJ58398, highly similar to A-kinase anchor protein 8   
cDNA FLJ61214, highly similar to Acid sphingomyelinase-like 
phosphodiesterase 3b (EC 3.1.4.-)   
cDNA FLJ75163, highly similar to Homo sapiens heterogeneous 
nuclear ribonucleoprotein U-like 1 (HNRPUL1), transcript 
variant 4, mRNA   
cDNA FLJ75871, highly similar to Homo sapiens staufen, RNA 
binding protein (STAU), transcript variant T3, mRNA   
cDNA FLJ76871, highly similar to Homo sapiens DEAH (Asp-Glu-
Ala-His) box polypeptide 38 (DHX38), mRNA   
cDNA FLJ76888, highly similar to Homo sapiens RNA binding 
motif protein 6 (RBM6), mRNA   
cDNA FLJ77037, highly similar to Homo sapiens RNA polymerase 
II associated protein 1, mRNA (Fragment)   
cDNA FLJ77404, highly similar to Homo sapiens small nuclear 
ribonucleoprotein 70kDa polypeptide (RNP antigen) (SNRP70), 
transcript variant 1, mRNA   
cDNA FLJ78268, highly similar to Homo sapiens fusion (involved 
in t(12;16) in malignant liposarcoma), transcript variant 1, 
mRNA   
cDNA FLJ78677, highly similar to Homo sapiens splicing factor 
3b, subunit 3, 130kDa (SF3B3), mRNA   
cDNA, FLJ92684, highly similar to Homo sapiens IK cytokine, 
down-regulator of HLA II (IK), mRNA   
cDNA, FLJ95128, highly similar to Homo sapiens sorting nexin 9 
(SNX9), mRNA   
cDNA, FLJ96507   
cDNA, FLJ96901, highly similar to Homo sapiens Rac GTPase 
activating protein 1 (RACGAP1), mRNA   
Coatomer subunit alpha (Alpha-coat protein) (Alpha-COP) (HEP-
COP) (HEPCOP) [Cleaved into: Xenin (Xenopsin-related peptide); 
Proxenin] COPA 
Coiled-coil domain-containing protein 138 CCDC138 
Coilin (p80) COIL CLN80 
Condensin complex subunit 1   
Crooked neck-like protein 1 (Crooked neck homolog) (hCrn) 
CRNKL1 CRN CGI-201 
MSTP021 
CTP synthase 1 (EC 6.3.4.2) (CTP synthetase 1) (UTP--ammonia 
ligase 1) CTPS 
CWF19-like protein 1 CWF19L1 
CYTSA protein (KIAA0376 protein, isoform CRA_a) 
CYTSA KIAA0376 
hCG_1811992 
DBH-like monooxygenase protein 1 (EC 1.14.17.-) MOXD1 MOX 
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(Monooxygenase X) UNQ2493/PRO5780 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 (DEAD box 
polypeptide 17 isoform p82 variant) (Fragment) DDX17 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 DDX52 
Desmoglein-2 (Cadherin family member 5) (HDGC) DSG2 CDHF5 
DNA repair protein RAD50 (hRAD50) (EC 3.6.-.-) RAD50 
DNA-binding protein A (Cold shock domain-containing protein 
A) (Single-strand DNA-binding protein NF-GMB) CSDA DBPA 
DNA-dependent protein kinase catalytic subunit (DNA-PK 
catalytic subunit) (DNA-PKcs) (EC 2.7.11.1) (DNPK1) (p460) PRKDC HYRC HYRC1 
DNA-directed RNA polymerase III subunit RPC1 (RNA 
polymerase III subunit C1) (EC 2.7.7.6) (DNA-directed RNA 
polymerase III largest subunit) (DNA-directed RNA polymerase 
III subunit A) (RNA polymerase III 155 kDa subunit) (RPC155) 
(RNA polymerase III subunit C160) POLR3A 
Double-stranded RNA-binding protein Staufen homolog 2 STAU2 
Dynactin 1 DCTN1 
EMILIN-2 (Elastin microfibril interface-located protein 2) (Elastin 
microfibril interfacer 2) (Protein FOAP-10) EMILIN2 
Eukaryotic translation initiation factor 3, subunit D (cDNA 
FLJ53917, highly similar to Eukaryotic translation initiation 
factor 3 subunit 7) EIF3D 
Eukaryotic translation initiation factor 3, subunit E interacting 
protein (Uncharacterized protein) 
EIF3EIP EIF3L AL022311.1-
001 
Extracellular sulfatase Sulf-2 (hSulf-2) (EC 3.1.6.-) 
SULF2 KIAA1247 
UNQ559/PRO1120 
Fanconi anemia group D2 protein (Protein FACD2) FANCD2 FACD 
Far upstream element (FUSE) binding protein 3 (HCG31253, 
isoform CRA_a) (cDNA FLJ58115, highly similar to Far upstream 
element-binding protein 3) 
FUBP3 hCG_31253 RP11-
57C19.3-002 
Fragile X mental retardation protein 1 (FMRP) (Protein FMR-1) FMR1 
G patch domain-containing protein 4 GPATCH4 GPATC4 
Golgi apparatus protein 1 (CFR-1) (Cysteine-rich fibroblast 
growth factor receptor) (E-selectin ligand 1) (ESL-1) (Golgi 
sialoglycoprotein MG-160) GLG1 CFR1 ESL1 MG160 
Guanine nucleotide-binding protein-like 3 (E2-induced gene 3 
protein) (Novel nucleolar protein 47) (NNP47) (Nucleolar GTP-
binding protein 3) (Nucleostemin) GNL3 E2IG3 NS 
Heat shock 70kDa protein 1A (Heat shock 70kDa protein 1B) 
(cDNA FLJ75127, highly similar to Homo sapiens heat shock 
70kDa protein 1A, mRNA) HSPA1A HSPA1B  
Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 
8) 
HSPA8 HSC70 HSP73 
HSPA10 
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Heterogeneous nuclear ribonucleoprotein H (hnRNP H) 
[Cleaved into: Heterogeneous nuclear ribonucleoprotein H, N-
terminally processed] HNRNPH1 HNRPH HNRPH1 
Heterogeneous nuclear ribonucleoprotein L (hnRNP L) HNRNPL HNRPL P/OKcl.14 
Heterogeneous nuclear ribonucleoprotein M (hnRNP M) HNRNPM HNRPM NAGR1 
Heterogeneous nuclear ribonucleoprotein Q (hnRNP Q) 
(Glycine- and tyrosine-rich RNA-binding protein) (GRY-RBP) 
(NS1-associated protein 1) (Synaptotagmin-binding, cytoplasmic 
RNA-interacting protein) SYNCRIP HNRPQ NSAP1 
Heterogeneous nuclear ribonucleoprotein R (hnRNP R) HNRNPR HNRPR 
Histone deacetylase (EC 3.5.1.98) HDAC1 
Insulin receptor substrate 4 (IRS-4) (160 kDa phosphotyrosine 
protein) (py160) (Phosphoprotein of 160 kDa) (pp160) IRS4 
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2 
mRNA-binding protein 1) (IMP-1) (Coding region determinant-
binding protein) (CRD-BP) (IGF-II mRNA-binding protein 1) 
(VICKZ family member 1) (Zip code-binding protein 1) (ZBP-1) 
(Zipcode-binding protein 1) 
IGF2BP1 CRDBP VICKZ1 
ZBP1 
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2 
mRNA-binding protein 2) (IMP-2) (Hepatocellular carcinoma 
autoantigen p62) (IGF-II mRNA-binding protein 2) (VICKZ family 
member 2) IGF2BP2 IMP2 VICKZ2 
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2 
mRNA-binding protein 3) (IMP-3) (IGF-II mRNA-binding protein 
3) (KH domain-containing protein overexpressed in cancer) 
(hKOC) (VICKZ family member 3) 
IGF2BP3 IMP3 KOC1 
VICKZ3 
Isoleucine--tRNA ligase, cytoplasmic (EC 6.1.1.5) (Isoleucyl-tRNA 
synthetase) (IRS) (IleRS) IARS 
Junction plakoglobin (Catenin gamma) (Desmoplakin III) 
(Desmoplakin-3) JUP CTNNG DP3 
Kelch-like protein 21 KLHL21 KIAA0469 
Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-
10) (K10) KRT10 KPP 
Keratin, type I cytoskeletal 16 (Cytokeratin-16) (CK-16) (Keratin-
16) (K16) KRT16 KRT16A 
Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) 
(K9) KRT9 
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-
1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin 
Kb1) KRT1 KRTA 
Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK-
2e) (Epithelial keratin-2e) (Keratin-2 epidermis) (Keratin-2e) 
(K2e) (Type-II keratin Kb2) KRT2 KRT2A KRT2E 
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KH domain-containing, RNA-binding, signal transduction-
associated protein 1 (GAP-associated tyrosine phosphoprotein 
p62) (Src-associated in mitosis 68 kDa protein) (Sam68) (p21 
Ras GTPase-activating protein-associated p62) (p68) KHDRBS1 SAM68 
KTN1 protein (cDNA FLJ61494, highly similar to Kinectin) KTN1 
La-related protein 1 (La ribonucleoprotein domain family 
member 1) LARP1 KIAA0731 LARP 
La-related protein 1B (La ribonucleoprotein domain family 
member 1B) (La ribonucleoprotein domain family member 2) 
(La-related protein 2) LARP1B LARP2 
La-related protein 7 (La ribonucleoprotein domain family 
member 7) (P-TEFb-interaction protein for 7SK stability) (PIP7S) LARP7 HDCMA18P 
Lectin, galactoside-binding, soluble, 3 binding protein 
(Uncharacterized protein) (cDNA FLJ53478, highly similar to 
Galectin-3-binding protein) LGALS3BP 
Melanoma-associated antigen D1 (MAGE tumor antigen CCF) 
(MAGE-D1 antigen) (Neurotrophin receptor-interacting MAGE 
homolog) 
MAGED1 NRAGE PRO2292 
PP2250 
Mov10, Moloney leukemia virus 10, homolog (Mouse) (Mov10, 
Moloney leukemia virus 10, homolog (Mouse), isoform CRA_a) 
(Uncharacterized protein) 
MOV10 hCG_38463 RP11-
426L16.2-003 
Myb-binding protein 1A MYBBP1A P160 
Myelin expression factor 2 (MEF-2) (MyEF-2) (MST156) MYEF2 KIAA1341 
MYH10 protein MYH10 
Myosin phosphatase Rho-interacting protein (M-RIP) (Rho-
interacting protein 3) (RIP3) (p116Rip) 
MPRIP KIAA0864 MRIP 
RHOIP3 
Myosin-14 (Myosin heavy chain 14) (Myosin heavy chain, non-
muscle IIc) (Non-muscle myosin heavy chain IIc) (NMHC II-C) MYH14 KIAA2034 FP17425 
Myosin-9 (Cellular myosin heavy chain, type A) (Myosin heavy 
chain 9) (Myosin heavy chain, non-muscle IIa) (Non-muscle 
myosin heavy chain A) (NMMHC-A) (Non-muscle myosin heavy 
chain IIa) (NMMHC II-a) (NMMHC-IIA) MYH9 
Nuclear pore complex protein Nup160 (160 kDa nucleoporin) 
(Nucleoporin Nup160) NUP160 KIAA0197 NUP120 
Nucleolar protein 58 (Nucleolar protein 5) 
NOP58 NOL5 NOP5 
HSPC120 
Nucleolin, isoform CRA_c (cDNA FLJ10452 fis, clone 
NT2RP1000966, highly similar to NUCLEOLIN) NCL hCG_33980 
PABPC4 protein (Poly(A) binding protein, cytoplasmic 4 
(Inducible form)) (Poly(A) binding protein, cytoplasmic 4 
(Inducible form), isoform CRA_c) (Uncharacterized protein) 
PABPC4 hCG_2031827 
RP11-69E11.6-002 
Pentatricopeptide repeat domain 1 (cDNA FLJ76276, highly 
similar to Homo sapiens pentatricopeptide repeat domain 1 
(PTCD1), mRNA) 
PTCD1 hCG_2023422 
tcag7.1151 
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Pentatricopeptide repeat-containing protein 3, mitochondrial 
(Transformation-related gene 15 protein) (TRG-15) PTCD3 TRG15 
Periodic tryptophan protein 1 homolog (Keratinocyte protein 
IEF SSP 9502) PWP1 
Poly(U)-binding-splicing factor PUF60 (60 kDa poly(U)-binding-
splicing factor) (FUSE-binding protein-interacting repressor) 
(FBP-interacting repressor) (Ro-binding protein 1) (RoBP1) 
(Siah-binding protein 1) (Siah-BP1) PUF60 FIR ROBPI SIAHBP1 
Polyadenylate-binding protein 1 (PABP-1) (Poly(A)-binding 
protein 1) 
PABPC1 PAB1 PABP1 
PABPC2 
Prelamin-A/C [Cleaved into: Lamin-A/C (70 kDa lamin) (Renal 
carcinoma antigen NY-REN-32)] LMNA LMN1 
Probable ATP-dependent RNA helicase DDX41 (EC 3.6.4.13) 
(DEAD box protein 41) (DEAD box protein abstrakt homolog) DDX41 ABS 
Probable ATP-dependent RNA helicase DDX5 (EC 3.6.4.13) 
(DEAD box protein 5) (RNA helicase p68) DDX5 G17P1 HELR HLR1 
Probable ATP-dependent RNA helicase DHX36 (EC 3.6.4.13) 
(DEAH box protein 36) (MLE-like protein 1) (RNA helicase 
associated with AU-rich element ARE) 
DHX36 DDX36 KIAA1488 
MLEL1 RHAU 
Probable ATP-dependent RNA helicase YTHDC2 (EC 3.6.4.13) YTHDC2 
Protein angel homolog 1 ANGEL1 KIAA0759 
Protein angel homolog 2 ANGEL2 KIAA0759L 
Protein C16orf88 (Testis-specific gene 118 protein) C16orf88 TSG118 
Protein FAM98A FAM98A 
Protein LYRIC (3D3/LYRIC) (Astrocyte elevated gene-1 protein) 
(AEG-1) (Lysine-rich CEACAM1 co-isolated protein) 
(Metadherin) (Metastasis adhesion protein) MTDH AEG1 LYRIC 
Protein phosphatase 2 (Formerly 2A), regulatory subunit A (PR 
65), alpha isoform (cDNA FLJ78455, highly similar to Homo 
sapiens protein phosphatase 2 (formerly 2A), regulatory subunit 
A (PR 65), alpha isoform (PPP2R1A), mRNA) (cDNA, FLJ96799, 
Homo sapiens protein phosphatase 2 (formerly 2A), regulatory 
subunit A (PR 65), alpha isoform (PPP2R1A), mRNA) PPP2R1A hCG_19686 
Protein transport protein Sec16A (SEC16 homolog A) 
SEC16A KIAA0310 SEC16 
SEC16L 
Putative ATP-dependent RNA helicase DHX57 (EC 3.6.4.13) 
(DEAH box protein 57) DHX57 
Putative protein FAM90A7 FAM90A7 
Putative RNA helicase Ski2w SKI2W 
Putative uncharacterized protein DKFZp686A13234 (Fragment) DKFZp686A13234 
RBM39 protein (Uncharacterized protein) (cDNA FLJ59214, 
highly similar to RNA-binding region-containing protein 2) RBM39 
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Regulator of nonsense transcripts 1 (EC 3.6.4.-) (ATP-dependent 
helicase RENT1) (Nonsense mRNA reducing factor 1) (NORF1) 
(Up-frameshift suppressor 1 homolog) (hUpf1) UPF1 KIAA0221 RENT1 
Ribonuclease 3 (EC 3.1.26.3) (Protein Drosha) (Ribonuclease III) 
(RNase III) (p241) 
DROSHA RN3 RNASE3L 
RNASEN 
RNA-binding protein 14 (Paraspeckle protein 2) (PSP2) (RNA-
binding motif protein 14) (RRM-containing coactivator 
activator/modulator) (Synaptotagmin-interacting protein) (SYT-
interacting protein) RBM14 SIP 
RSL1D1 protein (Fragment) RSL1D1 
SAFB protein (Scaffold attachment factor B) SAFB 
Scaffold attachment factor B2 (SAF-B2) SAFB2 KIAA0138 
SNW domain-containing protein 1 (Nuclear protein SkiP) 
(Nuclear receptor coactivator NCoA-62) (Ski-interacting protein) SNW1 SKIIP SKIP 
Splicing factor 3A subunit 2 (SF3a66) (Spliceosome-associated 
protein 62) (SAP 62) SF3A2 SAP62 
Splicing factor 3B subunit 1 (Pre-mRNA-splicing factor SF3b 155 
kDa subunit) (SF3b155) (Spliceosome-associated protein 155) 
(SAP 155) SF3B1 SAP155 
SRP72 protein (Fragment) SRP72 
Stress-70 protein, mitochondrial (75 kDa glucose-regulated 
protein) (GRP-75) (Heat shock 70 kDa protein 9) (Mortalin) 
(MOT) (Peptide-binding protein 74) (PBP74) HSPA9 GRP75 HSPA9B 
Structural maintenance of chromosomes protein 1A (SMC 
protein 1A) (SMC-1-alpha) (SMC-1A) (Sb1.8) 
SMC1A DXS423E KIAA0178 
SB1.8 SMC1 SMC1L1 
Synembryn-A (Protein Ric-8A) RIC8A 
TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 68kDa (TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 68kDa, isoform CRA_b) 
(cDNA, FLJ94920, Homo sapiens TAF15 RNA polymerase II, TATA 
box binding protein(TBP)-associated factor, 68kDa (TAF15), 
transcript variant 1, mRNA) TAF15 hCG_1992163 
TBC1 domain family, member 9B (With GRAM domain) TBC1D9B 
T-complex protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha) TCP1 CCT1 CCTA 
T-complex protein 1 subunit epsilon (TCP-1-epsilon) (CCT-
epsilon) CCT5 CCTE KIAA0098 
T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-
gamma) (hTRiC5) CCT3 CCTG TRIC5 
Tetratricopeptide repeat protein 37 (TPR repeat protein 37) 
(Thespin) TTC37 KIAA0372 
THO complex subunit 2 (Tho2) (hTREX120) THOC2 CXorf3 
Titin (EC 2.7.11.1) (Connectin) (Rhabdomyosarcoma antigen 
MU-RMS-40.14) TTN 
Transcription factor 25 (TCF-25) (Nuclear localized protein 1) TCF25 KIAA1049 NULP1 
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FKSG26 
Trifunctional enzyme subunit alpha, mitochondrial (78 kDa 
gastrin-binding protein) (TP-alpha) [Includes: Long-chain enoyl-
CoA hydratase (EC 4.2.1.17); Long chain 3-hydroxyacyl-CoA 
dehydrogenase (EC 1.1.1.211)] HADHA HADH 
Tubulin beta chain (Tubulin beta-5 chain) TUBB TUBB5 OK/SW-cl.56 
Tubulin beta-4B chain (Tubulin beta-2 chain) (Tubulin beta-2C 
chain) TUBB4B TUBB2C 
Twinkle protein, mitochondrial (EC 3.6.4.12) (Progressive 
external ophthalmoplegia 1 protein) (T7 gp4-like protein with 
intramitochondrial nucleoid localization) (T7-like mitochondrial 
DNA helicase) PEO1 C10orf2 
U2 small nuclear RNA auxiliary factor 2 isoform b U2AF2 
U2 snRNP-associated SURP motif-containing protein (140 kDa 
Ser/Arg-rich domain protein) (U2-associated protein SR140) U2SURP KIAA0332 SR140 
U4/U6.U5 tri-snRNP-associated protein 2 (Inactive ubiquitin-
specific peptidase 39) (SAD1 homolog) (U4/U6.U5 tri-snRNP-
associated 65 kDa protein) (65K) 
USP39 CGI-21 HSPC332 
PRO2855 
Unc-84 homolog B (C. elegans) (Uncharacterized protein) 
UNC84B SUN2 RP3-
508I15.15-002 
Uncharacterized protein GNL3L 
Uncharacterized protein (cDNA FLJ44920 fis, clone 
BRAMY3011501, highly similar to Heterogeneous nuclear 
ribonucleoprotein U) HNRNPU 
Uncharacterized protein (cDNA FLJ50109, highly similar to 
CDC45-related protein) CDC45 
Uncharacterized protein (cDNA FLJ54150, highly similar to 
Heterogeneous nuclear ribonucleoprotein D0) HNRNPD 
Uncharacterized protein (X-ray repair complementing defective 
repair in Chinese hamster cells 6 (Ku autoantigen, 70kDa)) XRCC6 CTA-216E10.7-005 
Unconventionnal myosin-X (Unconventional myosin-10) MYO10 KIAA0799 
UTP18 small subunit (SSU) processome component homolog 
(yeast) (cDNA, FLJ95176, Homo sapiens CGI-48 protein (CGI-48), 
mRNA) UTP18 
Uveal autoantigen with coiled-coil domains and ankyrin repeats UACA KIAA1561 
Versican core protein (Chondroitin sulfate proteoglycan core 
protein 2) (Chondroitin sulfate proteoglycan 2) (Glial 
hyaluronate-binding protein) (GHAP) (Large fibroblast 
proteoglycan) (PG-M) VCAN CSPG2 
Vigilin (High density lipoprotein-binding protein) (HDL-binding 
protein) HDLBP HBP VGL 
Voltage-dependent calcium channel subunit alpha-2/delta-1 
(Voltage-gated calcium channel subunit alpha-2/delta-1) 
[Cleaved into: Voltage-dependent calcium channel subunit 
CACNA2D1 CACNL2A 
CCHL2A MHS3 
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alpha-2-1; Voltage-dependent calcium channel subunit delta-1] 
Zinc finger protein 326 ZNF326 
 
Suplemental Table 2 
Screened PA Target Candidates 
Ataxin 2-like (ATXN2L) 
DEAH box polypeptide 57 (DHX57) 
DEAH box polypeptide 9 (DHX9) 
DEAD box helicase 17 (DDX17) 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 (KHDRBS1, 
SAM68) 
Histone deacetylase 6 (HDAC6) 
Heterogeneous nuclear ribonucleoprotein K 
(HNRNPK) 
Heterogeneous nuclear ribonucleoprotein L 
(HNRNPL) 
Heterogeneous nuclear ribonucleoprotein Q 
(HNRNPQ, SYNCRIP) 
Heterogeneous nuclear ribonucleoprotein U-
like 1 (HNRNPUL1) 
La ribonucleoprotein domain family member 
1 (LARP1) 
La ribonucleoprotein domain family member 
7  (LARP7) 
MYB binding protein (MYBBP1A) 
YTH domain containing 2 (YTHDC2) 
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Suplemental Figure 2 
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Figure S2. Heat map of alternative splicing events. 
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Chapter 5 
Future Directions: 
 
Effects of IIS Signaling on SOD1 Toxicity in C. elegans 
 
Are the Beneficial Effects of Reduced IIS on SOD1 Toxicity Cell Autonomous? 
Our work with the Psnb-1::G85R::YFP; sid-1(pk3321)[Punc119::sid-1] strain suggested a 
specific requirement of reduced IIS in the nervous system in order to rescue G85R induced 
toxicity.  While this approach allowed us to preferentially direct RNAi to the nervous system it 
did not provide us with cell specific activation of DAF-16.  This prevented us from definitively 
determining whether increased DAF-16 activity was required cell autonomously to rescue 
mutant SOD1 toxicity.  If so this finding would be in contrast to effects of reduced IIS on 
longevity.  Reduced IIS in specific tissues has been found to coordinate organismal aging and 
provide much of the same benefits on longevity as reducing IIS in the entire organism17.  This 
observation was made by mosaic analysis.  Similar studies have not been performed to analyze 
the effects of reduced IIS on stress resistance or more specifically, beneficial effects on 
proteotoxicity in a tissue/lineage specific fashion.  One potential approach to answering this 
question would be to rescue daf-16 function in the Psnb-1::G85R::YFP;daf-2(e1370);daf-
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16(mgDf50) background using tissue specific promoters.  Using the snb-1 promoter to rescue 
daf-16 function in this background, one could determine if restoration of DAF-16 activity 
exclusively in neurons that express G85R is sufficient to rescue locomotor function in these 
worms.  If expression of daf-16 under the snb-1 promoter offered similar protection against 
G85R toxicity as daf-2(e1370) does in a wild type daf-16 background, this would suggest that the 
beneficial effects of reduced IIS on proteotoxicity are being mediated in a cell autonomous 
manner.  Similarly, this approach would allow you to selectively restore daf-16 in any tissue of 
the Psnb-1::G85R::YFP;daf-2(e1370);daf-16(mgDf50) worm in order to determine if this was 
beneficial to locomotion.  If Psnb-1::daf-16 rescued locomotor function in the Psnb-
1::G85R::YFP;daf-2(e1370);daf-16(mgDf50) worm but expression of daf-16 in other tissues did 
not this would suggest a cell autonomous effect of decreased IIS reducing SOD1 toxicity.  An 
alternative interpretation could be that snb-1 expressing neurons act to coordinate an 
organismal response to SOD1 toxicity.  In order to control for this possibility, one could develop 
a SOD1 toxicity assay in a non-snb1 expressing tissue and ensure that rescue of daf-16 function 
under control of the snb-1 promoter does not affect SOD1 toxicity in this assay.  This would 
ensure that the effects of increased DAF-16 activity on G85R toxicity are truly cell autonomous 
and not coordinated by snb-1 expressing cells.  A cell autonomous effect of decreased IIS on 
SOD1 toxicity could be further validated through cell specific knockdown of daf-16 on the 
G85R;daf-2(e1370) background.  A daf-16 RNAi driven by Psnb-1 would be predicted to 
eliminate the rescue typically seen in these worms if the benefits of daf-2(e1370) are mediated 
cell autonomously.   
Developing an accurate model of the cell autonomous versus nonautonomous effects of 
reduced IIS on stress resistance is of clinical importance due to the potential for reduced IIS to 
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ameliorate toxicity associated with a broad range of neurodegenerative diseases.  Reduced IIS 
might have adverse effects in certain tissues.  If this were true therapies could be developed 
that target reductions in IIS to specific tissues or potentially even regions within the brain.  
Conversely if tissues or brain regions were found that were able to coordinate organismal stress 
response, as certain cell types regulate aging in the worm, reduced IIS in these cell types could 
be exploited to ameliorate disease globally. 
 
Molecular Mechanisms of PA Neuroprotection 
Although we were able to identify the target of PA as HNRNPK and determine that PA alters 
rRNA abundance presumably through HNRNPK, a number of questions remain.   
Are Reductions in rRNA Abundance Neuroprotective? 
 Reductions in rRNA abundance after stress are well documented, and are typically 
thought to be associated with apotosis144,146.  Consistent with these observations our data 
demonstrates an ability of PA to increase rRNA abundance under stressful conditions.  By 
preventing decreases in rRNA abundance PA may be acting to prevent apoptosis.  The fact that 
stressed neurons not treated with PA increase their abundance of rRNA suggests that increasing 
rRNA may be an endogenous mechanism for coping with cellular stress.  Increased rRNA 
abundance may facilitate increased translation that allows for translation of pro-survival factors.  
Alternatively increased rRNA could function in a translation independent fashion.  Non-coding 
RNAs are capable of having signaling pathways and the 5s rRNA has been shown to act as a 
brake on p53 activation by stabilizing mdmx142.  Possible pro-survival activities of rRNAs could be 
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investigated through overexpression of rRNA.  A Herpes Simplex Virus (HSV) could be 
engineered to expresss 5s, 5.8s, 18s or 28s rRNA and the neuroprotective capacity of 
overexpression of rRNA could be monitored in motor neuron cultures exposed to various 
stressors. 
A potential role for decreased rRNA in survival has not been investigated.  Knockdown of 
components necessary for translation, such as ribosomal proteins and translation initiation 
factors, is not only tolerated in C. elegans, such manipulations can significantly extend 
lifespan139,141.  Due to the proven record of knockdown of transcriptional machinery in worms, C. 
elegans might be an optimal system to begin investigating the effects of knockdown of 5s, 5.8s, 
18s, and 28s rRNAs.  It would be interesting to determine if knockdown of any of the rRNAs is 
tolerated and, if so, if this knockdown increases longevity or stress resistance.  If knockdown of 
rRNA is tolerated it would also be interesting to determine the effect of rRNA knockdown on 
daf-16::GFP reporter worms.  These worms show robust nuclear accumulation of DAF-16::GFP 
upon exposure to stimuli which activate DAF-16.  If RNAi to rRNAs increases stress resistance 
and DAF-16 activation in worms this would suggest that reduction of rRNA stability might 
represents the neuroprotective mechanism of PA.  Some manipulations in the worm that extend 
lifespan through inhibition of translation are not daf-16 dependent139, therefore it would be 
informative to determine whether daf-16 is necessary to mediate any lifespan extending or 
stress resistance effects of rRNA knockdown.  A positive result in the worm would suggest follow 
up experiments to determine if rRNA knockdown can be protective in mammalian cells as well.  
A HSV could be generated to knockdown rRNAs in neurons and its protective effects could be 
screened in the neuroprotection assays for which PA has already been determined to be 
effective. 
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Does Altered rRNA Abundance Represent the Only Functionally Significant Change in HNRNPK 
After PA Treatment?   
Although we were unable to find an effect of PA on many other HNRNPK functions, such 
as alternative splicing, activation of NFκB, or abundance of HNRNPK target mRNAs, our assays 
were somewhat limited in scope and therefore do not represent absolute evidence that PA is 
not altering these functions.  Our investigation into HNRNPK’s role as a transcription factor was 
limited to effects on NFκB.  HNRNPK effects the transcription of a number of other genes which 
we did not investigate54.  Similarly HNRNPK is known to effect alternative splicing of a number of 
the genes in the alternative splicing assay we performed, but these do not represent all of the 
HNRNPK mediated alternative splicing events.  In order to further investigate potential effects of 
PA on HNRNPK mediated splicing and gene expression, total RNA sequencing could be 
performed on PA treated cells and compared to vehicle.  This approach would allow for 
simultaneous quantification of changes in transcript abundance as well as alternative splicing.  
The ability to quantify non-coding RNA is another important advantage of this approach.  Since 
we already know that PA alters rRNA abundance, other non-coding RNAs might be important 
targets of HNRNPK which are altered by PA as well.  Alternatively this could be accomplished 
with an exon array, although the ability to quantify non-coding RNAs would be lost. 
 Another important experiment would be to identify all of the RNAs whose binding to 
HNRNPK is modified by PA treatment.  We know that PA decreases rRNA stability.  Work by Jiaqi 
Shi and colleagues suggests that HNRNPK binds to and is an important stabilizer of rRNAs and 
displacement of HNRNPK from rRNA leads to its degradation60.  Based on this model, PA’s ability 
to decrease rRNA abundance could potentially be mediated by a displacement of HNRNPK from 
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rRNA resulting in decreased rRNA stability.  There could be numerous other RNAs which are 
displaced, or preferentially bound, by HNRNPK after PA treatment.  One might be able to 
identify some of these transcripts simply by changes in transcript abundance, but they may be 
difficult to identify if they are not being actively targeted for degradation.  If they are not 
actively being degraded their abundance may be similar whether they are HNRNPK bound or 
not.  Stress or other stimuli may target these RNAs for degradation, at which point the effect of 
PA would become biologically significant, but the PA effect may be masked under basal 
conditions.  One way to identify all the RNAs whose binding to HNRNPK are altered by PA would 
be through Immunoprecipitation of HNRNPK followed by sequencing of HNRNPK bound 
transcripts under vehicle and PA treated conditions.  This would give a quantitative analysis of 
all the transcripts which are dissociated or preferentially bound to HNRNPK after PA treatment. 
 Another limitation of our analysis of PA activity was the use of HEK293 cells for most 
screening assays.  The neuroprotective properties of PA were described in spinal cord cultures 
which raises the possibility of cell type specific effects of PA.  It may be important to perform the 
experiments described above in neurons and, it may even be necessary to repeat some of the 
previously performed assays in neurons as well. 
Does PA Alter Other HNRNPK Activities in a Stress Dependent Fashion?   
A number of studies have shown that HNRNPK plays an important role in p53 biology, 
both as a transcriptional co-activator of p53 targets and as a transcriptional repressor of genes 
downregulated by LINCp21 upon p53 activation54,55.  This is of particular interest in light of work 
implicating p53 in neurodegeneration and preclinical data suggesting that p53 inhibitors may be 
effective therapeutics for neurodegenerative disease147.  Based on our observations regarding 
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rRNA and the fact that PA is neuroprotective, it is possible that PA plays a role in modifying 
other stress specific functions of HNRNPK.  For this reason it may prove important to do many of 
the experiments we already performed, as well as some of the ones described above, under 
basal as well as stressed conditions.  Unfortunately adding stress to the analysis of HNRNPK 
function after PA treatment makes data interpretation significantly more difficult; as you now 
have to tease apart what changes in HNRNPK function are cause by stress, and which are caused 
by PA under conditions of stress.   
Can Functional Data be Inferred by Determining the Structure of PA Bound HNRNPK?   
Another potential direction to take this project would be to try to determine where PA 
binds HNRNPK.  Several approaches could be considered to answering this question.  1) The 
BIACORE analysis that was performed on GST-HNRNPK could be repeated using overlapping 
truncated versions of the protein in order to define a minimal binding domain.  2) A truncated 
overlapping HNRNPK constructs could also be transfected into cells and analyzed using the 2B 
binding assay.  3) One could also attempt to crystalize PA bound to HNRNPK.  These approaches 
could be used to determine where PA is binding HNRNPK.  Many of the domains of HNRNPK are 
well characterized and knowing which domains PA is interacting with might give insight into its 
activity.  If PA is acting to occlude a KH domain this might suggest which HNRNPK might be 
displaced by PA binding.  If PA binds in or near the KI domain, this might suggest that PA is 
disrupting an HNRNPK protein-protein interaction.  Similarly, binding on or near a site of known 
post-translational modification might suggest a role for that residue in stabilizing rRNA, or 
interaction with an important protein partner. 
Could PA Have Therapeutic Potential Against Cancer?   
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While we set out trying to identify the neuroprotective mechanism of PA, we may have 
identified a cancer fighting activity of PA.  PA was originally described as potentially having 
cancer fighting properties based on its ability to relocalize FOXO1 to the nucleus in PTEN 
deficient cells.  Our work potentially suggests another cancer fighting property of PA.  Work by 
Jiaqi Shi, and colleagues, has described a significant reduction in eIF3f in various human cancers, 
including pancreatic cancer and melanoma148-150.  eIF3f appears to play an important role in 
decreasing translation by increasing rRNA degradation.  The molecular mechanism by which this 
is achieved is by dissociating HNRNPK from rRNA, thus decreasing their stability and facilitating 
their degradation60.  As we have found that PA decreases rRNA abundance, it is conceivable that 
administration of PA to eIF3f deficient cells might act to correct dysregulated translational 
control in these cells.  This could be of therapeutic benefit.  Shi and colleagues describe 
numerous cell growth and proliferation assays used to characterize cells that are transformed by 
a loss of eIF3f.  Monitoring changes in these assays in PA treated cells could be informative 
about whether PA treatment could be of therapeutic potential. 
Screening for Compounds with Similar Properties as PA. 
The intent of this study was to identify the mechanism of action of PA so that 
compounds with more “drug-likeness” than PA could eventually be identified.  Assuming it can 
be verified that altering the abundance of rRNA is PA’s protective mechanism, then a screen for 
rRNA modulating compounds could be undertaken.  This could be done by high throughput 
qPCR.  A potentially confounding aspect of this approach is that PA appears to change rRNA 
abundance in different ways under stressed and unstressed conditions.  It may be necessary to 
determine which represents the neuroprotective activity before undertaking this screen. 
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A more technically challenging but potentially more informative approach could be to 
utilize a fluorescent RNA aptamer to monitor the interaction between HNRNPK and rRNA.  Since 
HNRNPK binding to rRNA has been suggested to increase rRNA stability, PA might be changing 
HNRNPKs binding to rRNA.  Paige et al recently described an RNA aptamer, called spinach, which 
mimics GFP upon addition of the cell permeable fluorophore DFHBI.  In their work they attach 
spinach to 5s rRNA and are able to monitor its cellular localization and abundance in live cells in 
real time151.  While they do not perform any FRET experiments, it is possible that FRET between 
spinach and a fluorescently tagged protein (such as HNRNPK) could be used to monitor protein 
RNA interactions.  A screen could be designed where fluorescence from a fluorophore on 
HNRNPK excites 5s rRNA spinach and spinach fluorescence is used to monitor their interaction in 
the presence of various drugs.  This could be set up as a high throughput imaging screen looking 
for compounds that modify FRET between 5s rRNA and HNRNPK. 
Summary:  Our work has identified HNRNPK as the target of the neuroprotective compound PA.  
We have described a role for PA in modifying HNRNPKs ability to regulate rRNA abundance.  We 
show that neurons endogenously upregulate the abundance of the 5.8s rRNA when stressed and 
PA acts to enhance this effect.  rRNA degradation has been associated with apoptosis and the 
ability of PA to upregulate rRNA may represent PA’s mechanism of neuroprotection.  
Alternatively PA appears to decrease rRNA abundance when chronically administered under 
non-stressed conditions.  This may also represent a potential neuroprotective activity as 
disruption of translation machinery has been shown to increase lifespan in various model 
organisms. 
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Abstract 
 The Forkhead Box O (Foxo) proteins represent an evolutionarily conserved family of 
transcription factors that play an important role in regulating processes including metabolism, 
longevity, and cell death/survival.  How is it that a single transcription factor can initiate such 
divergent cellular responses?  We will review the evidence that specific patterns of post-
translational modifications play a key role in directing Foxo into various transcriptional readouts.  
This regulation appears to take on a two tiered regulatory model; with a group of well defined 
post-translational modifications regulating nuclear localization and transcriptional activity while 
a second set of modifications regulate the transcriptional specificity of Foxo. 
Introduction 
 The Forkead Box O (Foxo) transcription factors are members of the Forkhead 
superfamily of winged helix transcription factors.  The Foxo family regulates cellular processes 
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including metabolism, stress response, DNA damage repair and cell death.  The Foxo family is 
highly conserved evolutionarily, with Foxo orthologs exhibiting similar physiological functions in 
model organisms such as Caenorhabditis elegans, Drosophila melanogaster, and in vertebrates.  
There are four mammalian Foxos, FOXO1, FOXO3, FOXO4 and FOXO6.  FOXO2 is identical to 
FOXO3 and FoxO5 is the fish ortholog of FOXO3.    While all Foxo members are capable of 
binding the same core DNA sequence, 5’-TTGTTTAC-3’, the expression of individual Foxos is 
tissue specific.  In addition, some Foxos undergo specific regulation or lack the regulatory 
interactions of other isoforms.  In most cases groups study the regulation of a single Foxo 
isoform.  Frequently regulatory pathways that are discovered in a single Foxo isoform are 
conserved between isoforms, therefore, for the sake of simplicity, the general term Foxo will be 
used in this article instead of listing each individual isoform. 
 While much is known about signaling pathways that influence its nuclear localization, 
the necessary antecedent for transcriptional activity of Foxo, less is known about signaling 
pathways that control Foxo transcription of specific genes in specific contexts.  The ability of 
Foxo to regulate so many cellular processes would suggest that such signaling pathways exist in 
order to integrate cellular context and direct Foxo to specific targets.  For example nuclear 
localization of Foxo through Paclitaxel treatment causes cell death in breast cancer cells152, while 
nuclear localization of Foxo through Psammaplysene A treatment is neuroprotective in multiple 
models of motorneuron disease124.  Even within the same cell type Foxo can have opposing 
actions (mediating either apoptosis or survival of neurons100,124 depending on the cellular 
context), raising the question of how its opposing activities are regulated.  One mechanism of 
regulating Foxo transcriptional output is through its pattern of posttranslational modifications 
(i.e. phosphorylation, acetylation and ubiquitination).  We will review the evidence that these 
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patterns of posttranslational modification are responsible for regulating both transcriptional 
specificity and transcriptional activation.  In order to fully understand Foxo signaling it is 
important to consider both pathways – those that generally activate or inhibit Foxo (by 
regulating its subcellular localization), and those that direct Foxo to transcribe specific genes. 
Foxo Inhibitory Kinases 
 
 The following kinases are known, general inhibitors of Foxo signaling.  Their signaling 
activities are responsible for promoting translocation of Foxo out of the nucleus and regulating 
its degradation.  Because of their ability to turn off Foxo transcription, and therefore repress, for 
example, Foxo’s pro-apototic activity, these kinases are often considered in terms of Foxo’s role 
in cancer biology.  While it is clear that these signaling pathways play a role in controlling Foxo’s 
subcellular localization, the extent to which these posttranslational modifications (at any of 
these sites) play a role in the specificity of Foxo transactivation is unclear. 
PI3’K Regulates Foxo Activation through Its Downstream Kinases AKT and SGK 
The Phosphoinositide 3 Kinase (PI3’K) pathway is a major regulator of Foxo activation.  
Activation of PI3’K leads to phosphorylation and activation of downstream targets including 
Protein Kinase B (also known as AKT) and Serum and Glucocorticoid inducible Kinase(SGK).  AKT 
and SGK are both capable of recognizing the same motifs for substrate phosphorylation, 
RXRXXS/T, and are responsible for phosphorylation of Foxo at 3 key residues: Thr32, Ser253 and 
Ser315 (of Foxo3a).  When Foxo is phosphorylated at these residues it associates with 14-3-3 
proteins and is exported from the nucleus, where it is transcriptionally inactive97,153,154.   
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While AKT and SGK are capable of phosphorylating the same residues, there does seem 
to be some preference for specific sites between these two kinases.  In particular, the C-terminal 
most phosphorylation site, Ser315, seems to be preferentially phosphorylated by SGK, while 
Ser253 is preferentially phosphorylated by AKT155.  The N-terminal Thr32 is efficiently 
phosphorylated by both kinases.  Experiments using dominant negative forms of these two 
kinases have demonstrated that disruption of either AKT or SGK kinase activity leads to nuclear 
Foxo, suggesting a non-redundant role for these kinases in efficiently phosphorylating Foxo at 
these three sites and targeting it to the cytoplasm.   
Each of these three phosphorylation sites appears to mediate its own important 
function in the nuclear export of Foxo.  The most N-terminal phosphorylation site, Thr32, is 
involved in Foxo association with 14-3-3, which is essential for Foxo nuclear export.  The central 
phosphorylation site at Ser253 is located in the Foxo Nuclear Localization Sequence (NLS) and 
acts to disrupt NLS activity by introducing a negative charge to the basic NLS region.  This 
prevents re-entry of Foxo into the nucleus.  The C-terminal most phosphorylation site, Ser315, 
plays a key role in the rate of nuclear export.  Phosphorylation of Ser315 unmasks the Foxo 
Nuclear Export Sequence (NES) thus increasing its rate of nuclear export.  The importance of this 
residue is demonstrated by Foxo6, which lacks this phosphorylation site, and unlike the other 
three Foxos, is predominantly nuclear156.  Nuclear export of Foxo is an active process that 
depends on the association between CRM1 and Foxo.  Treatment of cells with the CRM1 specific 
inhibitor leptomycin B (which covalently modifies the CRM1 NES binding domain) results in a 
robust nuclear localization of Foxo even when Foxo is phosphorylated at Thr32, Ser253, and 
Ser315153. 
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Acetylation of Foxo influences AKT phosphorylation at Ser-253.  Foxo mutants that are 
acetylation-mimetic at Foxo lysine residues 242, 245, and 262 become highly phosphorylated 
under basal growth conditions.  Similarly, phosphorylation of wild type Foxo (Ser253) increases 
with deacetylase inhibitor treatment, while phosphorylation at Ser253 of non-acetylatable 
mutants is unaffected by deacetylase inhibitors157.  Acetylation of Foxo by the histone acetyl 
transeferases CBP and p300 inhibit Foxo DNA binding capacity in vitro.  Phosphorylation of Foxo 
at Thr32 disrupts the interaction between Foxo and CBP/p300.  These data suggest a model in 
which acetylation inhibits Foxo transcription in a sequential manner.  Once Foxo is acetylated on 
lysine 242, 245, and 262, its DNA binding capacity decreases. Acetylated Foxo, which does not 
interact with DNA, is a superior substrate for phosphorylation by AKT at nuclear export sites.   
Phospho Thr32/Ser253 Foxo loses the interaction between Foxo and CBP/p300 and thus negates 
the favorable chromatin remodeling that this interaction promotes. 
The ability of PI3’K to activate AKT and SGK is negatively regulated by the lipid 
phosphatase, phosphatase and tensin homolog (PTEN) which degrades PIP3 thus inhibiting 
PI3’K.  Inactivation of PTEN is common in glioblastomas and prostate cancer158,159.  Similarly, 
decreased PTEN activity has been characterized in breast cancer160,161.  The ability of this 
pathway to robustly control Foxo nuclear localization helps explain the oncogenic properties of 
PTEN.  Normally, PTEN hydorlyzes PIP3, the product of PI3’K, and therefore decreases the 
activity of AKT and SGK.  PTEN deficiency results in a constitutively cytoplasmic Foxo.  The lack of 
nuclear Foxo in these cells could contribute to oncogenic transformation through a loss of the 
cell cycle arrest and proappototic capabilities of Foxo.  
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Phosphorylation of Ser315 by SGK Primes Foxo for CK1 Phosphorylation and Increases the 
Rate of Nuclear Export 
 Casein Kinase 1 (CK1) plays a role in cell differentiation and circadian rhythm control and 
its dysregulation can contribute to neurodegeneration and cancer development162.   CK1 can 
phosphorylate Ser318 and Ser321 but only after phosphorylation of Ser315 by SGK.  
Phosphorylation of Ser315 by SGK creates a consensus sequence for CK1 phosphorylation, 
S/T(P)XXS/T, at Ser318 which in turn creates a CK1 consensus sequence at Ser321.  Ser to Ala 
mutations and phosphospecific antibodies have been used to demonstrate that phosphorylation 
at these residues is, in fact, hierarchical, with phosphorylation of Ser315 by SGK being necessary 
for the subsequent phosphorylation of Ser318 and Ser321 by CK1.  As mutations at any of these 
sites have no effect on nuclear import rates; they probably function by increasing nuclear 
export.  It is thought that in conjunction with Ser325 this grouping of highly phosphorylated 
residues creates an acidic patch that increases Foxo’s association with its nuclear export 
complex163. 
Dual Specificity Tyrosine Phosphorylated and Regulated Kinase 1A (DYRK1A) Increases Nuclear 
Export of Foxo 
 DYRK1A is a serine/threonine kinase found in both the nuclear and cytoplasmic 
compartments.  While some DYRK1A targets are known, a detailed understanding of its cellular 
functions is lacking.  Decreased levels of the Drosphila ortholog, MiniBrain Kinase, results in 
decreased brain size suggesting a role in the regulation of neurogenesis.  Based on its 
chromosomal location, and the role of MiniBrain, DYRK1A has been implicated in the 
pathogenesis of Down syndrome164.  DYRK1A has been shown to phosphorylate Foxo at Ser325.  
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Phosphorylation at this residue decreases the amount of Foxo in the nuclear fraction and 
accordingly decreases Foxo transcriptional activity.  DYRK1A activity is SGK-and-CK1-
independent and a Ser to Ala mutation at Ser325 increases the amount of nuclear Foxo165.  
Although DYRK1A activity is PI3’K independent, phosphorylation of Foxo at Ser325 by DYRK1A 
seems to have a synergistic effect with SGK and CK1 perhaps by enhancing the acidic patch 
effect that promotes Foxo to interact with its nuclear export complex.  
IKK Regulates Foxo Inactivation and Degradation in an AKT Independent Fashion 
 The IкB Kinase (IKK) is best known for its regulation of the Nuclear Factor-κB family of 
transcription factors166.  Activation of the IKK has also been shown to inactivate Foxo.  
Constitutive activation of IKK has been linked to breast carcinoma, suggesting a model where 
constitutive activation of IKK increases pro-survival factor expression and inhibits the pro-
apoptotic functions of Foxo.  Hu et.al. demonstrated that the ability of IKK to induce cytoplasmic 
localization of Foxo is AKT independent167.  This AKT independence was characterized using 
mutant forms of Foxo that are non-phosphorylatable at the three AKT/SGK sites described 
above, as well as cell lines lacking AKT activity.  Activation of IKK has been shown to induce 
phosphorylation of Foxo at ser644.  Phosphorylation at this residue results in both nuclear 
exclusion and degradation of Foxo.  Phosphorylation at ser644 has been shown to induce 
ubiquitination of Foxo and a subsequent decrease in Foxo levels that can be inhibited using the 
proteasomal inhibitor MG132.  
ERK Inhibits and Degrades Foxo 
 The RAS-ERK pathway is a signaling cascade that regulates cellular proliferation and 
survival168.  Many tumors are RAS overexpressors or express a mutant, constitutively active, 
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form of RAS.  When this is the case, ERK activity is upregulated and there is an accompanying 
decrease in Foxo transcriptional activity in two ways.  First, ERK has been shown to 
phosphorylate Foxo (at Ser294, Ser344, and Ser425 on Foxo3a) and this phosphorylation results 
in increasing amounts of cytoplasmic Foxo.  Second, Foxo phosphorylated at these three 
residues is less stable, and is degraded in a proteasome dependent fashion.  This decreased 
stability may be based on its increased interaction with the E3-ligase, MDM2169. 
Foxo Activating Kinases 
 
Stressors Induce Nuclear Accumulation of Foxo  
 A number of different kinases (MST1, JNK, and CDK1) are capable of promoting 
translocation of Foxo into the nucleus under conditions of cellular stress.  Once localized to the 
nucleus, Foxo seems to execute either a pro-survival or pro-death transcriptional pattern 
dependent on the cellular context and severity of the insult.  While phosphorylation at any of 
the sites described bellow seems to be sufficient to induce nuclear localization, little is known 
about the consequences of activating these pathways together.  Do these multiple stress 
dependent kinases represent redundant pathways of Foxo activation, thus ensuring that Foxo 
responds to stressors, or might they act to integrate data to help determine the severity of the 
stressor and thus signal the appropriate transcriptional pattern to execute? 
Oxidative Stress Activates JNK which Activates Foxo 
 c-Jun N-terminal Kinase (JNK) is a kinase which is activated by cell stress, including 
inflammatory signals, ultraviolet light and Reactive Oxygen Species (ROS), and upon activation 
can increase Foxo transcription.    ROS activate the small GTPase Ral, and Ral, in turn activates 
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JNK.  JNK then phosphorylates Foxo at Thr447 and Thr451 leading to an increase in its 
transcriptional activity170.  The JNK dependent effect on Foxo transcription appears to be 
antagonized by the AKT/SGK signaling pathway.   ROS are known to induce nuclear localization 
of Foxo even in the presence of serum (when AKT is active and would otherwise lead to 
cytoplasmic localization of Foxo).  Nevertheless, Foxo proteins which are phosphomimetic at the 
JNK sites show similar association with 14-3-3 upon insulin treatment as wild type Foxo, and 
undergo cytoplasmic localization.  This suggests that the nuclear localization of Foxo after ROS 
treatment is not regulated by JNK.  While Foxo is regulated normally by PI3’K after JNK 
phosphorylation, JNK phosphorylation of Foxo makes Foxo transcriptionally more active.   
CDK1 Activates Foxo as a Key Check in the Cell Cycle 
 Cyclin Dependent Kinase 1 (CDK1) phosphorylates Foxo in the forkhead domain at 
Ser249.  CDK1 is a kinase associated with cell cycle progression, predominantly the G2/M 
transition.  As opposed to the PI3’K/AKT pathway, phosphorylation at Ser249 by CDK1 disrupts 
the interaction between Foxo and 14-3-3, thus leading to its nuclear localization.  
Phosphorylation at this site varies with the cell cycle, with Foxo being highly phosphorylated at 
Ser249 during the G2/M transition (when CDK1 is most active) and relatively unphosphorylated 
during the G0/G1 transition.  The ability of CDK1 to increase Foxo transcription likely correlates 
with Foxo’s ability to induce expression of DNA damage repair genes such as GADD45 and genes 
that eliminate ROS.  These genes are turned on at the G2/M transition and ensure the cell is in 
an optimal state before the cell cycle continues171.   
Another interesting aspect of this pathway is that aberrant activation of the cell cycle 
has been associated with cell death in post-mitotic neurons.  For example depriving cerebellar 
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granule neurons of action potential firing (through blockage of calcium flux) causes cell death.  
This activity deprivation is also associated with an increase in CDK1 activity, leading to Foxo 
activation171.  Foxo-dependent cell death is mediated by the expression of pro-apoptotic factors 
such as Bim.  There is some disagreement about this as some have suggested that 
phosphorylation at Ser249 results in inhibition of Foxo potentially leading to tumorogenesis172. 
MST1 Phosphorylates Foxo Leading to its Activation 
 Mammalian Sterile 20-like kinase 1 (MST1) is known to control cell proliferation, survival 
and morphology173.  The fly ortholog of MST1, Hippo, is a known tumor suppressor and it is 
suspected that MST1 has a tumor suppressor capacity as well.  MST1 is capable of 
phosphorylating Foxo at Ser207174.  Once phosphorylated at this site the interaction between 
Foxo and 14-3-3 is disrupted and Foxo localizes to the nucleus.  Phosphorylation at this site can 
be initiated by ROS or activity/trophic factor deprivation in neurons.  Neuronal death induced by 
trophic factor/activity withdrawal or ROS exhibit a dependence on MST1 and Foxo175.  While not 
characterized, it is likely that this signaling pathway may also be adaptive allowing for survival 
depending on the severity of the insult.  Insults resulting in cell death are generally studied due 
to the fact that they result in an easily quantifiable phenotype (i.e. death/survival).  For this 
reason it is difficult to say definitively that this pathway is adaptive when less severe insults are 
administered, but the Foxo transcriptome would suggest that this is the case176. 
Kinases That Dictate a Transcriptional Profile 
 
 Foxo is the transcriptional regulator of a group of proteins whose cellular functions, 
when considered as a whole, are not directed towards a single purpose.  For example Foxo is the 
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regulator of GADD45a and manganese superoxide dismutase, which are involved in DNA 
damage repair and ROS scavenging respectively.  Yet Foxo also regulates expression of FAS-
ligand and BIM which are involved in apoptosis177.  These four proteins would likely never be 
activated in unison as there is no clear purpose in clearing cellular ROS and repairing DNA in a 
cell which has initiated an apoptotic pathway.  This suggests that Foxo is capable of integrating 
cellular signals in order to select the transcriptional profile suited to affect a specific outcome.  
This is analogous to the cellular function of the transcription factor p53, which acts to initiate 
cell survival and DNA damage repair in the case of mild insults but initiates cell death when 
insults are severe178.   
It is clear that post-translational modifications play an important role in specifying the 
transcriptional outputs of Foxo.  It has been technically challenging thus far to profile the Foxo 
transcriptome in the case of every post translational modification due to the sheer number of 
potential modifications and pathways that act upon Foxo.  While it is likely that some of the 
aforementioned inhibitory and activating kinases are specifying more than an on/off type signal, 
AMPK is the only kinase whose effect on Foxo’s transcriptional profile has been well 
characterized. 
AMPK acts to Integrate Data on Energy Levels into Foxo Transcriptional Activity 
 The AMP-activated Protein Kinase (AMPK) is a key regulator of energy homeostasis in 
cells.  It is regulated by the ratio of AMP to ATP in a cell, with higher AMP/ATP ratios resulting in 
AMPK activation.  AMPK can phosphorylate Foxo at six sites.  While phosphorylation at these 
sites appears not to have any effect on the localization or overall activity of Foxo, these sites do 
influence the transcriptional profile of Foxo.  Microarray studies of cells expressing mutant Foxo 
120 
 
that is non-phosphorylatable at the six AMPK sites has revealed a transcript profile in which 
genes involved in ROS resistance are up regulated179.  Simultaneously, others are turned down 
and many remain unchanged.  This is particularly interesting because it represents a second 
layer of control dictated by post translational modification.  AMPK does not regulate Foxo in a 
binary manner (i.e. transcriptionaly active versus inactive) instead it is dictating a specific 
transcriptional output.  The mechanism by which phosphorylation at these sites alters Foxo’s 
transcriptional pattern been well explored.  Potential mechanisms for AMPK’s control of Foxo 
dependent transcription include: recruitment of additional proteins to a transcriptional complex 
or direction of Foxo to specific promoter regions. 
 
Figure 1. Numerous residues on Foxo are regulated via phosphorylation.  These sites influence 
Foxo’s subcellular localization, transcriptional potency and specify gene targets for activation.  
*This SGK site is not present in Foxo6.  ** This JNK site is only present in Foxo4. 
 
Acetylation of Foxo 
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 The effect of acetylation on Foxo activity represents a complex balance between histone 
deacetylases (hDACs) such as Silent Information Regulator 2 (SIRT1) and (SIRT2) and the Histone 
Acetyl Transfreases (HATs) CREB Binding Protein (CBP) and p300.  The histone acetyltransferase 
activity of the coavtivators CBP/p300 could enhance Foxo transcription indirectly through their 
ability to acetylate histones and favorably remodel chromatin.  In contrast, acetylation of Foxo 
has been shown to inhibit its DNA binding capacity157.  This negative feedback mechanism is 
most likely offset by the activity of SIRT1 and 2 which are capable of deacetylating Foxo.  
Monoubiquitination of Foxo lysines which can prevent acetylation, should both keep Foxo non-
acetylated and extend its association with DNA promoter regions. 
SIRT1 and 2 
 SIRT1 and SIRT2 are members of the sirtuin family of decacetylases and are the 
mammalian homologs of the yeast deacetylase Sir2.  In yeast, Sir2 plays an important role in 
oraganismal longevity through histone deacetylation and gene silencing.  Deacetylation of other 
contributory proteins by Sir2, such as acetyl-coenzyme A, may also play a role in longevity 
through regulation of intermediary metabolism180.  In mammals, SIRT1 and SIRT2 interact with 
Foxo in a ROS-dependent manner.  ROS promotes nuclear localization of Foxo and nuclear 
localization of Foxo is necessary for the Foxo SIRT1 interaction since SIRT1 is constitutively 
nuclear.  Yet, nuclear localization alone is not sufficient to initiate the Foxo-SIRT1 interaction; 
cells must be exposed to increased levels of ROS to induce this protein-protein interaction.  
SIRT2 on the other hand shuttles between the nucleus and the cytoplasm, so it is conceivable 
that SIRT2 could deacetylate Foxo in the nucleus or the cytoplasm.   
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Based on the work of several groups, it appears that deacetylation of Foxo by SIRT1 
imparts transcriptional specificity, shifting Foxo’s transcriptional profile away from apoptosis 
and towards expression of survival promoting genes181-184.  This is consistent with findings that 
inhibition of SIRT1 or disruption of its interaction with Foxo promotes the expression of 
apoptotic genes controlled by Foxo in prostate cancer derived cell lines185,186.  Experiments in 
mouse embryonic fibroblasts that are null for SIRT1 suggest that deacetylation of Foxo by SIRT1 
selectively increases the expression of ROS resistance genes while having little effect on pro-
apoptotic gene expression181.  SIRT1 deacetylation of Foxo also seems to increase the ability of 
Foxo to induce cell cycle arrest.  These two findings taken together suggest the role for 
deacetylation of Foxo, by SIRT1, is to pause the cell cycle in order to allow cells to repair DNA 
damage and remove ROS prior to cell division.    SIRT2 has also been reported to upregulate 
transcription of Foxo targets that allow cells to cope with ROS, such as p27kip and manganese 
superoxide disumatase187.  In addition over expression of SIRT2 is capable of inducing 
transcription of the pro-apoptotic factor Bim188.  This scenario is quite reminiscent of p53178.   
CBP/p300 
 The HATs CBP and p300 have two distinct activities on Foxo transcription.  Acetylation of 
Foxo by CBP/p300 results in a decrease in Foxo transcriptional activity.  CBP is able to acetylate 
Foxo at Lys242, 245 and 262157.  These residues are all located in the DNA binding domain of 
Foxo, and in vitro experiments using mutants which mimic the acetylated state at these residues 
(by replacing the basic lysine residues with Alanines or Glutamines) have severely diminished 
DNA binding capacity in vitro157.  This is a mechanism through which CBP/p300 can act to inhibit 
Foxo-dependent transcription.   
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The second activity of CBP/p300 is to acetylate histones in a manner that allows Foxo 
increased access to promoter regions189.  One example of this activity is during treatment of 
cells with ROS.  Treatment with ROS has been shown to increases the association of CBP/p300 
with Foxo.  This interaction has been shown to be mediated by a redox sensitive disulfide bridge 
that covalently links Foxo to CBP/p300 through Cys477 on Foxo190.  This could potentially lead to 
acetylation of Foxo and decreased levels of Foxo transcription, yet ROS are known to increase 
the expression levels of many Foxo regulated genes.  The most probable explanation for this 
result is that CBP/p300 acetylation of histones favorably remodels chromatin while SIRT1/2 
prevents acetylation of Foxo and allows it to bind DNA.  Thus while CBP/p300 can act as 
repressors of Foxo through their protein acetyltransferase activity, they also act as coactivators, 
increasing Foxo transcription through their histone acetyltransferase activity.  A structural 
representation of how CBP/p300 binds Foxo and acts as a coactivator to increase Foxo 
transcription has recently been solved189.  
Ubiquitination of Foxo 
 
 Ubituitination plays a key role in the regulation of Foxo proteins.  Foxo, like many other 
proteins, is targeted for proteasomal degradation through polyubiquitination.  In addition to this 
canonical role for ubiquitination in protein degradation, monoubiquitination also plays a role in 
Foxo response to ROS.   This is achived by controlling transcriptional activity and localization of 
Foxo.  This suggests a complex role for ubiquitination in Foxo signaling.  Monoubiquitination of 
Foxoleads to activation of its transcriptional activity.  This is balanced by polyubiquitination 
which leads to degredation – essentially depression of Foxo transcription through degradation.  
Therefore, from the monoubiquitinated state, polyubiquitination can be used for long term 
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inactivation of Foxo transcription or deubiquitination can occur, allowing for quick reactivation 
of Foxo if necessary. 
Monoubiquitination by MDM2 
 Exposure of cells to ROS results in monoubiquitination of Foxo at multiple sites.  This 
monoubiquitination is lost upon treatment of cells with MDM2 siRNA suggesting this E3 ligase 
directly ubiquitinates Foxo.  Expression of Foxo-ubiquitin fusion constructs suggest that 
monoubiquitination of Foxo results in an increase in nuclear localization of Foxo as well 
enhancement of Foxo transcriptional activity.  While MDM2 likely acts as a monoubiquitinating 
E3 ligase for Foxo, this event probably primes Foxo for branching ubiquitination by SKP2.  This is 
suggested by the observation that very high levels of MDM2 expression (or phosphorylation of 
Foxo by ERK), which increases MDM2-Foxo interaction, results in decreased levels of Foxo 
protein191. 
Mutant Foxo constructs and treatment with deacetylase inhibitors suggests that the 
lysine residues that are ubiquitinated are the same residues that are acetylated by CBP/p300192.  
Under some circumstances a competition exists between the ubiquitin ligases and acetylases for 
these residues.  This is potentially important as it suggests a posttranslationaly modified state of 
Foxo where acetylases could interact with Foxo as cofactors (allowing optimal chromatin 
structure) without acetylating Foxo (which would inhibit its transcriptional activity).  It is 
important to note that this state is independent of SIRT deacetylation. 
Deubiquitination by USP7 
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 Deubiquitination of Foxo is mediated by the deubiquitinating enzyme USP7.  Foxo has 
been shown to interact with USP7 both through yeast two hybrid and immunoprecipitation 
experiments.  This interaction is enhanced by increased levels of ROS with kinetics which are 
slower than the monoubiquitination of Foxo192.  These observations suggest that Foxo exists in a 
dynamic equilibrium: Foxo monoubiquitination by MDM2 is induced by ROS, and this 
monoubiquitination is offset by USP7-dependent deubiquitination.  Deubiquitinated Foxo is less 
transcriptionally active, thus USP7 acts as a negative regulator on Foxo transcription.  While 
USP7 inhibits Foxo through deubiquitination it has no effect on protein levels of Foxo reinforcing 
the view that monoubiquitination of Foxo acts independent of protein degradation. 
Polyubiquitination by SKP2 
 SKP2 physically interacts with Foxo in a phosphorylation-dependent manner.  
Phosphorylation of Foxo at Ser253 (preferentially phosphorylated by AKT) is required for Foxo 
SKP2 interaction and its subsequent ubiquitination193.  SKP2 polybuiquitinates Foxo after binding 
and the ability of SKP2 to decrease Foxo protein levels is proteasome-dependent (it is abolished 
by MG132 treatment194).  Elevated SKP2 levels are found in a wide variety of human cancers, 
and overexpression of this protein in mice leads to tumor formation.  The ability to degrade 
Foxo (and thus eliminate its pro-apoptotic activity) may help explain the oncogenic properties of 
SKP2.  This is also consistent with the oncogenic properties of PTEN deficiency.  The loss of PTEN 
activity enhances AKT signaling and phosphorylation of Foxo at Ser253.  This not only promotes 
nuclear exclusion of Foxo but polyubiquitination by SKP2 which leads to degradation of Foxo.  
This link between SKP2 and AKT phosphorylation also helps to explain the capacity of PTEN 
deficiency to induce tumorogenesis.  
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Figure 2.  The acetylases CBP and p300 play an important role in chromatin remodeling, allowing 
Foxo to effectively transcribe its targets.  Interestingly CBP/p300 also have an inhibitory effect 
on Foxo DNA binding through acetylation of the Foxo DNA binding domain.  This negative 
regulatory effect is counteracted by the histone deacetylases SIRT1 and SIRT2.  Foxo acetylation 
can also potentially be prevented through monoubiquitination of the lysines in Foxo’s DNA 
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bidning domain.  Monoubiquitinaiton also primes Foxo for potential polyubiquitination and 
eventual degredation. 
 
Foxo Cofactors and Foxo as a Cofactor 
 
 Foxo transcriptional activity can be affected by cofactors.  These cofactors may have a 
general effect on Foxo transcriptional activity or they may confer Foxo transcriptional specificity.  
In addition, Foxo acts as a cofactor for a number of other transcription factors, affecting their 
transcriptional activity independently of Foxo’s own DNA binding activity.  This increases the 
scope of Foxo activity beyond the already impressively large number of Foxo transcriptional 
processes. 
β-Catenin Increases Foxo Transcriptional Activity 
 β-Catenin directly binds to Foxo and increases its transcriptional activity.  ROS increase 
the interaction between β-catenin and Foxo195.  This interaction may play a role in determining 
whether cells progress through the cell cycle or arrest.  In the absence of ROS, β-catenin 
interacts with members of the T cell factor (TCF) family of transcription factors, which act to 
promote progression of the cell cycle.  In contrast, increased Foxo transcription results in higher 
levels of cell cycle inhibitors such as p27kip.  In this way the ROS dependent interaction between 
Foxo and β-catenin may act like a switch, allowing cells to pause and clear harmful ROS when 
Foxo and β-catenin interact.  When oxidative stress subsides, β-catenin preferentially interacts 
with TCF, allowing cells to proceed through the cell cycle. 
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Foxo acts as a Corepressor of HIF1 
 As mentioned before, PTEN deficiency results in a lack of nuclear Foxo and is associated 
with tumorogenesis.  PTEN-deficient tumors are known to be quite aggressive and highly 
vascular.  This knowledge led to a study of the effects of PTEN on Hypoxia Inducible Factor 1 
(HIF1) a key transcription factor controlling the expression of many angiogenic genes.  PTEN 
alters HIF1 transcriptional activation via Foxo’s cellular localization196.  Even in PTEN deficient 
cells, if Foxo is localized to the nucleus, then HIF1 transactivation is inhibited.  This is 
accomplished by Foxo complexing with HIF1 and interfering with HIF1’s interaction with its 
coactivator p300196.  This discovery adds to the complexity of Foxo’s anticancer properties.  In 
addition to affecting cell cycle progression, clearing ROS, and proappoptotic capacity, Foxo also 
seems to act as a repressor of the HIF1 transcription factor and neovascularization. 
Foxo is a Corepressor of the Androgen Receptor 
 Much like its effect on HIF-1, Foxo is capable of repressing the transcriptional activity of 
the Androgen Recptor (AR).  This inhibition is not dependent on the transcriptional capacity of 
Foxo but simply on its nuclear localization.  Transcriptionally inactive Foxo (mutant in its DNA 
binding domain) inhibits AR as robustly as the wild type protein197.  Much like HIF-1, Foxo and 
the AR form a complex on AR promoter regions.  HDAC3 is also a part of this complex and seems 
to play an important role in Foxo’s ability to inhibit AR transcription.  Foxo inhibition of the AR 
prevents both adrenergic and non-adrenergic activation of the AR197. 
Foxo Acts as a Coactivator of Ets-1 
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 There are 15 consensus phosphorylation sites on Foxo which are predicted to be 
regulated by members of the Mitogen Activated Protein Kinase (MAPK) family.  Nine of the 
serine residues are capable of being phosphorylated in vivo by ERK and of these, five can also be 
phosphorylated by p38.  Mutational analysis has revealed that phosphorylation at these sites 
can influence Foxo interaction with another transcription factor, Ets-1.  Foxo interaction with 
Ets-1 leads to an increase in Ets-1 transcriptional activity as assessed by Ets-1 activity on the Flk-
1 promoter, which promotes angiogensis.  Foxo has no activity at the Flk-1 promoter region but 
Ser to Ala mutations at the putative ERK/p38 sites that disrupt the Foxo-Ets-1 interaction greatly 
diminish Ets-1 interaction with Flk-1198.  This suggests that Foxo can act as a cofactor for other 
transcription factors indicating an even broader role of Foxo in transcriptional regulation.  As 
discussed previously, phosphorylation of Foxo by ERK decreases Foxo stability potentially acting 
as a negative regulator of this signaling pathway. 
Foxo Signaling as a Potential Therapeutic Target for Disease 
 
 As of yet, the only clinical use of drugs that target the Foxo signaling pathway is in 
cancer.  Inactivation of Foxo through aberrant PTEN, AKT, IKK or ERK signaling have all been 
shown to promote tumorogenesis.  A number of chemotherapeutic drugs have been shown to 
mediate their activity at least in part through restoring Foxo activity to cells, inducing Foxo pro-
apoptotic target genes such as Bim.  For example, Paclitaxel is known to increase Foxo activity 
through repression of AKT and induction of JNK signaling which cooperatively lead to nuclear 
localization and activation of Foxo152.  While no drugs that function through the Foxo signaling 
pathway are currently available for treating diseases other than cancer, some research has 
suggested that under certain circumstances promoting Foxo signaling may be used in a pro-
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survival manner as well.  The marine sponge compound Psammaplysene A has been shown to 
be neuroprotective both in vitro and in vivo against neurotoxic insults124.  This reinforces the 
observation that induction of Foxo can have varying activity based on the cellular context of 
Foxo activation.  This raises the intriguing possibility of developing drugs in the future which act 
on Foxo to modulate its transcriptional profile.  Current drug strategies take advantage of the 
fact that Foxo, through the integration of various posttranslational modifications, is able to 
activate pro-survival or pro-death genes depending on the state of cell.  If we fully understood 
the signaling pathways that mediate Foxo gene expression choice, we could develop more 
potent drugs that not only activate Foxo, but ensure that it is transcribing only those genes 
which will give the greatest benefit in a specific disease state. 
 
Appendix 2 
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Abstract: 
 
Aging is a risk factor for the development of adult-onset neuro-degenerative diseases.  
While some of the molecular pathways regulating longevity and stress resistance in lower 
organisms are defined (i.e., those activating the transcriptional regulators DAF-16 and HSF-1 in 
C. elegans), their relevance to mammals and disease susceptibility are unknown.  We studied 
the signaling controlled by the mammalian homolog of DAF-16, FOXO3a, in model systems of 
motor neuron disease.  Neuron death elicited in vitro by excitotoxic insult or the expression of 
mutant SOD1, mutant p150glued  or polyQ-expanded androgen receptor was abrogated by 
expression of nuclear-targeted FOXO3a.  We identify a compound (Psammaplysene A, PA) that 
increases nuclear localization of FOXO3a in vitro and in vivo and show that PA also protects 
against these insults in vitro.  Administration of PA to invertebrate model systems of 
neurodegeneration similarly blocked neuron death in a DAF-16/FOXO3a-dependent manner. 
These results indicate that activation of the DAF-16/FOXO3a pathway, genetically or 
pharmacologically, confers protection against the known causes of motor neuron diseases. 
Introduction: 
 
Although motor neuron diseases due to single gene mutations are unusual (~10% of 
cases), the affected genes have been successfully used to model these diseases in experimental 
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systems 87.  Rare, genetic forms of motor neuron disease that arise from mutations in 
superoxide dismutase (SOD) or p150glued  have a disease phenotype that strongly resembles 
sporadic ALS with lower motor neuron predominance 88.  Another predominantly lower motor 
neuron disease, called spinobulbar muscular atrophy (SBMA or Kennedy’s Disease) is due to a 
polyglutamine expansion in the androgen receptor 89.  Despite identification of the “disease 
protein”, the underlying pathogenic mechanism(s) remain incompletely understood. 
In most cases of sporadic ALS, motor neuron death is triggered by the interaction of a 
genetic pre-disposition and environmental factors 90.  Genome-wide association studies have 
failed to reveal consistent susceptibility loci 91,92.  Correlative evidence suggests that aging is a 
risk factor for the development of ALS as well as other adult-onset neurodegenerative disorders 
93.  Studies from a variety of experimental systems have provided insight into the genetic factors 
controlling aging, in particular, the insulin/insulin-like growth factor signaling pathway 94,95.  In 
Caenorhabditis elegans, hypomorphic alleles of the daf-2 gene (mammalian homolog, 
insulin/insulin-like growth factor receptor) and the downstream signaling molecule age-1 
(mammalian homolog, phosphotidylinositol-3’-kinase, PI3’K) promote longevity and lifespan 
extension.  These effects require the activity of the DAF-16 transcription factor (mammalian 
homolog, FOXO3a)96.   
 DAF-16/FOXO3a shuttles between the cytoplasm (where it is inactive) and the nucleus 
in a process that is controlled by its phosphorylation state 97.  Phosphorylation of DAF-
16/FOXO3a by the PI3’K substrate kinases Akt and SGK 98 leads to the 14-3-3 protein-dependent 
export of nuclear DAF-16/FOXO3a and re-entry into the nucleus requires dephosphorylation and 
release of 14-3-3 98,99.  Within the nucleus, DAF-16/FOXO3a leads to the expression of a number 
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of genes that have context-dependent effects on cellular physiology.  Expression of a 
constitutively nuclear FOXO3a can promote the death of purified motor neurons and cerebellar 
granule cells and this has been linked to the expression of FasL 97,100.  In contrast, active FOXO3a 
protects a variety of quiescent cells against death evoked by oxidative stress or glucose 
deprivation and this has been linked to the expression of manganese superoxide dismutase 
(MnSOD) and catalase 101,102.  Thymocyte survival and differentiation is FOXO3a-dependent 103.  
Differences in beneficial versus harmful effects of FOXO3a probably relate to cell-circumstance-
specific level of activation and post-translational modifications 104.  
 Some of the stresses that contribute to motor neuron death in ALS include 
excitotoxicity, reactive oxygen species, accumulation of insoluble aggregates of neurofilaments, 
and defects in axonal transport 87,105-107. Since DAF-16/FOXO3a-dependent gene transcription, in 
some contexts, combats cellular stresses, we inquired whether manipulating FOXO3a signaling 
protected neurons from insults relevant to motor neuron diseases.  We show FOXO3a activation 
is neuroprotective across phyla and identify a toxicity-sparing pharmacological approach for 
enhancement of DAF-16/FOXO3a signaling activation.  
Methods: 
 
Source of Reagents: Trophic factors (ciliary neuronotrophic factor (CNTF), brain-derived 
neurotrophic factor (BDNF), neurotrophin 4 (NT 4), cardiotrophin 1 (CT 1) and glial-derived 
neurotrophic factor (GDNF)) were obtained from Alomone Labs (Jerusalem, Israel). 
Psammaplysene A was synthesized as described 110.  All other reagents were obtained from 
Sigma (St. Louis, MO) and were of the highest grade available. 
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Tissue Culture: Embryonic Sprague-dawley rat spinal cord neurons were grown on confluent 
monolayers of cortical astrocytes, as previously described 120.  The substratum was acid washed 
glass coverslips when imaging was performed and Primaria tissue culture plasticware (Falcon, 
Becton-Dickinson) when biochemistry was performed.   Culture media consisted of astrocyte-
conditioned media supplemented with 10 ng/ml CNTF, BDNF, NT 4, CT 1 and GDNF and 50% of 
media was replaced with fresh media every 3 days. 
 Male SBMA mice transgenic for the prion protein promoter-driven androgen receptor 
cDNA containing an expanded (112) CAG repeat tract were mated with non-transgenic C57Bl/6 
female mice 121.  Dissociated, mixed spinal cord cultures obtained from 13.5-day embryos were 
grown for 3 weeks in conditioned medium (conditioned on normal mouse astrocytes) containing 
charcoal-stripped serum to remove hormones. At 3 weeks, motor neurons were well 
differentiated and distinguishable from other neurons, including sensory neurons, by size and 
morphology.  At this time, cultures were treated with indicated conditions for 7 days; cells were 
then fixed with 4% paraformaldehyde and immunostained using antibodies to neurofilament 
heavy chain (NF-H) (SMI32; Sternberger Monoclonal Inc.). Motor neurons were visualized using 
a Leica DMR fluorescence microscope, photographed, and analyzed using IP Labs software.  
Statistical analyses of results were carried out using Student's t-test (viral infections) or ANOVA 
(compound treatments; SigmaStat).  
 
Recombinant HSV: cDNAs were cloned into the PrpUC amplicon plasmid to generate 
recombinant HSV as previously described 122.  The titer of virus used in these studies was 
routinely 3-5 x 107 plaque-forming units/ml.  The sources of constructs were: Michael 
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Greenberg, Harvard University (HA-tagged wild type and triple mutant human FOXO3a), David 
Borchelt, University of Florida (WT and G85R mutant SOD), Erika Holzbaur, University of 
Pennsylvania (WT and mutant p150glued) and Anne Brunet (3xFHRE-luciferase). 
 
Excitotoxicity Assay:  After 14 days in vitro (DIV), culture media was removed (and saved) and 
cells were exposed to 100 µM kainic acid (KA) for 1 hour.  Subsequently they were washed three 
times in Locke’s buffer not containing KA, the original media was replaced and incubated for 
another 24 hours at 37 oC. in 5% CO2 before fixation in 4% paraformaldehyde.  Motor neurons 
were identified in mixed culture by immunostaining for nonphosphorylated neurofilaments and 
counting only labeled cells with cell body diameter of 25 µm or greater.  We have previously 
validated this method as a means of specifically recognizing motor neurons (Figure 1 in 123).  In 
experiments involving recombinant HSV, 1 µL of viral stock was added to 1mL of culture media 
24 hours or more prior to the next manipulation.  Tubes containing viruses were color coded so 
that the operator was blinded to the specific virus used. 
 
Quantification of motor neurons:  The # of immunostained cells were counted in 3 randomly 
selected fields/coverslip and the mean value obtained.  In each experiment 3+ independent 
coverslips were used per condition and the results presented were obtained for 4+ independent 
cultures and experiments. 
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Immunocytochemistry:  Tissue culture cells were fixed in freshly prepared 4% paraformaldehyde 
in 0.1 M pH 7.4 phosphate buffer for 30 minutes prior to extensive washing in phosphate 
buffered saline.  Overnight incubation with primary antibody was performed at room 
temperature and after washing, coverslips were incubated with Alexafluor conjugated 
secondary antibody (2 – 4 hrs.).  When double labeling experiments were performed, species-
specific secondary antibodies with distinct emission spectra were employed.  Coverslips were 
washed prior to mounting in PermaFluor (Thermo Electron Corporation) and viewing on an 
Olympus FV300 Fluoview laser confocal microscope.   
 
Western Blots and quantification:  Cultures were lysed in NP-40 lysis buffer (1% NP-40, 40 mM 
Tris pH = 7.4, 0.15 M NaCl, 10% glycerol, 0,1% SDS, 0.1% deoxycholate + protease inhibitors and 
phosphatase inhibitors), sonicated, particulate matter removed by centrifugation and subjected 
to PAGE-SDS prior to transfer to nitrocellose.  Equal amounts of protein (determined using BCA 
reagents from Pierce) were loaded in each lane.  After blocking in 5% milk in phosphate buffer 
saline, membranes were incubated in primary antibody overnight, washed, incubated with 
secondary antibody, washed and visualized to GE Healthcare (Buckinghamshire, U.K.) 
chemiluminescent substrate according to the manufacturers directions.  Densitometric analysis 
of films was obtained using TINA (Isotopenmegeräte, GmbH) from 4+ independent 
experiments, the results averaged and mean values ± S.E. formed the basis of the statistical 
comparisons.  Quantitative data on band intensity was expressed as the fold change in 
comparison with values of HSV-LacZ infected cultures.  The displayed western blot data are 
representative of the results obtained from at least 4 independent cultures.  In some 
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experiments the LI-COR Odysseus system was used for visualizing and quantifying western blot 
bands.  Secondary antibodies were from LI-COR Biosciences (IR 800 or 680 goat anti-mouse IgG 
or anti-rabbit IgG).The source of primary antibodies was: (Calbiochem, Oncogene Research 
Products, rabbit anti- MnSOD (Stressgen Bioreagents, Victoria, British Columbia, Canada), rabbit 
anti- FKHRL1/FOXO3a and anti-phospho FKHRL1/FOXO3a (T32) (Upstate, Lake Placid, NY), anti-
phosphoFOXO3a (S253) (Abcam) and rabbit anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA).   
Species-specific HRP-conjugated secondary antibodies were from Amersham  (GE Healthcare, 
Buckinghamshire, U.K.) and Alexa 488-conjugated anti rabbit secondary antibody from 
Molecular Probes, Invitrogen (Eugene, OR). 
 
Subcellular fractionation 
Nuclear protein lysate was prepared using Sigma N-Xtract Tm kit. Briefly, cells collected from 
one 60 mm dish were suspended in 150 ul hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM 
MgCl2, and 10 mM KCl). After incubating on ice for 10 minutes, 10% IGEPA CA-630 was added to 
final concentration of 0.6%. Vortexed vigorously for 10 seconds and centrifuged immediately at 
10,000-11,000g for 30 seconds. The supernatant is cyoplasmic fraction and the pellet is nuclear 
fraction. 
 
Luciferase reporter assay 
Human embryonic kidney 293 cells were grown to approximately 80% confluence and then 
transfected either 3x Fork Head Response Element Luciferase (FHRE), the parent vector lacking 
138 
 
the FHREs (pGL3), or pGL3 vector containing 3x Retinoic Acid Response Element (RARE-
luciferase from Addgene).  In all cases, the Renilla luciferase reporter construct, driven by the 
thymidine kinase promoter (pRL-TK), was co-transfected as an internal control for transfection 
efficiency and cell death.  After 24 hrs the cells were trypsinized and replated into media 
containing the appropriate concentration of PA or vehicle.  After 48 hrs the cells were 
trypsinized again and replated into a 96 well plate in fresh media containing PA or vehicle (12 
replicates per condition).  Twenty four hours later the plates were analyzed using the Dual-Glo 
Luciferase Assay System (Promega) on the Xenogen In Vitro Imaging System.  The ratio of 
Luciferase signal to Renilla signal for each well was calculated and the various treatment groups 
were compared to vehicle. 
 
Bioinformatics 
In order to identify genes that were differentially expressed in ALS we accessed the NCBI 
GEO database and searched the available data sets for ALS-related microarray data.  Five data 
sets were identified and these were analyzed using the two-tailed t-test analysis with a 0.050 
significance level, as provided on the GEO site, to compare the control group to the ALS group in 
each of the data sets.   The data from these differentially expressed genes was then downloaded 
into a spreadsheet and searched for genes that were previously determined to be controlled by 
FOXO 176.  Genes that were present in both lists were added to the Supplement Table and their 
direction of regulation was indicated. 
 
Study of mice.  B6SJL-Tg(SOD1-G93A)1Gur/J mice were obtained from Jackson labs and were 
bred to the F1 generation of C57Bl/6 x SJL mice.  The offspring of this cross was used for all of 
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the biochemical studies (n=4 in each experimental group).  Lumbar spinal cord was obtained at 
P87, frozen on dry ice until use.  The spinal cord segments were homogenized with a dounce in 
NP-40 buffer as above (10:1 volume to weight).  All other manipulation of the lysates was as 
described tissue culture cells. 
 
Study of Drosophila 
Drosophila stocks were crossed on standard cornmeal agar media at 29°C. Food was 
supplemented with DHT (Steraloids) and Psammaplysene A once it had cooled to <50 °C, to final 
concentrations of 1 mM and 0.5 mM, respectively. Eye phenotypes of female flies of each 
condition were examined and blindly scored according to the criteria described with one scoring 
modification to increase sensitivity to differences in affected eye areas 111.   
Flies haploinsufficient for dFOXO were generated by mating GMR-GAL4, AR52Q flies to 
the following fly stock lines: foxoBG01018 (Bloomington stock 12530); foxo21, foxo25 114 and 
foxoc01841 (Exelixis, Harvard). 
 
Study of C. elegans 
The following C. elegans strains were obtained from the C. elegans Genetic Center 
(biosci.umn.edu/CGC) or constructed by us: ∆glt-3: ZB1096 glt-3(bz34) IV; nuIs5: KP742[glr-
1::gfp; glr-1::Gs(Q227L) V; lin-15(+)]; ∆glt-3; nuIs5: ZB1102 glt-3(bz34) IV; nuIs5 V; age-1; ∆glt-
3; nuIs5 Strain ZB1102 glt-3(bz34) IV; nuIs5 V was crossed with strain BE13 sqt-1(sc13)II. sqt-1 
was then kicked out and replaced by age-1 using strain TJ1052 age-1(hx546) II. Pmyo-3:daf-16::gfp 
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Strain ZB2283 was produced by Jian Xue and Carolina Ibanez-Ventoso by making transgenic 
animals carrying an extra-chromosomal array containing Pmyo-3:daf-16:gfp. 
For PA treatment, we soaked the diluted drug into standard NGM culture plates. We 
transferred freshly growing nematode cultures to these plates and allowed them to grow for 2 
days before assessing the effect.  To determine the ratio of nuclear vs. cytoplasmic DAF-16 levels 
we used a strain transgenic for Pmyo-3:daf-16::gfp, where the DAF-16::GFP reporter is expressed 
in body wall muscle cells. We compared the intensity of GFP labeling in the nucleus and adjacent 
cytoplasm using NIH-Image. We monitored the effect of PA or age-1 on nematode excitotoxicity 
by measuring the extent of neurodegeneration in ∆glt-3; nuIs5 animals ± PA or ± age-1 
mutation. We observed free-moving animals with an inverted scope under Nomarski DIC optics 
with no anesthetics. Swollen cells in the nerve-ring region were counted as head necrotic figures 
indicative of neurodegeneration. 
 
Statistics.  Pairwise comparisons employed two-tailed Students’s t-test and when three or more 
groups were compared we used Analysis of Variance (ANOVA) and post hoc analysis with 
significance set at p< 0.05. 
Results: 
 
In fibroblasts, expression of FOXO3a with alanine substitutions at three phosphorylation 
sites (Threonine 32, “T32”; Serine 253, “S253” and Serine 315, “S315”) leads to nuclear 
retention of the transcriptionally active protein 98.  Cultures of rat spinal cord neurons were 
infected with recombinant HSV engineered to express the triple mutant (TM) or wild type (WT) 
FOXO3a.  Immuno-staining for the transgene demonstrated that the WT-FOXO3a is restricted to 
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the neuronal cytoplasm and the TM-FOXO3a is largely nuclear (Figure 1A).  The transgene 
products were detectable in all neurons for >5 days without any apparent toxicity.  To 
determine if these transgenes influenced the susceptibility of motor neurons to excitotoxic 
insult, 14 days in vitro (DIV) mixed spinal cord cultures were infected with HSV- WT-FOXO3a, 
HSV- TM-FOXO3a, HSV-LacZ or no virus, the following day exposed to an excitotoxic challenge 
(100 µM kainic acid (KA) or vehicle for 1h) and the number of surviving motor neurons 
determined 24 hours later 199,200.  While approximately 45% of motor neurons were killed by KA 
in the HSV-LacZ and HSV-WT-FOXO3a infected cultures, no KA-induced motor neuron death 
occurred in the HSV-TM-FOXO3a infected cultures (Figure 1B).  ANOVA using transgene 
expression as the between-group factor and survival as the within-group factor demonstrated a 
significant difference between groups (F(5,12) = 15.68; p< 0.001, ANOVA).  The post-hoc 
comparisons between groups using Scheffé’s F test with significance set at p < 0.05 showed that 
significant motor neuron death only occurred in the cultures expressing the WT-FOXO3a or LacZ.  
Thus expression of the TM-FOXO3a protects cultured motor neurons from excitotoxic insult. 
Next we explored the capacity of TM-FOXO3a to protect motor neurons in vitro from a 
variety of proteotoxic insults relevant to motor neuron diseases.  In spinobulbar muscular 
atrophy a polyglutamine expansion in the androgen receptor (AR) leads to testosterone-
dependent motor neuron death 121.  We made cultures from spinal cord of mutant AR-
expressing mice and found that a 7 day treatment with dihydrotestosterone (DHT) led to the 
loss of approximately 25% of motor neurons compared with the vehicle-treated cultures (p < 
0.05) (Figure 1C).  We observed an equivalent rate of DHT-dependent motor neuron death in 
cultures treated with HSV-WT-FOXO3a (p < 0.05).  Infection of cultures with HSV-TM-FOXO3a, 
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however, completely blocked DHT-dependent death of motor neurons, with all motor neurons 
surviving in the presence of DHT (Figure 1C). 
Proteotoxic motor neuron death can also be precipitated by expression of mutant forms 
of human superoxide dismutase or p150glued 201.  We asked if treating cultures expressing these 
mutant proteins with TM-FOXO3a affected motor neuron death.  We began these studies by 
determining concentrations of viruses that led to co-expression of both transgenes in neurons 
but did not lead to toxicity owing to the viral burden.  We established that infection of spinal 
cord neurons with ~8 x 104 pfu of HSV-mutant SOD/ml culture media reliably induced 50% 
motor neuron loss 7 days post infection.  Addition of ~8 x 104 more pfu of HSV-LacZ to these 
wells did not exacerbate motor neuron death.  Immunocytological localization studies revealed 
that 97 ± 2 % of motor neurons expressing mutant SOD also expressed ß-galactosidase (Figure 
1D).  In all subsequent studies we confirmed a >95% co-expression of the toxicity-inducing 
mutant protein (SOD or p150glued) and LacZ or TM-FOXO3a.  We also established that co-
expression of LacZ with either WT SOD or WT p150glued had no adverse effect on motor neuron 
survival.  We previously have shown that this concentration of HSV-mutant SOD infects all 
motor neurons at this plating density 120,201.   
We compared next the outcome of cultures infected with HSV-mutant SOD + HSV-LacZ 
or HSV-TM-FOXO3a as well as cultures infected with HSV- mutant p150glued + HSV-LacZ or HSV-
TM-FOXO3a (Figure 1 E).  The ANOVA indicates that statistically significant differences between 
groups existed (F(5,12) = 70.14, p < 0.0001).  Infection of cultures with HSV-mutant SOD + HSV-
LacZ led to significantly lower motor neuron numbers when compared with cultures infected 
with HSV-mutant SOD + HSV-TM-FOXO3a (35.0 ± 4.0 versus 69.0 ± 2.0, p < 0.05 in post hoc 
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analysis).  Similarly motor neuron numbers from cultures infected with HSV- mutant p150glued + 
HSV-LacZ were significantly lower than motor neuron numbers from cultures infected with 
mutant p150glued + HSV-TM-FOXO3a (36.0 ± 4.0 versus 68.0 ± 3.0, p < 0.05 in post hoc analysis) 
(Figure 1E). Thus the toxicity of three different mutant proteins that cause motor neuron 
disease can be blocked by expression of a version of FOXO3a that constitutively resides in the 
nucleus. 
 
Figure 1.  Triple-mutant FOXO3a is retained in the nucleus and protects against excitotoxic and proteotoxic insults.  Panel A. Mixed 
spinal cord neurons were transfected using Lipofectamine 2000 (Invitrogen) with HA-tagged wild type FOXO3a (WT-FOXO3a) or 
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triple mutant FOXO3a (TM-FOXO3a) and 24 hours later fixed and immunostained with anti-HA antibody and Alexa-488 conjugated 
secondary antibody.  In the left frame, WT-FOXO3a is present in neurites and the soma cytoplasm while the nucleus appears devoid 
of immunoreactivity.  In the right frame, TM-FOXO3a is seen largely concentrated in the nucleus while soma and neurite staining is 
weak.  Calibration bar = 24 microns.  Panel B., Mixed spinal cord cultures were maintained for 14 DIV before infection with HSV-LacZ, 
HSV-WT-FOXO3a, or HSV-TM-FOXO3a.  24 hrs later, the cultures underwent a 1 hr excitotoxic insult and after 24 hrs, the cultures 
were fixed and stained for SMI-32.  The number of SMI32(+) motor neurons surviving each treatment is noted on the ordinate axis.  
A statistically significant reduction in motor neuron number is seen in all groups except the cultured treated with HSV-TM-FOXO3a.  
Panel C., 14 DIV mixed spinal cord cultures from mice engineered to express polyQ expanded AR were infected with HSV-LacZ, HSV, 
WT-FOXO3a, or HSV-TM-FOXO3a and then treated with DHT or vehicle.  After 7 days, fixed cultures were stained and the number of 
motor neurons surviving was determined.  A statistically significant, DHT-dependent death was found in the uninfected group and 
the HSV-WT-FOXO (but not HSV- TM-FOXO3a) group.  Panel D., Cultures were infected with HSV-mutant SOD (green) and HSV-LacZ 
(red) and subsequently stained with specific antibodies.  A high degree of co-localization is evident (yellow, merge image).  
Calibration bar = 40 microns.  Panel E., The number of motor neurons surviving each treatment was determined after infecting 14 
DIV cultures with combinations of HSV-LacZ, TM-FOXO3a, mutant SOD, mutant p150glued, WT-SOD or WT p150glued.  Mutant SOD and 
mutant p150glued motor neuron death is blocked when TM-FOXO3a is expressed.  
Inhibition of PI3’K should lead to accumulation of FOXO3a dephosphorylated at T32, 
S253 and S315 and enhanced partitioning of FOXO3a into the nucleus.  Given this, we wondered 
if PI3’K inhibition would confer neuroprotection.  We began these experiments by determining 
that application of the PI3’K inhibitor LY294002 (final concentration, 20 µM) every other day for 
six days, did not adversely affect motor neuron survival under our culture conditions (data not 
shown).  Next we examined the biochemical effects of LY294002.  For this set of experiments, 
the culture media was supplemented with CNTF, CT-1, NT4 and GDNF but lacked BDNF.  
Neurons were pre-treated with LY294002 or vehicle for 30 minutes prior to acute stimulation 
with BDNF (50 ng/ml) or vehicle and then lystates were prepared 30 minutes later (Figure 2A).  
In the absence of LY294002, BDNF evoked an increase in the phosphorylation of AKT, MAPK and 
T32 and S253 of FOXO3a.  No changes in the abundance of the non-phosphorylated species 
were noted.  In cultures pre-treated with LY294002, application of BDNF evoked an increase in 
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MAPK phosphorylation but there were no changes in the phosphorylation of AKT and T32 and 
S253 of FOXO3a.  No changes in the abundance of the non-phosphorylated species were noted.  
These results suggest that LY294002 selectively inhibit the PI3’K signaling pathway and 
phosphorylation of FOXO3a.  Next we investigated the effects of chronic LY294002 application 
to cultures supplemented with all five of the above trophic factors.   Twenty-four hour 
incubation with LY-294002, in comparison with vehicle treated cultures, led to a decrease in the 
abundance of phosphoAKT and phosphorylation at the S253 site on FOXO3a (Figure 2B).  No 
other changes were noted in the phosphorylated proteins studied and no changes were 
detected in the abundance of the non-phosphorylated species.  Next we looked at the effects of 
6 day incubation with LY294002 (fresh drug applied every other day – Figure 2 C).  We found 
that incubation with LY-294002, in comparison with vehicle treated cultures, led to a decrease in 
the abundance of phosphoAKT, phosphoMAPK and phosphorylation of T32 and S253 of FOXO3a.  
In sum, these experiments indicate that inhibition of PI3’K has the desired effect of decreasing 
the abundance of phosphorylated FOXO3a.   
To determine if LY294002 was neuroprotective, cultures were infected with either WT 
or mutant SOD expressing viruses and LY294002 or vehicle added to the culture media every 
other day for 6 days (Figure 2D).  In the presence of WT SOD, equivalent levels of motor neuron 
survival was found in the presence or absence of LY294002.  In addition, in the presence of 
mutant SOD, equivalent levels of motor neuron death were found in the presence or absence of 
LY294002.  These results indicate that LY294002 is not toxic on its own and does not protect 
motor neurons from mutant SOD toxicity.  Since LY294002 reduces FOXO3a phosphorylation but 
is not neuroprotective, it may be that phosphorylation of other PI3’K targets in mammalian cells 
offset any potential beneficial actions of dephosphorylated FOXO3a.   
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Figure 2.  Inhibition of PI3’K reduces FOXO3a phosphorylation but does not protect against mutant SOD toxicity.  Mixed spinal cord 
cultures were grown in the absence of BDNF and pretreated with LY294002 or vehicle prior to acute stimulation with BDNF.  Thirty 
minutes after application of BDNF, lysates were prepared for western blot analysis.  Panel A shows that LY294002 blocks the BDNF 
stimulated increase in P-AKT, P-MAPK and phosphorylation of FOXO3a onT32 and S253.  Panel B shows the effect of a 24 hours 
treatment with LY294002 of cultures chronically grown in 5 trophic factors including BDNF.  By western blot analysis, LY294002 
suppresses P-AKT and phosphorylation of FOXO3a on S253. Panel C shows the effect of a 6 day treatment with LY294002 of cultures 
chronically grown in 5 trophic factors including BDNF.  By western blot analysis, LY294002 suppresses P-AKT, P-MAPK and 
phosphorylation of FOXO3a on T32 and S253.  Panel D shows the number of motor neurons surviving 6 days of infection with HSV-
WT-SOD or HSV-mutant SOD grown in the presence or absence of chronic LY294002.  Mutant SOD led to approximately 50% motor 
neuron loss and LY294002 did not abrogate the process. 
A chemical-genetic screen recently reported the identification of a series of compounds 
that can inhibit FOXO1a nuclear export.  Compounds fell into two classes: 1) inhibitors of 
general nuclear export machinery and 2) inhibitors specific to the FOXO1a pathway 108.  We 
inquired whether compounds in the second class would also block the nuclear export of FOXO3a 
since they would be predicted (based on the results above) to display neuro-protective activity.  
We focused on Psammaplysene A (PA), which was isolated from a marine sponge, because it 
was the most potent of the class 2 inhibitors (Figure 3A) 109.  In addition PA was reported to have 
no effect on AKT phosphorylation suggesting it acted either downstream of AKT or in a 
synergistic pathway. 
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We began by looking at the effect of a synthetic sample of PA (for synthesis see 110) on 
the distribution of FOXO3a endogenously expressed by neurons.  We biochemically isolated 
nuclei from spinal cord cultures treated with PA or vehicle (Figure 3B).  Based on the distribution 
of the nuclear envelope protein lamin, it is clear that our subcellular fractionation procedure 
greatly enriched nuclei.  There was an ~ 2.5 fold increase in the nuclear FOXO3a/nuclear lamin 
ratio in the PA treated cultures in comparison to vehicle-treated cultures.  Total FOXO3a and 
lamin levels were unaffected by drug treatment.  These observations indicate that PA promotes 
the sequestration of FOXO3a into nuclei.   
We next tested the ability of PA to promote FOXO-dependent transcription.  HEK 293 
cells were transfected with a plasmid containing a minimal promoter containing 3x Fork Head 
Response Elements (3x FHRE) driving luciferase expression and then treated with various 
concentrations of PA or vehicle for 72 hours.  As a control for a non-specific action of PA on 
transcription, a parallel set of cells were transfected with the parent plasmid (pGL3) that lacked 
the 3x FHRE.  In all experiments, an internal control plasmid expressing Renilla luciferase was 
cotransfected and all results are expressed as the ratio Luciferase/Renilla fluorescence.  PA 
treatment led to a dose-dependent increase in luciferase signal in 3x FHRE, but not pGL3, -
expressing cells (Figure 3C).  As an added control for specificity we looked at the ability of PA to 
enhance transcription from a 3x retinoic acid response element (RARE) luciferase construct and 
found that PA had no effect on this promoter.  These results indicate that PA can promote FOXO 
transcriptional activity.   
To determine if PA had neuroprotective activity, spinal cord cultures were treated with 
the drug (10 nM) for two days and then subjected to an excitotoxic challenge (Figure 3D).  The 
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percent of KA-induced cell death was ~50 % in vehicle-treated cultures (65 ± 2 versus 35 ± 3 
vehicle versus KA, p < 0.01, Student’s t-test) and ~3 % in PA treated cultures (67 ± 3 versus 65 ± 2 
vehicle versus KA,  p < 0.6, Student’s t-test) indicating that PA protected motor neurons from 
excitotoxic challenge.  Next we looked at mutant AR proteotoxicity (Figure 3D). Significant 
differences between groups (F(2,6) = 18.84, by ANOVA)  were found in the three-way comparison 
of 1) No DHT, 2) DHT + vehicle, and 3) DHT + PA).  The post hoc analysis demonstrated a DHT-
dependent ~25 % loss of motor neurons in vehicle-treated cultures (p < 0.01) and 
neuroprotection in the PA treated cultures (P > 0.05 in the comparison of no DHT versus DHT + 
PA).  
 We followed up these observations by asking if PA blocked the proteotoxicity of SOD or 
p150glued.  Spinal cord cultures were infected with HSV engineered to express the WT or mutant 
forms of SOD or the WT or mutant forms of p150glued and received PA (or vehicle) every other 
day for 4 days.  The drug treatment had no effect on transgene expression (not shown).  After 4 
days, the cultures were fixed and motor neuron number was determined.  ANOVA revealed 
statistically significant differences between groups in LacZ versus WT SOD versus mutant SOD (± 
PA) comparisons (F(5,12) = 18.41, p < 0.001) as well as LacZ versus WT p150
glued versus mutant 
150glued (± PA)  comparisons (F(5,12) = 19.26, p < 0.001) (Figure 3E).  The post hoc analysis revealed 
that statistically significant protection against the toxicity of mutant SOD or p150glued was 
conferred by PA treatment on motor neuron survival.  PA had no adverse effect on survival of 
motor neurons expressing LacZ or wild type versions of SOD or p150glued.  Thus PA is non-toxic 
on its own, but can protect against four different insults in vitro that are directly relevant to 
motor neuron diseases. 
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Figure 3. Psammaplysene A (PA) drives FOXO3a into the neuronal nucleus, promotes FOXO-dependent transcription and protects 
against the proteotoxicity of mutant SOD and mutant p150glued .  Panel A. The chemical structure of PA.  Panel B.  Subcellular 
fractionation of DIV14 spinal cord culture lysates treated with PA or vehicle.  Nuclear fraction (enriched for the nuclear marker, 
lamin) contains more FOXO3a in PA- versus vehicle-treated cultures.  The abundance of total FOXO3a, lamin or actin is the same 
under both conditions.  Quantification of band intensities show that PA treatment leads to a statistically significant increase in 
nuclear FOXO3a/nuclear lamin in comparison with vehicle treated cultures.  Panel C. PA promotes transcription from a 3x FHRE-
luciferase reporter in a dose-dependent manner.  PA affected neither transcription from the parent vector (pGL3 that lacks the 
FHREs) nor from a 3x RARE luciferase reporter.  There was a statistically significant difference between vehicle treatment of 3xFHRE 
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versus PA concentrations 10 nM (*, p < 0.05), 50 nM (**, p< 0.01) and 100nM (***, p < 0.001).  Panel D. Pretreatment of mixed 
spinal cord cultures with PA (+PA) protected motor neurons from excitotoxic insult (left bar graph) and DHT-dependent death of 
polyQ expanded AR toxicity (right bar graph).  Panel E. One set of 14 DIV mixed spinal cord cultures was infected with HSV-LacZ, HSV-
WT-SOD or HSV-mutant SOD and a second set of cultures was infected with HSV-LacZ, HSV-WT-p150glued or HSV-mutant p150glued.  
Survival of SMI-32 stained motor neurons was determined 4 days later.  Infected cultures were either treated with Vehicle (“- PA”) 
or PA (“+ PA”).  Mutant SOD led to a statistically significant reduction in motor neuron number (by ANOVA, see text for details) and 
this was prevented in PA-treated cultures.   Similarly mutant p150glued  led to a statistically significant reduction in motor neuron 
number and this was prevented in PA-treated cultures. * p < 0.05. 
Although the direct molecular target of PA is unknown, we examined the effect of PA on 
some candidate biochemical and cell biological processes that have previously been implicated 
in neuron death.  Neurotrophins (such as brain-derived neurotrophic factor, BDNF) can promote 
neuronal survival by activating its receptor, TrkB, both during development and after insult (202-
204, but see 201,205) and so we wondered if PA had demonstrable effects on this signaling pathway.  
Spinal cord cultures grown for 14 DIV were infected with HSV-mutant SOD and then PA or 
vehicle was added to the cultures.  Under these conditions, in the absence of BDNF, the level of 
active, phosphoTrk receptor is very low (Figure 4A).  Similarly, downstream signaling involving 
AKT and MAPK are only modestly active.  In response to BDNF addition to the media, there is a 
rapid and robust activation of the Trk receptor (as monitored by assaying for the 
phosphorylated form of the receptor) as well as phosphoAKT and phosphoMAPK.  The temporal 
pattern of receptor activation and downstream signaling in our cultures conforms to previous 
observations 120,200 (Figure 4A).  Identical results were obtained in cultures uninfected with 
viruses (not shown).  Thus we find no evidence that pre-treatment of cultures with PA has any 
effect on the magnitude or duration of BDNF-TrkB signaling. 
Insoluble aggregates of mutant SOD are detectable within cells from transgenic mice 
engineered to express mutant SOD 206,207.  We wondered if WT or mutant SOD aggregated in 
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neurons in vitro and if treating cultures with PA influenced the cellular distribution of human 
transgene SOD.  Immunocytological location of human SOD in cultures infected with HSV-WT-
SOD revealed that the protein is homogeneously distributed throughout the cytoplasm and 
extends centrifugally for >100 microns into axons and dendrites (Figure 4B).  In contrast, in 
cultures infected with HSV- mutant SOD immunoreactivity is concentrated into puncta (the 
cytological signature of insoluble aggregated proteins) in the soma cytoplasm and neurites.  
Double labeling studies reveal that mutant SOD puncta are present in motor neurons (identified 
by SMI32 immunoreactivity) as well as non-motor neurons in our cultures (Figure 4B).  
Treatment of cultures with PA had no effect on the subcellular distribution of human SOD in 
cultures infected with either of the recombinant HSVs.  Although the pathophysiological 
significance of aggregated protein is controversial, these results indicate that the 
neuroprotective action of PA is dissociable from the accumulation of aggregated mutant SOD.  A 
similar observation has been made in C. elegans wherein DAF-16 protects against A1-42 toxicity 
but does not influence the accumulation of protein aggregates 15. 
Since the neuroprotection conferred by PA does not seem to be linked to alterations in 
trophic factor signaling or the generation of macroscopic mutant SOD aggregates, perhaps PA 
action is linked to its capacity to promote nuclear localization of FOXO3a.  This would be 
consistent with the observations that PA causes nuclear partitioning of FOXO3a in neurons and 
constitutive localization of FOXO3a in the nucleus is broadly neuroprotective.  We began with 
biochemical studies of spinal cord neurons in vitro expressing WT SOD or mutant SOD.  In the 
absence of PA, the abundance of phosphorylated FOXO3a at T32 (or its ratio to the non-
phosphorylated species) is the same in mutant- versus WT-SOD, expressing cultures (Figure 4C).  
The same was true when we assayed phosphorylation of S253 (not shown).  On the other hand, 
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one transcriptional target of FOXO3a is MnSOD and the abundance of this protein is markedly 
depressed in mutant SOD, in comparison with WT-SOD-expressing cultures.  Expression of 
neither mutant- nor WT-SOD led to measurable changes in total FOXO3a or actin.  In the 
presence of PA treatment, the abundance of phosphorylated FOXO3a (or its ratio to the non-
phosphorylated species) is the same in mutant- versus WT-SOD, expressing cultures (Figure 4C).  
Interestingly, PA treatment rescued the mutant SOD effect on the level of MnSOD such that 
MnSOD abundance was equal in the mutant- versus WT-SOD expressing cultures.  PA had no 
effect on the abundance of total FOXO3a or actin.  These findings suggest that mutant SOD 
proteotoxic stress in vitro is not associated with a change in the state of phosphorylation of 
FOXO3a at sites that regulate it subcellular distribution.  On the other hand, mutant SOD 
expression results in a reduction in the abundance of a FOXO3a transcriptional target (MnSOD) 
raising the possibility that proteotoxic stress might influence FOXO3a signaling pathway.  How 
PA treatment reverses the mutant SOD-dependent effect on MnSOD expression, and if it is 
linked to FOXO3a, will require further study.    
Given these in vitro observations, we wondered if a similar phenomenon occurs in 
mutant SOD mice. We examined lysates from spinal cords of mice expressing the G93A mutant 
form of human SOD or wild type controls for the expression of phosphoFOXO3a and target 
genes.  The mice were 87 days old, a time when they are asymptomatic in terms of weakness, 
but do manifest other subtle abnormalities 208-210. A consistent increase in the phosphorylation 
of T32 of FOXO3a (and the ratio of phosphoFOXO3a to the non-phosphorylated species) was 
seen in the G93A mice in comparison with the wild type animals (n=4 in each experimental 
group) (figure 4D).  This was associated with a reduction in MnSOD in the G93A mice in 
comparison to the wild type animals.  No differences were noted in the abundance of actin in 
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the mutant versus wild type animals.  Thus in both in vitro and in vivo experiments, mutant SOD 
expression is associated with a reduction in MnSOD expression.  The effect of mutant SOD 
expression on FOXO3a phosphorylation differed in the in vitro versus in vivo paradigms.  
 
Figure 4. Effects of PA on the distribution of WT and mutant SOD in vitro and biochemical consequences of WT and mutant SOD in 
vitro and in vivo.  Panel A. Mixed spinal cord cultures infected with HSV-WT-SOD or HSV-G87R-SOD were treated with PA or vehicle 
overnight prior to stimulation with 50 ng/ml BDNF.  Lysates of unstimulated cells or stimulated cells at the given time points were 
subjected to Western blot analysis.  The kinetics and degree of TrkB pathway stimulation is the same in PA- versus vehicle-treated 
cells.  Panel B. Mixed spinal cord cultures infected with HSV-WT-SOD or HSV-G85R-SOD were treated with PA or vehicle for 3 days 
prior to fixation and immunostaining for human SOD.  WT-SOD is homogenously distributed throughout the cytoplasm in the 
neuronal soma and processes in the absence of PA (“- PA”) and in the presence of PA (“+ PA”).  In contrast, G87R SOD assumes a 
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punctate pattern of expression indicative of aggregates of the protein, both in the absence of PA (“- PA”) and in the presence of PA 
(“+ PA”).  Calibration bar = 20 microns. Below, using cultures infected with HSV-G85R-SOD, motor neurons are stained with SMI-32 
(left panel) and anti-human SOD (middle panel).  Aggregated mutant SOD is localized within motor neurons (yellow in right panel).  
Calibration bar = 15 microns.  Panel C.  In the absence of PA (“-PA”) treatement, spinal cord cultures expressing mutant SOD or WT 
SOD have the same abundance of phosphoFOXO3a (T32) and the non-phosphorylated species.  In addition, mutant SOD expressing 
cultures have decreased abundance of MnSOD.  In the presence of PA (“+PA”), there is no difference in the abundance of phospho- 
or non-phosphorylated FOXO3a in cultures expressing WT or mutant SOD.  In addition, the level of expression of MnSOD is no longer 
suppressed by mutant SOD expression in PA treated cultures. Panel D.  Western blots of lumbar spinal cord lysates from 2 wild type 
(labeled 1 and 2) and G93A mutant SOD mice (labeled 1 and 2).  Representative western blots show an increase in the abundance of 
T32 phosphoFOXO3a in the lysates from the mutant mice as well as a decrease in the abundance of MnSOD.  Quantification of these 
results are shown in the histograms below. 
 To further explore this issue we employed bioinformatics tools to query existing 
microarray profiles for a potential connection between motor neuron disease and FOXO3a-
dependent transcription. We identified five microarray datasets located in the National Center 
for Biotechnology Information Gene Expression Omnibus (NCBI GEO) server that are relevant to 
motor neuron disease.  These datasets come from studies of postmortem tissue from ALS 
patients and mutant SOD mouse or rat tissues at various stages of disease.  To our knowledge 
the only description of the FOXO3a transcriptome comes from a study of PTEN null 786-O renal 
carcinoma cells 176.  This study identified 198 transcripts whose level of expression is changed 
2-fold when a DNA binding-competent, constitutively nuclear (triple mutant) FOXO3a is 
expressed in these cells.  When we asked how many genes in the motor neuron disease data set 
were also components of the FOXO3a transcriptome, we identified 22 transcripts in both 
datasets (Supplemental Table).  Even given the disparate experimental platforms employed in 
these studies, the presence of any overlapping dataset is intriguing.  A better-controlled 
prospective study is required to obtain a more full understanding of the potential importance of 
FOXO3a in motor neuron disease pathogenesis. 
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In light of the neuroprotective effect of PA in vitro, we examined the effects of the drug 
in two in vivo model systems of neuronal degeneration. Expression of polyglutamine-expanded 
AR in the Drosophila eye leads to DHT-dependent degeneration 111,112.  We found that flies 
reared on food supplemented with 0.5 mM PA had a reduced degenerative phenotype when 
compared with vehicle treated flies (Figure 5a, b). These in vivo results complement the 
observations made in spinal cord cultures from mice expressing polyglutamine-expanded AR 
wherein we found expression of TM-FOXO or treatment with PA blunts DHT-dependent mutant 
AR toxicity. 
We next asked if the neuroprotective action of PA depended on FOXO.  To this end, we 
examined the efficacy of PA in flies that both expressed the polyglutamine expanded AR and 
were haploinsufficient for Drosophila Foxo (dFOXO) (Figure 5c, d).  In a dFOXO-deficient 
background (foxoBG01018 allele)113, PA lost its ability to protect against DHT-dependent 
degeneration.  To corroborate these observations, we studied two additional dFOXO loss-of-
function alleles (foxo21 and foxo25) and one predicted loss-of function allele (foxoC01841) 114,115.  As 
above, on all of these dFOXO-deficient backgrounds, PA lost its ability to protect against DHT-
dependent degeneration.  Using a quantitative rating score, we found that PA led to a 
statistically significant mitigation of polyglutamine-expanded AR degeneration but this was lost 
in the dFOXO haploinsufficient flies (Figure 5 bar graph).  Variation in the baseline (no PA 
provided) level of neurodegeneration phenotype among the studied fly lines is likely due to 
differences in the background genotype.  These observations indicate that PA confers protection 
against mutant AR proteotoxicity in a FOXO-dependent manner. 
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Figure 5: PA suppresses degeneration in a Drosophila model of SBMA in a dFOXO-dependent manner. Right panel of each diptych 
shows higher magnification of the posterior margin of the eye, where degeneration is concentrated. Panel a, flies expressing 
polyglutamine-expanded human androgen receptor (GMR, AR52Q) show degeneration when reared on food containing 1 mM 
dihydrotestosterone (+DHT).  Panel b, this degeneration is suppressed when food is supplemented with 0.5 mM PA.  Panels c and d, 
PA fails to rescue AR52Q-mediated degeneration in a dFoxo-deficient background. Bar graph below - Quantification of the 
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degenerative eye phenotype (scored according to Pandey et al. 111) shows that the neuroprotective effect of PA is lost when flies are 
haploinsufficient for dFOXO.  Number of eyes scored:  GMR, AR52 – DMSO n=34, PA n = 41; GMR, AR52; foxoBG01018 DMSO n=37, PA n 
= 47; GMR, AR52; foxo21 DMSO n=20, PA n=16; GMR, AR52; foxo25 DMSO n=8, PA n=14; GMR, AR52; foxoC01841 DMSO n=28, PA n=20. 
Mean values are indicated with standard error. P value was determined using Student's t-test. * - p < 0.05 
We developed a C. elegans model system of neurodegeneration by combining a null 
mutation in the glutamate transporter GLT-3 (∆glt-3) with a transgenic strain (nuIs5 - 116) in 
which the glr-1 promoter drives expression of an activated form of Gs (abbreviated Gs*) and 
GFP in glutamatergic neurons 117.  The ∆glt-3; nuIs5 double mutants exhibit necrotic neuron 
death at all stages of postembryonic development, with the strongest effect seen in 
developmental stage L3.  PA had a dose-dependent neuroprotective effect at the L3 stage, with 
complete rescue from death using 10 nM PA (Figure 6A).  This concentration of PA had no 
adverse effect on WT nematodes. We asked if the effect of PA is mediated by changing the 
timing of neurodegeneration or by reducing it throughout development (Figure 6B).  To examine 
this, we studied the effect of PA on the ∆glt-3; nuIs5 double mutants as a function of larval stage 
and we found neuronal death was reduced in all developmental stages, with the strongest effect 
observed in the developmental stages most prone to excitotoxicity.  Neuron death was reduced 
in a statistically significant manner in larval stages L2 (3.4 ± 0.2 versus 2.5 ± 0.2 dying 
neurons/animals, n = 44 versus n = 49, vehicle versus PA, p = 0.006) and L3 (4.2 ± 0.2 versus 2.2 
± 0.1 dying neurons/animals, n = 63 versus n = 65, vehicle versus PA, p < 0.001) (Figure 6B).   
In C. elegans, stress resistance and longevity is promoted by a reduction in the activity 
of insulin growth factor receptor (IGFR) signaling pathway (i.e., hypomorphic alleles of IGFR, daf-
2, and PI3’K, age-1) and this requires daf-16, the nematode homolog of FOXO3a. This led us to 
wonder if reducing activity in the IGFR signaling pathway would alleviate nematode 
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excitotoxicity. To that end, we crossed the ∆glt-3; nuIs5 double mutants with an age-1 mutant 
that carries the hx546 allele.  This allele has a specific anti-aging effect but does not affect 
development 211.  We generated triple mutant nematodes (age-1; ∆glt-3; nuIs5) and found a 
robust neuroprotective effect of age-1 at larval stages L1, L2 and L3 (all p values  0.001) (Figure 
6C).   
Finally, while we showed that PA leads to accumulation of FOXO3a in mammalian 
neuronal nuclei, we wished to determine if the same was true in C. elegans.  To this end, we 
studied nematodes in which a DAF-16::GFP fusion protein was expressed in body wall muscles.  
Addition of PA, but not vehicle, to the growth substrate led to nuclear localization of the fusion 
protein and quantification of the nucleus/cytoplasm ratio of DAF-16::GFP revealed a statistically 
significant effect of PA (1.46 ± 0.05 versus 3.44 ± 0.55, n = 36 versus n=27, vehicle versus PA, p < 
0.0001) (Figure 6D).  This result indicates that PA has an evolutionarily conserved capacity to 
promote nuclear localization of the DAF16/FOXO3a transcription factor and this is associated 
with resistance to necrotic neuron death.  Another method for promoting nuclear localization of 
DAF-16 (i.e., mutation of age-1) has a neuroprotective effect and further re-enforces the notion 
that manipulation of the IGFR signaling pathway could have promise as a neuroprotective 
strategy.   
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Figure 6. PA treatment or reducing the activity of IGFR signaling pathway alleviate nematode excitotoxicity. Panel A. PA has a dose-
dependent neuroprotective effect on nematode excitotoxicity: ∆glt-3; nuIs5 double mutant nematodes were cultured in presence of 
increasing concentrations of PA in the medium. The number of swollen, degenerating head neurons was scored under Nomarski DIC 
optics in live animals at the L3 developmental stage. PA shows a statistically significant, dose-dependent neuroprotective effect. 
Panel B. The neuroprotective effect of PA is mediated by reducing the extent of neurodegeneration throughout development.  Panel 
C. age-1(hx546), a mutation that reduces IGFR signaling pathway without altering developmental decisions, protects C. elegans from 
excitotoxicity. Degenerating head neurons were scored in live animals as above. Panel D. PA causes preferential nuclear localization 
of DAF-16, the nematode homolog of FOXO3a. Animals express a transgene (Pmyo-3:daf-16::gfp) that directs the expression of DAF-
16::GFP fusion protein in body-wall muscle cells. In control animals (i.) DAF-16::GFP is abundantly present in the cytoplasm. Animals 
grown in the presence of 10nM PA (ii.) show preferential (though not uniform) accumulation of DAF-16::GFP in the nucleus.  
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Discussion: 
 
 Biochemical pathways that regulate longevity in yeast, C. elegans, Drosophila 
melanogaster and mice also play a fundamental role in resistance to stresses such as UV 
radiation, oxidative conditions, heat shock and misfolded and aggregation-prone proteins 118.  
Two transcription factors, Heat-shock factor 1 and DAF-16/FOXO3a, are essential mediators of 
this longevity/stress resistance program in nematodes 4,119.  Here we show that genetic and 
pharmacological maneuvers that enhance nuclear localization of FOXO3a protect mammalian 
motor neurons in vitro from 4 insults directly relevant to motor neuron diseases and abrogate 
neurodegeneration in two in vivo invertebrate model systems.  The broad neuroprotective 
action of PA suggests it acts on a phylogenetically conserved, core stress resistance pathway. 
 
Nuclear FOXO3a and PA can evoke a neuroprotective program 
We have employed several complementary experimental platforms (each with its own 
unique advantage) to investigate the biological actions of PA.  In sum the experimental result 
suggest that the neuroprotective actions of PA are mediated, at least in part, by FOXO3a/DAF-
16.  First, in both rat neuron cultures and C. elegans, application of PA promotes nuclear 
accumulation of FOXO3a or DAF-16.  Second, PA evokes a dose-dependent increase in FOXO-
dependent transcription.  Third, constitutive nuclear localization of FOXO3a mimics the 
neuroprotective action of PA.  Fourth, PA-mediated protection against mutant AR-evoked 
degeneration is dFOXO-dependent.  Even without knowledge of the direct molecular target of 
PA, this evidence favors the view that PA acts, at least in part, in a FOXO3a transcription-
dependent manner.  
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Upon nuclear localization, members of the FOXO family of transcription factors can 
control the expression of messages that impact glucose metabolism, tumor suppression 
(through effects on cell cycle progression and apoptotic responses), stress resistance and 
longevity 99,176.  The specific effects of FOXOs are both cell-type and context-dependent and 
specific posttranslational modifications (i.e. phosphorylation, ubiquitination, acetylation) play a 
key role in controlling the transcriptional read-out 97,167,181,212}.  For example, work from the 
Brunet lab has demonstrated that AMPK phosphorylates FOXO3a at 6 sites and the state of 
phosphorylation at these sites does not affect nuclear localization 179.  Instead these sites are 
vital for expression of genes involved in oxidative stress management and energy metabolism.  
Our finding that induction of MnSOD by PA in cultures expressing mutant SOD parallels the 
observation of Greer et al. that AMPK induction of sod-3 expression in nematodes is FOXO/DAF-
16-dependent 213.  Our preliminary studies suggest that expression of mutant SOD ± PA does not 
influence the state of phosphorylation of FOXO3a at AMPK sites S413 or S588 (unpublished 
observations).  Further work is required to determine if FOXO3a undergoes posttranslational 
modifications in cells expressing mutant SOD, if PA influences such a change, and whether this 
has functional consequences. 
It is noteworthy that expression of mutant SOD in neurons in vivo, prior to neuron loss, 
is associated with an increase in FOXO3a phosphorylation at T32 (one of the three key sites 
controlling nuclear/cytoplasmic partitioning) and a reduction in the abundance of MnSOD.  
These observations may indicate that as a consequence of expressing mutant SOD, neurons 
upregulate the activity of FOXO3a kinases (and/or decrease the activity of FOXO3a 
phosphatases) and this results in a reduction in the expression of FOXO3a-regulated transcripts 
that combat proteotoxicity.  In fact, there is a 2.5 fold increase in PI3’K activity and protein in 
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spinal cords of ALS patients (the activator of the FOXO3a kinases AKT and SGK 214) as well as a 
3.6 fold increase in phosphoAKT itself in mutant SOD mice 215.  These observations may indicate 
that a putatively beneficial response to stress, such as increased expression and activity of an 
anti-apoptotic pathway, may have an unintended adverse additional action on FOXO3a 
transcription. 
While we found that constitutive nuclear localization of FOXO3a is neuroprotective, 
other groups obtained the opposite result.  Heterologous expression of TM-FOXO3a led to death 
of purified motor neurons and cerebellar granule neurons  (97 as well as PTEN-deficient tumor 
cells 216.  One factor that may contribute to these disparate observations is experimental 
platform.  A second contributory factor may be the level of transgene expression.  It has been 
suggested that the level of nuclear FOXO3a dictates the cellular read-out 102 and the promoter in 
the HSV-based system we employ generally evokes moderate level of transgene expression 122. 
 
Invertebrate models support PA acts via a conserved mechanism  
Given the potent neuroprotective activity of PA in vitro we sought to examine its effects 
in vivo.  The two model systems we chose have features that are reminiscent of human motor 
neuron diseases.  Neurons in the ∆glt-3: nuIs5 nematode die an excitotoxic cell death and there 
is abundant evidence that implicating excitotoxic mechanisms in ALS 106.  Spinobulbar muscular 
atrophy is caused by expression of the proteotoxic polyQ expanded AR and transgenic 
expression of this mutant in the fly eye similarly causes degeneration 111.  The neuroprotective 
activity of PA in these model systems complements the in vitro studies with mammalian motor 
neurons.  A simple explanation for these observations is that PA operates on a biochemical 
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pathway common in all these experimental systems that can overcome a diversity of noxious 
insults.  
Extending these observations to the mutant SOD mouse model of ALS at the present 
time is hindered by the lack of evidence that PA can cross the blood-brain barrier.  In preliminary 
studies we have not detected PA in brain homogenates after intraperitoneal administration.  
Administration using an intrathecal catheter/osmotic minipump may be a viable option 217, 
although the long-term stability of PA at body temperatures is not known.  It may be possible to 
synthesize derivatives of PA that retain the essential biological activity and cross the blood-brain 
barrier 218.  
 
Healthful aging and the FOXO3a signaling pathway 
The onset of many neurodegenerative diseases in adulthood raises the possibility that 
the causes of aging are specific contributors to disease pathogenesis.  To the extent that this is 
true, applying our understanding of the molecular biology of longevity may lead to new types of 
therapy for neurodegenerative diseases.  The present work on FOXO3a is an example of how 
manipulation of a phylogenetically conserved, longevity-promoting signaling pathway can 
effectively block neurodegeneration.  This is particularly interesting in light of a recent 
population-based study of human longevity showing a strong association of FOXO3a and healthy 
aging 27.  Agents that trigger neurodegeneration may act in part by subverting the normally 
healthful actions of an aging pathway.     
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